Microtubule-binding agents: a dynamic field of cancer t

Nature Reviews Drug Discovery 9, 790-803 DOI: 10.1038/nrd3253

Citation Report

#	Article	IF	CITATIONS
2	Investigational antibody drug conjugates for solid tumors. Expert Opinion on Investigational Drugs, 2011, 20, 1131-1149.	1.9	85
3	A Survey of Marine Natural Compounds and Their Derivatives with Anti-Cancer Activity Reported in 2010. Molecules, 2011, 16, 5629-5646.	1.7	31
4	Antibody-DM1 conjugates as cancer therapeutics. Cancer Letters, 2011, 307, 113-118.	3.2	74
5	Enzymatic methods for glyco(diversification/randomization) of drugs and small molecules. Natural Product Reports, 2011, 28, 1811.	5.2	214
6	Concise syntheses of N-aryl-5,6,7-trimethoxyindoles as antimitotic and vascular disrupting agents: application of the copper-mediated Ullmann-type arylation. Organic and Biomolecular Chemistry, 2011, 9, 3154.	1.5	20
7	Cell Death Signaling and Anticancer Therapy. Frontiers in Oncology, 2011, 1, 5.	1.3	46
9	Identification of Cytotoxic Drugs That Selectively Target Tumor Cells with MYC Overexpression. PLoS ONE, 2011, 6, e27988.	1.1	25
10	Mechanism of Cell Adaptation. Cancer Journal (Sudbury, Mass), 2011, 17, 89-95.	1.0	162
11	Microtubule-Severing ATPase Spastin in Glioblastoma: Increased Expression in Human Glioblastoma Cell Lines and Inverse Roles in Cell Motility and Proliferation. Journal of Neuropathology and Experimental Neurology, 2011, 70, 811-826.	0.9	32
12	Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma. Blood, 2011, 117, 6638-6649.	0.6	79
13	Identification of Novel Antitubulin Agents by Using a Virtual Screening Approach Based on a 7â€Point Pharmacophore Model of the Tubulin Colchiâ€Site. Chemical Biology and Drug Design, 2011, 78, 913-922.	1.5	25
14	Eribulin mesylate. Nature Reviews Drug Discovery, 2011, 10, 173-174.	21.5	78
15	Synthesis and biological evaluation of 1-(4′-Indolyl and 6′-Quinolinyl) indoles as a new class of potent anticancer agents. European Journal of Medicinal Chemistry, 2011, 46, 3623-3629.	2.6	30
16	Synthesis, biochemical and molecular modelling studies of antiproliferative azetidinones causing microtubule disruption and mitotic catastrophe. European Journal of Medicinal Chemistry, 2011, 46, 4595-4607.	2.6	41
17	Gold from the sea: Marine compounds as inhibitors of the hallmarks of cancer. Biotechnology Advances, 2011, 29, 531-547.	6.0	112
18	Synthesis and biological evaluation of phenstatin metabolites. Bioorganic and Medicinal Chemistry, 2011, 19, 6042-6054.	1.4	28
19	Potent Taccalonolides, AF and AJ, Inform Significant Structure–Activity Relationships and Tubulin as the Binding Site of These Microtubule Stabilizers. Journal of the American Chemical Society, 2011, 133, 19064-19067.	6.6	48
20	Synthesis of hydrophilic and lipophilic 4-arylcoumarin phosphates. Russian Chemical Bulletin, 2011, 60, 2003-2009.	0.4	9

#	Article	IF	CITATIONS
21	Synthesis, evaluation and structural studies of antiproliferative tubulin-targeting azetidin-2-ones. Bioorganic and Medicinal Chemistry, 2011, 19, 2306-2325.	1.4	62
22	2â€Aminoâ€3,4,5â€Trimethoxybenzophenones as Potent Tubulin Polymerization Inhibitors. ChemMedChem, 2011, 6, 450-456.	1.6	11
23	Cdc20 control of cell fate during prolonged mitotic arrest. BioEssays, 2011, 33, 903-909.	1.2	15
24	Waterâ€Soluble Prodrug of Antimicrotubule Agent Plinabulin: Effective Strategy with Click Chemistry. Chemistry - A European Journal, 2011, 17, 12587-12590.	1.7	15
25	UA62784 Is a Cytotoxic Inhibitor of Microtubules, not CENP-E. Chemistry and Biology, 2011, 18, 631-641.	6.2	20
26	Novel second generation analogs of eribulin. Part III: Blood–brain barrier permeability and in vivo activity in a brain tumor model. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 1639-1643.	1.0	21
27	Novel second generation analogs of eribulin. Part II: Orally available and active against resistant tumors in vivo. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 1634-1638.	1.0	19
28	Novel second generation analogs of eribulin. Part I: Compounds containing a lipophilic C32 side chain overcome P-glycoprotein susceptibility. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 1630-1633.	1.0	23
29	Cellular studies reveal mechanistic differences between taccalonolide A and paclitaxel. Cell Cycle, 2011, 10, 2162-2171.	1.3	37
30	Identification of Chemosensitivity Nodes for Vinblastine through Small Interfering RNA High-Throughput Screens. Journal of Pharmacology and Experimental Therapeutics, 2011, 339, 851-858.	1.3	16
31	Vascular disrupting agents. Current Opinion in Oncology, 2012, 24, 305-315.	1.1	37
32	NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies. Molecular Cancer Therapeutics, 2012, 11, 1006-1016.	1.9	87
33	Evading Pgp Activity in Drug-Resistant Cancer Cells: A Structural and Functional Study of Antitubulin Furan Metotica Compounds. Molecular Cancer Therapeutics, 2012, 11, 1103-1111.	1.9	12
34	Aurora-B protein expression is linked to initial response to taxane-based first-line chemotherapy in stage III ovarian carcinoma. Journal of Clinical Pathology, 2012, 65, 29-35.	1.0	10
35	Cabazitaxel: More Than a New Taxane for Metastatic Castrate-Resistant Prostate Cancer?. Clinical Cancer Research, 2012, 18, 6574-6579.	3.2	48
36	Vinflunine. Anti-Cancer Drugs, 2012, 23, 1-11.	0.7	19
37	Prodrug Study of Plinabulin Using a Click Strategy Focused on the Effects of a Replaceable Water-Solubilizing Moiety. Chemical and Pharmaceutical Bulletin, 2012, 60, 877-881.	0.6	7
38	Synthesis and biological evaluation of 2-substituted-4-(3′,4′,5′-trimethoxyphenyl)-5-aryl thiazoles as anticancer agents. Bioorganic and Medicinal Chemistry, 2012, 20, 7083-7094.	1.4	56

#	Article	IF	CITATIONS
39	Synthesis and biological evaluation of novel heterocyclic derivatives of combretastatin A-4. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 7227-7231.	1.0	28
40	Asymmetric Synthesis of the C14–C26 Building Block of Eribulin Mesylate. European Journal of Organic Chemistry, 2012, 2012, 6959-6966.	1.2	16
41	Polygamain, a New Microtubule Depolymerizing Agent That Occupies a Unique Pharmacophore in the Colchicine Site. Molecular Pharmacology, 2012, 81, 431-439.	1.0	21
42	Application of Suzuki arylation, Sonogashira ethynylation and Rosenmund–von Braun cyanation in the exploration of substitution effects on the anticancer activity of 2-aroylquinolines. Organic and Biomolecular Chemistry, 2012, 10, 9593.	1.5	4
43	Anti-neoplastic agent thymoquinone induces degradation of α and β tubulin proteins in human cancer cells without affecting their level in normal human fibroblasts. Investigational New Drugs, 2012, 30, 1813-1819.	1.2	47
44	Indole molecules as inhibitors of tubulin polymerization: potential new anticancer agents. Future Medicinal Chemistry, 2012, 4, 2085-2115.	1.1	122
45	Acquired Resistance to Peloruside A and Laulimalide is Associated with Downregulation of Vimentin in Human Ovarian Carcinoma Cells. Pharmaceutical Research, 2012, 29, 3022-3032.	1.7	15
46	Optimising the Delivery of Tubulin Targeting Agents through Antibody Conjugation. Pharmaceutical Research, 2012, 29, 2972-2984.	1.7	13
47	Combined expression of KLK4, KLK5, KLK6, and KLK7 by ovarian cancer cells leads to decreased adhesion and paclitaxel-induced chemoresistance. Gynecologic Oncology, 2012, 127, 569-578.	0.6	33
48	A novel sulfonamide agent, MPSP-001, exhibits potent activity against human cancer cells in vitro through disruption of microtubule. Acta Pharmacologica Sinica, 2012, 33, 261-270.	2.8	26
49	Pretubulysin derived probes as novel tools for monitoring the microtubule network via activity-based protein profiling and fluorescence microscopy. Molecular BioSystems, 2012, 8, 2067.	2.9	48
50	A-Ring Dihalogenation Increases the Cellular Activity of Combretastatin-Templated Tetrazoles. ACS Medicinal Chemistry Letters, 2012, 3, 177-181.	1.3	42
51	Identification of Simple Compounds with Microtubule-Binding Activity That Inhibit Cancer Cell Growth with High Potency. ACS Medicinal Chemistry Letters, 2012, 3, 35-38.	1.3	67
52	Growing the growth cone: remodeling the cytoskeleton to promote axon regeneration. Trends in Neurosciences, 2012, 35, 164-174.	4.2	99
53	Synthesis and structure–activity relationships of benzophenone-bearing diketopiperazine-type anti-microtubule agents. Bioorganic and Medicinal Chemistry, 2012, 20, 4279-4289.	1.4	40
54	Zampanolide, a Potent New Microtubule-Stabilizing Agent, Covalently Reacts with the Taxane Luminal Site in Tubulin α,β-Heterodimers and Microtubules. Chemistry and Biology, 2012, 19, 686-698.	6.2	81
55	Discovery and Optimization of a Series of 2-Aryl-4-Amino-5-(3′,4′,5′-trimethoxybenzoyl)Thiazoles as Nove Anticancer Agents. Journal of Medicinal Chemistry, 2012, 55, 5433-5445.	2.9	57
56	Discovery of Novel Tubulin Inhibitors via Structure-Based Hierarchical Virtual Screening. Journal of Chemical Information and Modeling, 2012, 52, 2730-2740.	2.5	34

#	Article	IF	CITATIONS
57	Total Synthesis of Indoleâ€Đerived Allocolchicine Analogues Exhibiting Strong Apoptosisâ€Inducing Activity. Chemistry - A European Journal, 2012, 18, 12096-12102.	1.7	32
58	Kalanchoe tubiflora extract inhibits cell proliferation by affecting the mitotic apparatus. BMC Complementary and Alternative Medicine, 2012, 12, 149.	3.7	18
59	Glycophthalocyanines as Photosensitizers for Triggering Mitotic Catastrophe and Apoptosis in Cancer Cells. Chemical Research in Toxicology, 2012, 25, 940-951.	1.7	44
60	Antiâ€angiogenic effects of the tubulysin precursor pretubulysin and of simplified pretubulysin derivatives. British Journal of Pharmacology, 2012, 167, 1048-1061.	2.7	38
61	Pyrrole-Based Antitubulin Agents: Two Distinct Binding Modalities Are Predicted for C-2 Analogues in the Colchicine Site. ACS Medicinal Chemistry Letters, 2012, 3, 53-57.	1.3	20
62	Synthesis of tetrazole–isoxazoline hybrids as a new class of tubulin polymerization inhibitors. MedChemComm, 2012, 3, 1386.	3.5	22
63	Unusual expression of red fluorescence at M phase induced by anti-microtubule agents in HeLa cells expressing the fluorescent ubiquitination-based cell cycle indicator (Fucci). Biochemical and Biophysical Research Communications, 2012, 428, 224-229.	1.0	12
64	Synthesis and biological evaluation of a series of podophyllotoxins derivatives as a class of potent antitubulin agents. Bioorganic and Medicinal Chemistry, 2012, 20, 6285-6295.	1.4	16
65	Online chromatic and scale-space microvessel-tracing analysis for transmitted light optical images. Microvascular Research, 2012, 84, 330-339.	1.1	5
66	Molecular simulations of drug–receptor complexes in anticancer research. Future Medicinal Chemistry, 2012, 4, 1961-1970.	1.1	5
67	A Rhodanine Derivative CCR-11 Inhibits Bacterial Proliferation by Inhibiting the Assembly and GTPase Activity of FtsZ. Biochemistry, 2012, 51, 5434-5442.	1.2	39
68	Towards dual photodynamic and antiangiogenic agents: design and synthesis of a phthalocyanine-chalcone conjugate. Organic and Biomolecular Chemistry, 2012, 10, 1154.	1.5	25
69	Antimitotic Inhibitors. Hematology/Oncology Clinics of North America, 2012, 26, 607-628.	0.9	14
70	Patupilone and Ixabepilone: The Effect of a Point Structural Change on the Exo–Endo Conformational Profile. Journal of Physical Chemistry B, 2012, 116, 7605-7617.	1.2	3
71	Synthesis and Antimitotic and Tubulin Interaction Profiles of Novel Pinacol Derivatives of Podophyllotoxins. Journal of Medicinal Chemistry, 2012, 55, 6724-6737.	2.9	77
72	Effect of Cross-Linking on the Performance of Micelles As Drug Delivery Carriers: A Cell Uptake Study. Biomacromolecules, 2012, 13, 814-825.	2.6	74
73	Synthesis and Structure–Activity Relationship Study of Antimicrotubule Agents Phenylahistin Derivatives with a Didehydropiperazine-2,5-dione Structure. Journal of Medicinal Chemistry, 2012, 55, 1056-1071.	2.9	88
74	Interfacial inhibitors: targeting macromolecular complexes. Nature Reviews Drug Discovery, 2012, 11, 25-36.	21.5	204

#	Article	IF	Citations
75	Securin Enhances the Anti-Cancer Effects of 6-Methoxy-3-(3′,4′,5′-Trimethoxy-Benzoyl)-1H-Indole (BPR0L075) in Human Colorectal Cancer Cells. PLoS ONE, 2012, 7, e36006.	1.1	14
76	Novel Quinazolinone MJ-29 Triggers Endoplasmic Reticulum Stress and Intrinsic Apoptosis in Murine Leukemia WEHI-3 Cells and Inhibits Leukemic Mice. PLoS ONE, 2012, 7, e36831.	1.1	58
77	An Antitubulin Agent BCFMT Inhibits Proliferation of Cancer Cells and Induces Cell Death by Inhibiting Microtubule Dynamics. PLoS ONE, 2012, 7, e44311.	1.1	31
78	Dynamics of Tumor Hypoxia in Response to Patupilone and Ionizing Radiation. PLoS ONE, 2012, 7, e51476.	1.1	13
79	Roles of the PI3K/Akt pathway in Epstein-Barr virus-induced cancers and therapeutic implications. World Journal of Virology, 2012, 1, 154.	1.3	66
80	Killing cells by targeting mitosis. Cell Death and Differentiation, 2012, 19, 369-377.	5.0	198
81	Random Mutagenesis of β-Tubulin Defines a Set of Dispersed Mutations That Confer Paclitaxel Resistance. Pharmaceutical Research, 2012, 29, 2994-3006.	1.7	21
82	βII-Tubulin and βIII-Tubulin Mediate Sensitivity to Peloruside A and Laulimalide, but not Paclitaxel or Vinblastine, in Human Ovarian Carcinoma Cells. Molecular Cancer Therapeutics, 2012, 11, 393-404.	1.9	28
83	Discovery of Novel 2-Aryl-4-benzoyl-imidazole (ABI-III) Analogues Targeting Tubulin Polymerization As Antiproliferative Agents. Journal of Medicinal Chemistry, 2012, 55, 7285-7289.	2.9	100
84	Discovery of Novel 2â€ <i>N</i> â€Aryl‣ubstituted Benzenesulfonamidoacetamides: Orally Bioavailable Tubulin Polymerization Inhibitors with Marked Antitumor Activities. ChemMedChem, 2012, 7, 680-693.	1.6	16
85	Comparative Binding Energy (COMBINE) Analysis Supports a Proposal for the Binding Mode of Epothilones to βâ€ī ubulin. ChemMedChem, 2012, 7, 836-843.	1.6	13
86	Synthesis and Evaluation of 1,5-Disubstituted Tetrazoles as Rigid Analogues of Combretastatin A-4 with Potent Antiproliferative and Antitumor Activity. Journal of Medicinal Chemistry, 2012, 55, 475-488.	2.9	109
87	Pharmacological Inhibition of LIM Kinase Stabilizes Microtubules and Inhibits Neoplastic Growth. Cancer Research, 2012, 72, 4429-4439.	0.4	67
88	Whole cell microtubule analysis by flow cytometry. Analytical Biochemistry, 2012, 420, 26-32.	1.1	29
89	MG-2477, a new tubulin inhibitor, induces autophagy through inhibition of the Akt/mTOR pathway and delayed apoptosis in A549 cells. Biochemical Pharmacology, 2012, 83, 16-26.	2.0	111
90	Kinetic stabilization of microtubule dynamics by indanocine perturbs EB1 localization, induces defects in cell polarity and inhibits migration of MDA-MB-231 cells. Biochemical Pharmacology, 2012, 83, 1495-1506.	2.0	39
91	Increased endothelial cell selectivity of triazole-bridged dihalogenated A-ring analogues of combretastatin A–1. Bioorganic and Medicinal Chemistry, 2012, 20, 1749-1759.	1.4	18
92	Discovery of Small Molecule Inhibitors that Interact with γâ€Tubulin. Chemical Biology and Drug Design, 2012, 79, 639-652.	1.5	33

#	Article	IF	CITATIONS
93	Synthesis of 3-methoxy-9-(3,4,5-trimethoxyphenyl)-6,7-dihydro-5H-benzo[7]annulen-4-ol, a potent antineoplastic benzosuberene derivative for anti-cancer chemotherapy. Tetrahedron Letters, 2012, 53, 64-66.	0.7	11
94	Transcript and metabolite profiling in cell cultures of 18 plant species that produce benzylisoquinoline alkaloids. Phytochemistry, 2012, 77, 79-88.	1.4	50
95	New achievements on biological aspects of copper complexes CasiopeÃnas®: Interaction with DNA and proteins and anti-Trypanosoma cruzi activity. Journal of Inorganic Biochemistry, 2012, 109, 49-56.	1.5	48
96	Expression of βâ€ŧubulin isotypes in classical Hodgkin's lymphoma. Pathology International, 2012, 62, 287-290.	0.6	5
97	The Tubulin Colchicine Domain: a Molecular Modeling Perspective. ChemMedChem, 2012, 7, 33-42.	1.6	138
98	Determination of the optimal tubulin isotype target as a method for the development of individualized cancer chemotherapy. Theoretical Biology and Medical Modelling, 2013, 10, 29.	2.1	14
99	Mechanism of mitotic arrest induced by dolastatin 15 involves loss of tension across kinetochore pairs. Molecular and Cellular Biochemistry, 2013, 382, 93-102.	1.4	13
100	Synthesis and evaluation of diaryl sulfides and diaryl selenide compounds for antitubulin and cytotoxic activity. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 4669-4673.	1.0	67
101	<i>cis</i> -Restricted 3-Aminopyrazole Analogues of Combretastatins: Synthesis from Plant Polyalkoxybenzenes and Biological Evaluation in the Cytotoxicity and Phenotypic Sea Urchin Embryo Assays. Journal of Natural Products, 2013, 76, 1485-1491.	1.5	37
102	CXI-benzo-84 reversibly binds to tubulin at colchicine site and induces apoptosis in cancer cells. Biochemical Pharmacology, 2013, 86, 378-391.	2.0	45
103	Rearrangement of microtubule network under biochemical and mechanical stimulations. Methods, 2013, 60, 195-201.	1.9	14
104	A new assay for measuring chromosome instability (CIN) and identification of drugs that elevate CIN in cancer cells. BMC Cancer, 2013, 13, 252.	1.1	34
105	N-Aryl-6-methoxy-1,2,3,4-tetrahydroquinolines: A novel class of antitumor agents targeting the colchicine site on tubulin. European Journal of Medicinal Chemistry, 2013, 67, 196-207.	2.6	49
106	Analgesic and anti-inflammatory activity of podophyllotoxin derivatives. Pharmaceutical Biology, 2013, 51, 566-572.	1.3	21
107	Induction of Cell Cycle Arrest and Apoptosis in Human Osteosarcoma U-2 OS Cells by <i>Solanum lyratum</i> Extracts. Nutrition and Cancer, 2013, 65, 469-479.	0.9	18
108	TR-644 a novel potent tubulin binding agent induces impairment of endothelial cells function and inhibits angiogenesis. Angiogenesis, 2013, 16, 647-662.	3.7	33
109	Structure–Activity Relationship and in Vitro and in Vivo Evaluation of the Potent Cytotoxic Anti-microtubule Agent <i>N</i> -(4-Methoxyphenyl)- <i>N</i> ,2,6-trimethyl-6,7-dihydro-5 <i>H</i> -cyclopenta[<i>d</i>]pyrimidin-4-aminiu Chloride and Its Analogues As Antitumor Agents. Journal of Medicinal Chemistry, 2013, 56, 6829-6844.	2.9 Im	24
110	(4-Methoxyphenyl)(3,4,5-trimethoxyphenyl)methanone inhibits tubulin polymerization, induces G2/M arrest, and triggers apoptosis in human leukemia HL-60 cells. Toxicology and Applied Pharmacology, 2013, 272, 117-126.	1.3	26

#	Article	IF	CITATIONS
111	Identification of tubulin beta chain, thymosin beta-4-like protein 3, and cytochrome b–c1 complex subunit 1 as serological diagnostic biomarkers of gastric cancer. Clinical Biochemistry, 2013, 46, 1578-1584.	0.8	15
113	The Bat Flower: A Source of Microtubule-Destabilizing and -Stabilizing Compounds with Synergistic Antiproliferative Actions. Journal of Natural Products, 2013, 76, 1923-1929.	1.5	20
114	Furanylazaindoles: Potent Anticancer Agents in Vitro and in Vivo. Journal of Medicinal Chemistry, 2013, 56, 8008-8018.	2.9	40
115	Concise Synthesis and Biological Evaluation of 2-Aroyl-5-Amino Benzo[<i>b</i>]thiophene Derivatives As a Novel Class of Potent Antimitotic Agents. Journal of Medicinal Chemistry, 2013, 56, 9296-9309.	2.9	44
116	Synthesis and Biological Evaluation of Aryloxazole Derivatives as Antimitotic and Vascular-Disrupting Agents for Cancer Therapy. Journal of Medicinal Chemistry, 2013, 56, 9008-9018.	2.9	40
117	Conformational Preferences of Zampanolide and Dactylolide. Organic Letters, 2013, 15, 5246-5249.	2.4	16
118	Synthesis of N4-(substituted phenyl)-N4-alkyl/desalkyl-9H-pyrimido[4,5-b]indole-2,4-diamines and identification of new microtubule disrupting compounds that are effective against multidrug resistant cells. Bioorganic and Medicinal Chemistry, 2013, 21, 891-902.	1.4	14
119	Enantioselective Effects of (+)- and (â``)-Citronellal on Animal and Plant Microtubules. Journal of Natural Products, 2013, 76, 1598-1604.	1.5	10
120	How to Deal with Low-Resolution Target Structures: Using SAR, Ensemble Docking, Hydropathic Analysis, and 3D-QSAR to Definitively Map the αβ-Tubulin Colchicine Site. Journal of Medicinal Chemistry, 2013, 56, 7382-7395.	2.9	37
121	Growth of confined cancer spheroids: a combined experimental and mathematical modelling approach. Integrative Biology (United Kingdom), 2013, 5, 597.	0.6	52
122	Paclitaxel resistance by random mutagenesis of αâ€ŧubulin. Cytoskeleton, 2013, 70, 849-862.	1.0	18
123	AMG 900, a Small-Molecule Inhibitor of Aurora Kinases, Potentiates the Activity of Microtubule-Targeting Agents in Human Metastatic Breast Cancer Models. Molecular Cancer Therapeutics, 2013, 12, 2356-2366.	1.9	42
124	Developing novel C-4 analogues of pyrrole-based antitubulin agents: weak but critical hydrogen bonding in the colchicine site. MedChemComm, 2013, 4, 417.	3.5	17
125	On the synthesis and biological properties of isocombretastatins: a case of ketone homologation during Wittig reaction attempts. RSC Advances, 2013, 3, 3683.	1.7	6
126	Synthesis and biological evaluation of N-alkyl-N-(4-methoxyphenyl)pyridin-2-amines as a new class of tubulin polymerization inhibitors. Bioorganic and Medicinal Chemistry, 2013, 21, 632-642.	1.4	23
127	Molecular Mechanism of Action of Microtubule-Stabilizing Anticancer Agents. Science, 2013, 339, 587-590.	6.0	436
128	Kinase–Kinase Interaction and Modulation of Tau Phosphorylation. International Review of Cell and Molecular Biology, 2013, 300, 121-160.	1.6	33
129	Aberrant expression of the neuronal-specific protein DCDC2 promotes malignant phenotypes and is associated with prostate cancer progression. Oncogene, 2013, 32, 2315-2324.	2.6	21

#	Article	IF	CITATIONS
130	Functional genomic analysis of chromosomal aberrations in a compendium of 8000 cancer genomes. Genome Research, 2013, 23, 217-227.	2.4	139
131	Synthesis of (Z) isomers of benzoheterocyclic derivatives of combretastatin A-4: a comparative study of several methods. Tetrahedron, 2013, 69, 2336-2347.	1.0	17
132	Synthesis and anticancer activity of analogues of phenstatin, with a phenothiazine A-ring, as a new class of microtubule-targeting agents. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 147-152.	1.0	32
133	Inhibition of Microtubule Assembly by a Complex of Actin and Antitumor Macrolide Aplyronine A. Journal of the American Chemical Society, 2013, 135, 18089-18095.	6.6	54
134	TW01001, a novel piperazinedione compound, induces mitotic arrest and autophagy in non-small cell lung cancer A549 cells. Cancer Letters, 2013, 336, 370-378.	3.2	12
135	The microtubule binding drug EM011 inhibits the growth of paediatric low grade gliomas. Cancer Letters, 2013, 335, 109-118.	3.2	6
136	Interference of a novel indolylmaleimide with microtubules induces mitotic arrest and apoptosis in human progenitor and cancer cells. Biochemical Pharmacology, 2013, 85, 763-771.	2.0	11
137	Synthesis and Biological Evaluation of 2-(Alkoxycarbonyl)-3-Anilinobenzo[<i>b</i>]thiophenes and Thieno[2,3- <i>b</i>]pyridines as New Potent Anticancer Agents. Journal of Medicinal Chemistry, 2013, 56, 2606-2618.	2.9	80
138	Design, synthesis, biological evaluation and molecular modeling studies of 1-aryl-6-(3,4,5-trimethoxyphenyl)-3(Z)-hexen-1,5-diynes as a new class of potent antitumor agents. European Journal of Medicinal Chemistry, 2013, 62, 526-533.	2.6	3
139	Synthesis of combretastatin A4 analogues on steroidal framework and their anti-breast cancer activity. Journal of Steroid Biochemistry and Molecular Biology, 2013, 137, 332-344.	1.2	29
140	Use of Epothilone B (Patupilone) in Refractory Lymphoma and Advanced Solid Tumors in Dogs. Journal of Veterinary Internal Medicine, 2013, 27, 120-125.	0.6	3
141	Endowing Indole-Based Tubulin Inhibitors with an Anchor for Derivatization: Highly Potent 3-Substituted Indolephenstatins and Indoleisocombretastatins. Journal of Medicinal Chemistry, 2013, 56, 2813-2827.	2.9	62
142	Screening organometallic binuclear thiosemicarbazone ruthenium complexes as potential anti-tumour agents: cytotoxic activity and human serum albumin binding mechanism. Dalton Transactions, 2013, 42, 7131.	1.6	83
143	The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics. Natural Product Reports, 2013, 30, 625.	5.2	93
144	A Synthetic Dolastatin 10 Analogue Suppresses Microtubule Dynamics, Inhibits Cell Proliferation, and Induces Apoptotic Cell Death. Journal of Medicinal Chemistry, 2013, 56, 2235-2245.	2.9	40
145	Synthesis and Evaluation of Biphenyl Compounds as Kinesin Spindle Protein Inhibitors. Chemistry and Biodiversity, 2013, 10, 538-555.	1.0	5
146	Drug onjugated antibodies for the treatment of cancer. British Journal of Clinical Pharmacology, 2013, 76, 248-262.	1.1	126
147	Nek7 kinase accelerates microtubule dynamic instability. Biochimica Et Biophysica Acta - Molecular Cell Research, 2013, 1833, 1104-1113.	1.9	32

		CITATION REPORT	
#	Article	IF	CITATIONS
148	Tubulin: an example of targeted chemotherapy. Future Medicinal Chemistry, 2013, 5, 339-352.	1.1	67
149	The Binding Sites of Microtubule-Stabilizing Agents. Chemistry and Biology, 2013, 20, 301-315.	6.2	106
150	Natural Product Scaffolds in Cancer Therapy. , 2013, , 123-173.		1
151	Cell Survival and Apoptosis Signaling as Therapeutic Target for Cancer: Marine Bioactive Compour International Journal of Molecular Sciences, 2013, 14, 2334-2354.	nds. 1.8	103
152	A Concise Synthesis of Pyrazole Analogues of Combretastatin A1 as Potent Anti‶ubulin Age ChemMedChem, 2013, 8, 633-643.	ents. 1.6	30
153	Design and synthesis of biaryl aryl stilbenes/ethylenes asÂantimicrotubule agents. European Journ Medicinal Chemistry, 2013, 60, 305-324.	al of 2.6	28
154	Synthesis and biological evaluation of fluoro analogues of antimitotic phenstatin. Bioorganic and Medicinal Chemistry, 2013, 21, 2932-2940.	1.4	29
155	Design, Synthesis, and Biological Evaluation of (<i>E</i>)- <i>N</i> -Aryl-2-arylethenesulfonamide Analogues as Potent and Orally Bioavailable Microtubule-Targeted Anticancer Agents. Journal of Medicinal Chemistry, 2013, 56, 5562-5586.	2.9	22
156	MicroRNAs: Novel mediators of resistance to microtubule-targeting agents. Cancer Treatment Reviews, 2013, 39, 161-170.	3.4	40
157	Microtubule stabilising agents and ionising radiation: Multiple exploitable mechanisms for combin treatment. European Journal of Cancer, 2013, 49, 245-253.	ed 1.3	18
158	Chromenes: potential new chemotherapeutic agents for cancer. Future Medicinal Chemistry, 2013 1647-1660.	3, 5, 1.1	138
159	Development of a Novel Class of Tubulin Inhibitors with Promising Anticancer Activities. Molecular Cancer Research, 2013, 11, 856-864.	1.5	37
160	Dissecting Paclitaxel–Microtubule Association: Quantitative Assessment of the 2′-OH Group. Biochemistry, 2013, 52, 2328-2336.	1.2	28
161	Microtubule Dynamics Control Tail Retraction in Migrating Vascular Endothelial Cells. Molecular Cancer Therapeutics, 2013, 12, 2837-2846.	1.9	30
162	Cytoskeletal Alterations that Confer Resistance to Anti-tubulin Chemotherapeutics. Anti-Cancer Agents in Medicinal Chemistry, 2013, 13, 147-158.	0.9	24
163	Antiproliferative effect of benzimidazole anthelmintics albendazole, ricobendazole, and flubendazo in intestinal cancer cell lines. Anti-Cancer Drugs, 2013, 24, 911-919.	ole 0.7	53
164	Targeting mitotic exit with hyperthermia or APC/C inhibition to increase paclitaxel efficacy. Cell Cy 2013, 12, 2598-2607.	rcle, 1.3	43
165	Antibody-Directed Phototherapy (ADP). Antibodies, 2013, 2, 270-305.	1.2	35

#	Article	IF	CITATIONS
166	Hydrogel Microwell Arrays Allow the Assessment of Protease-Associated Enhancement of Cancer Cell Aggregation and Survival. Microarrays (Basel, Switzerland), 2013, 2, 208-227.	1.4	11
167	Trial watch. Oncolmmunology, 2013, 2, e23082.	2.1	130
168	Tubulin Beta Chain, Filamin A Alpha Isoform 1, and Cytochrome b-c1 Complex Subunit 1 As Serological Diagnostic Biomarkers of Esophageal Squamous Cell Carcinoma: A Proteomics Study. OMICS A Journal of Integrative Biology, 2013, 17, 215-223.	1.0	19
169	Tubulinâ€ŧargeting agent combination therapies: dosing schedule could matter. British Journal of Pharmacology, 2013, 168, 1555-1557.	2.7	3
170	Biologyâ€Oriented Synthesis of a Tetrahydroisoquinolineâ€Based Compound Collection Targeting Microtubule Polymerization. ChemBioChem, 2013, 14, 295-300.	1.3	37
171	Reovirus Cell Entry Requires Functional Microtubules. MBio, 2013, 4, .	1.8	59
172	Medicinal Chemistry and Chemical Biology of Diketopiperazine-Type Antimicrotubule and Vascular-Disrupting Agents. Chemical and Pharmaceutical Bulletin, 2013, 61, 889-901.	0.6	30
173	Rational Design, Synthesis, and Biological Evaluation of Third Generation α-Noscapine Analogues as Potent Tubulin Binding Anti-Cancer Agents. PLoS ONE, 2013, 8, e77970.	1.1	54
174	Mitochondria: A Promising Target for Anticancer Alkaloids. Current Topics in Medicinal Chemistry, 2013, 13, 2171-2183.	1.0	34
175	Conventional Cancer Treatment. , 2013, , .		6
175 176	Conventional Cancer Treatment. , 2013, , . Microtubule inhibitor-based antibody–drug conjugates for cancer therapy. OncoTargets and Therapy, 2014, 7, 2227.	1.0	6 36
	Microtubule inhibitor-based antibody–drug conjugates for cancer therapy. OncoTargets	1.0	
176	Microtubule inhibitor-based antibody–drug conjugates for cancer therapy. OncoTargets and Therapy, 2014, 7, 2227. The NFL-TBS.40-63 Anti-Glioblastoma Peptide Disrupts Microtubule and Mitochondrial Networks in the		36
176 177	Microtubule inhibitor-based antibody–drug conjugates for cancer therapy. OncoTargets and Therapy, 2014, 7, 2227. The NFL-TBS.40-63 Anti-Clioblastoma Peptide Disrupts Microtubule and Mitochondrial Networks in the T98G Glioma Cell Line. PLoS ONE, 2014, 9, e98473. The Actin Targeting Compound Chondramide Inhibits Breast Cancer Metastasis via Reduction of	1.1	36 9
176 177 178	Microtubule inhibitor-based antibody–drug conjugates for cancer therapy. OncoTargets and Therapy, 2014, 7, 2227. The NFL-TBS.40-63 Anti-Glioblastoma Peptide Disrupts Microtubule and Mitochondrial Networks in the T98G Glioma Cell Line. PLoS ONE, 2014, 9, e98473. The Actin Targeting Compound Chondramide Inhibits Breast Cancer Metastasis via Reduction of Cellular Contractility. PLoS ONE, 2014, 9, e112542.	1.1	36 9 26
176 177 178 179	Microtubule inhibitor-based antibody–drug conjugates for cancer therapy. OncoTargets and Therapy, 2014, 7, 2227. The NFL-TBS.40-63 Anti-Clioblastoma Peptide Disrupts Microtubule and Mitochondrial Networks in the T98G Clioma Cell Line. PLoS ONE, 2014, 9, e98473. The Actin Targeting Compound Chondramide Inhibits Breast Cancer Metastasis via Reduction of Cellular Contractility. PLoS ONE, 2014, 9, e112542. Conjugates of Small Molecule Drugs with Antibodies and Other Proteins. Biomedicines, 2014, 2, 1-13.	1.1	36 9 26 26
176 177 178 179 180	 Microtubule inhibitor-based antibody&ndash;drug conjugates for cancer therapy. OncoTargets and Therapy, 2014, 7, 2227. The NFL-TBS.40-63 Anti-Clioblastoma Peptide Disrupts Microtubule and Mitochondrial Networks in the T98G Glioma Cell Line. PLoS ONE, 2014, 9, e98473. The Actin Targeting Compound Chondramide Inhibits Breast Cancer Metastasis via Reduction of Cellular Contractility. PLoS ONE, 2014, 9, e112542. Conjugates of Small Molecule Drugs with Antibodies and Other Proteins. Biomedicines, 2014, 2, 1-13. New Perspectives in Cancer Therapy: The Biotin-Antitumor Molecule Conjugates. , 2014, S, . Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma. 	1.1 1.1 1.4	36 9 26 25

#	Article	IF	CITATIONS
184	A novel synthetic 1,3-phenyl bis-thiourea compound targets microtubule polymerization to cause cancer cell death. Cancer Biology and Therapy, 2014, 15, 895-905.	1.5	25
185	Orally active microtubule-targeting agent, MPT0B271, for the treatment of human non-small cell lung cancer, alone and in combination with erlotinib. Cell Death and Disease, 2014, 5, e1162-e1162.	2.7	18
186	In Search of the Active Metabolites of an Anticancer Piperazinedione, TW01003, in Rats. BioMed Research International, 2014, 2014, 1-6.	0.9	1
187	Inorganic nanoparticles as tubulin binding agents for cancer therapy. Nanomedicine, 2014, 9, 2075-2077.	1.7	5
188	Identification of DW532 as a novel anti-tumor agent targeting both kinases and tubulin. Acta Pharmacologica Sinica, 2014, 35, 916-928.	2.8	22
189	Novel 9′-substituted-noscapines: Synthesis with Suzuki cross-coupling, structure elucidation and biological evaluation. European Journal of Medicinal Chemistry, 2014, 84, 476-490.	2.6	17
190	Centmitor-1, a Novel Acridinyl-Acetohydrazide, Possesses Similar Molecular Interaction Field and Antimitotic Cellular Phenotype as Rigosertib, ON 01910.Na. Molecular Cancer Therapeutics, 2014, 13, 1054-1066.	1.9	6
191	Metronomic Chemotherapy Regimens Using Microtubule-Targeting Agents: Mechanisms of Action, Preclinical Activity and Future Developments. , 2014, , 69-90.		0
192	Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel. Clinical Cancer Research, 2014, 20, 2466-2475.	3.2	91
193	The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents. Bioorganic and Medicinal Chemistry, 2014, 22, 3753-3772.	1.4	38
194	Plant-derived vascular disrupting agents: compounds, actions, and clinical trials. Phytochemistry Reviews, 2014, 13, 191-206.	3.1	25
195	The paradox of paclitaxel neurotoxicity: Mechanisms and unanswered questions. Neuropharmacology, 2014, 76, 175-183.	2.0	185
196	Hemiasterlin analogues incorporating an aromatic, and heterocyclic type C-terminus: design, synthesis and biological evaluation. Molecular Diversity, 2014, 18, 357-373.	2.1	7
197	Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy. Angewandte Chemie - International Edition, 2014, 53, 3796-3827.	7.2	779
199	Thymoquinone inhibits microtubule polymerization by tubulin binding and causes mitotic arrest following apoptosis in A549 cells. Biochimie, 2014, 97, 78-91.	1.3	38
200	Podoverine A—a novel microtubule destabilizing natural product from the Podophyllum species. Bioorganic and Medicinal Chemistry, 2014, 22, 5110-5116.	1.4	5
201	Movers and shakers: cell cytoskeleton in cancer metastasis. British Journal of Pharmacology, 2014, 171, 5507-5523.	2.7	453
202	In Situ Imaging in C.Âelegans Reveals Developmental Regulation of Microtubule Dynamics. Developmental Cell, 2014, 29, 203-216.	3.1	34

	Сітат	ION REPORT	
#	Article	IF	Citations
203	Mitotic spindle multipolarity without centrosome amplification. Nature Cell Biology, 2014, 16, 386-394.	4.6	134
204	Interphase microtubules: chief casualties in the war on cancer?. Drug Discovery Today, 2014, 19, 824-829.	3.2	34
205	Microtubule drugs: action, selectivity, and resistance across the kingdoms of life. Protoplasma, 2014, 251, 991-1005.	1.0	40
206	Structural Basis of Microtubule Stabilization by Laulimalide and Pelorusideâ€A. Angewandte Chemie - International Edition, 2014, 53, 1621-1625.	7.2	154
207	Diversity-oriented synthesis as a tool for identifying new modulators of mitosis. Nature Communications, 2014, 5, 3155.	5.8	73
208	Recent progress with microtubule stabilizers: new compounds, binding modes and cellular activities. Natural Product Reports, 2014, 31, 335-355.	5.2	119
209	3-(5-)-Amino-o-diarylisoxazoles: Regioselective synthesis and antitubulin activity. European Journal of Medicinal Chemistry, 2014, 73, 112-125.	2.6	17
210	Design, synthesis and biological evaluation of 3,5-disubstituted 2-amino thiophene derivatives as a novel class of antitumor agents. Bioorganic and Medicinal Chemistry, 2014, 22, 5097-5109.	1.4	40
211	Differential Induction of Cytoplasmic Vacuolization and Methuosis by Novel 2-Indolyl-Substituted Pyridinylpropenones. ACS Medicinal Chemistry Letters, 2014, 5, 73-77.	1.3	37
212	Diaryl-substituted ortho-carboranes as a new class of hypoxia inducible factor-1α inhibitors. Dalton Transactions, 2014, 43, 4941-4944.	1.6	19
213	4′-Demethyl-deoxypodophyllotoxin glucoside isolated from Podophyllum hexandrum exhibits potential anticancer activities by altering Chk-2 signaling pathway in MCF-7 breast cancer cells. Chemico-Biological Interactions, 2014, 224, 100-107.	1.7	35
214	Characterizing the laulimalide–peloruside binding site using site-directed mutagenesis of TUB2 in S. cerevisiae. Molecular BioSystems, 2014, 10, 110-116.	2.9	2
215	Synthesis, Molecular Editing, and Biological Assessment of the Potent Cytotoxin Leiodermatolide. Journal of the American Chemical Society, 2014, 136, 15719-15729.	6.6	86
216	Proteomics of Cancer Cell Lines Resistant to Microtubule-Stabilizing Agents. Molecular Cancer Therapeutics, 2014, 13, 260-269.	1.9	18
217	Mechanical Aspects of Microtubule Bundling in Taxane-Treated Circulating Tumor Cells. Biophysical Journal, 2014, 107, 1236-1246.	0.2	9
218	Discovery of Antitubulin Agents with Antiangiogenic Activity as Single Entities with Multitarget Chemotherapy Potential. ACS Medicinal Chemistry Letters, 2014, 5, 480-484.	1.3	32
219	Synthesis and structure–activity relationship of 4-azaheterocycle benzenesulfonamide derivatives as new microtubule-targeting agents. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 5055-5058.	1.0	19
220	Synthesis and antiproliferative activity of 6-phenylaminopurines. European Journal of Medicinal Chemistry, 2014, 87, 421-428.	2.6	8

#	Article	IF	CITATIONS
221	Tivantinib (ARQ 197) Exhibits Antitumor Activity by Directly Interacting with Tubulin and Overcomes ABC Transporter–Mediated Drug Resistance. Molecular Cancer Therapeutics, 2014, 13, 2978-2990.	1.9	57
222	Synthesis and biological evaluation of novel 3,4-diaryl-1,2,5-selenadiazol analogues of combretastatin A-4. European Journal of Medicinal Chemistry, 2014, 87, 1-9.	2.6	48
223	Novel third-generation water-soluble noscapine analogs as superior microtubule-interfering agents with enhanced antiproliferative activity. Biochemical Pharmacology, 2014, 92, 192-205.	2.0	19
224	Development of a New Benzophenone–Diketopiperazine-Type Potent Antimicrotubule Agent Possessing a 2-Pyridine Structure. ACS Medicinal Chemistry Letters, 2014, 5, 1094-1098.	1.3	33
225	The Quest for a Simple Bioactive Analog of Paclitaxel as a Potential Anticancer Agent. Accounts of Chemical Research, 2014, 47, 2682-2691.	7.6	33
226	Discovery of Potent Cytotoxic Ortho-Aryl Chalcones as New Scaffold Targeting Tubulin and Mitosis with Affinity-Based Fluorescence. Journal of Medicinal Chemistry, 2014, 57, 6364-6382.	2.9	46
227	Hypoxiaâ€inducible factorâ€2α (HIFâ€2α), but not HIFâ€1α, is essential for hypoxic induction of class III βâ€ŧub expression in human glioblastoma cells. FEBS Journal, 2014, 281, 5220-5236.	ulin 2:2	31
229	Synthesis, Antimitotic and Antivascular Activity of 1-(3′,4′,5′-Trimethoxybenzoyl)-3-arylamino-5-amino-1,2,4-triazoles. Journal of Medicinal Chemistry, 2014, 6795-6808.	5279	52
230	Synthesis, biological evaluation, and molecular docking studies of novel chalcone oxime derivatives as potential tubulin polymerization inhibitors. RSC Advances, 2014, 4, 32263-32275.	1.7	11
231	A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 13817-13821.	3.3	229
232	Comparative in vivo evaluation of polyalkoxy substituted 4H-chromenes and oxa-podophyllotoxins as microtubule destabilizing agents in the phenotypic sea urchin embryo assay. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 3914-3918.	1.0	17
233	High Content Screening of Diverse Compound Libraries Identifies Potent Modulators of Tubulin Dynamics. ACS Medicinal Chemistry Letters, 2014, 5, 598-603.	1.3	15
234	Optimization of 4-(<i>N</i> -Cycloamino)phenylquinazolines as a Novel Class of Tubulin-Polymerization Inhibitors Targeting the Colchicine Site. Journal of Medicinal Chemistry, 2014, 57, 1390-1402.	2.9	60
235	Synthesis of Indoleâ€Derived Allocolchicine Congeners through Pd atalyzed Intramolecular Câ€H Arylation Reaction. European Journal of Organic Chemistry, 2014, 2014, 6481-6492.	1.2	20
236	Drug-induced amplification of nanoparticle targeting to tumors. Nano Today, 2014, 9, 550-559.	6.2	22
237	New benzimidazole-2-urea derivates as tubulin inhibitors. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 4250-4253.	1.0	38
238	The convenient aqueous synthesis and biological evaluation of ortho-(3,4,5-trimethoxybenzoyl)-acetanilides as novel anti-cancer agents. RSC Advances, 2014, 4, 41510-41520.	1.7	5
240	End-binding protein 1 stimulates paclitaxel sensitivity in breast cancer by promoting its actions toward microtubule assembly and stability. Protein and Cell, 2014, 5, 469-479.	4.8	28

#	Article	IF	CITATIONS
241	MicroRNA-452 contributes to the docetaxel resistance of breast cancer cells. Tumor Biology, 2014, 35, 6327-6334.	0.8	27
242	Identification alpha-2-HS-glycoprotein precursor and tubulin beta chain as serology diagnosis biomarker of colorectal cancer. Diagnostic Pathology, 2014, 9, 53.	0.9	30
243	Antiproliferative Mechanism of Action of the Novel Taxane Cabazitaxel as Compared with the Parent Compound Docetaxel in MCF7 Breast Cancer Cells. Molecular Cancer Therapeutics, 2014, 13, 2092-2103.	1.9	68
244	A prospective study of biomarker-guided chemotherapy in patients with non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2014, 74, 839-846.	1.1	16
245	Synthesis and Biological Evaluation of Novel Millepachine Derivatives As a New Class of Tubulin Polymerization Inhibitors. Journal of Medicinal Chemistry, 2014, 57, 7977-7989.	2.9	52
246	Zampanolide and dactylolide: cytotoxic tubulin-assembly agents and promising anticancer leads. Natural Product Reports, 2014, 31, 1202-1226.	5.2	36
247	Synthesis and biological evaluation of cinnamido linked benzophenone hybrids as tubulin polymerization inhibitors and apoptosis inducing agents. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 2309-2314.	1.0	17
248	Microtubule-targeting agents are clinically successful due to both mitotic and interphase impairment of microtubule function. Bioorganic and Medicinal Chemistry, 2014, 22, 5050-5059.	1.4	204
249	Pharmacological characterization of actin-binding (â^')-Doliculide. Bioorganic and Medicinal Chemistry, 2014, 22, 5117-5122.	1.4	14
250	The Role of Src in Colon Cancer and Its Therapeutic Implications. Clinical Colorectal Cancer, 2014, 13, 5-13.	1.0	106
251	Pretubulysin: a new option for the treatment of metastatic cancer. Cell Death and Disease, 2014, 5, e1001-e1001.	2.7	30
252	High-Resolution Microtubule Structures Reveal the Structural Transitions in αβ-Tubulin upon GTP Hydrolysis. Cell, 2014, 157, 1117-1129.	13.5	582
253	Small Molecule Modulators of Protein–Protein Interactions: Selected Case Studies. Chemical Reviews, 2014, 114, 4640-4694.	23.0	71
254	Combretastatin Aâ€4 induces p53 mitochondrialâ€relocalisation independentâ€apoptosis in nonâ€small lung cancer cells. Cell Biology International, 2014, 38, 296-308.	1.4	13
255	Tubulin inhibitors: a patent review. Expert Opinion on Therapeutic Patents, 2014, 24, 69-88.	2.4	78
256	Design, synthesis and biological evaluation of (E)-3-(3,4-dihydroxyphenyl)acrylylpiperazine derivatives as a new class of tubulin polymerization inhibitors. Bioorganic and Medicinal Chemistry, 2014, 22, 4285-4292.	1.4	11
257	SB-RA-2001 Inhibits Bacterial Proliferation by Targeting FtsZ Assembly. Biochemistry, 2014, 53, 2979-2992.	1.2	35
258	Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Science, 2014, 105, 1334-1342.	1.7	206

		CITATION REPORT		
#	Article		IF	Citations
264	Antibody–drug conjugates as novel anti-cancer chemotherapeutics. Bioscience Repo	orts, 2015, 35, .	1.1	327
265	Identification of flubendazole as potential anti-neuroblastoma compound in a large cel Scientific Reports, 2015, 5, 8202.	l line screen.	1.6	68
266	A novel microtubule de-stabilizing complementarity-determining region C36L1 peptide antitumor activity against melanoma in vitro and in vivo. Scientific Reports, 2015, 5, 1		1.6	30
267	Elucidating the Mechanism of Action of the Clinically Approved Taxanes: A Comprehen of Local and Allosteric Effects. Chemical Biology and Drug Design, 2015, 86, 1253-126	sive Comparison 6.	1.5	22
268	<scp>BT</scp> â€benzoâ€29 inhibits bacterial cell proliferation by perturbing FtsZ ass 2015, 282, 4015-4033.	embly. FEBS Journal,	2.2	21
269	Medicinal Plants: A Potential Source of Compounds for Targeting Cell Division. Drug Ta 2015, 9, DTI.S24946.	arget Insights,	0.9	22
270	Positional Scanning Synthesis of a Peptoid Library Yields New Inducers of Apoptosis th Karyopherins and Tubulin. ChemBioChem, 2015, 16, 1580-1587.	at Target	1.3	10
271	Optochemistry to control the microtubuleÂcytoskeleton. EMBO Journal, 2015, 34, 21	14-2116.	3.5	4
272	miR-130a activates apoptotic signaling through activation of caspase-8 in taxane-resis cancer cells. Prostate, 2015, 75, 1568-1578.	tant prostate	1.2	38
273	Design, Synthesis and Molecular Docking Studies of Novel Indole–Pyrimidine Hybrid Polymerization Inhibitors. Chemical Biology and Drug Design, 2015, 86, 1491-1500.	s as Tubulin	1.5	35
274	Drug Targets for Cancer Treatment: An Overview. , 2015, 5, .			60
275	Diverse Molecular Targets for Chalcones with Varied Bioactivities. , 2015, 5, 388-404.			72
276	Mitochondrial Dysfunction in Chemotherapy-Induced Peripheral Neuropathy (CIPN). To 198-223.	oxics, 2015, 3,	1.6	143
277	The application of click chemistry in the synthesis of agents with anticancer activity. D Development and Therapy, 2015, 9, 1585.	rug Design,	2.0	33
278	High-Affinity Accumulation of a Maytansinoid in Cells via Weak Tubulin Interaction. PLe e0117523.	oS ONE, 2015, 10,	1.1	14
279	HYS-32-Induced Microtubule Catastrophes in Rat Astrocytes Involves the PI3K-GSK3be Pathway. PLoS ONE, 2015, 10, e0126217.	ta Signaling	1.1	7
280	Detailed Per-residue Energetic Analysis Explains the Driving Force for Microtubule Disa Computational Biology, 2015, 11, e1004313.	ssembly. PLoS	1.5	22
281	Synthesis and Biological Evaluation of 3-Alkyl-1,5-Diaryl-1H-Pyrazoles as Rigid Analogue Combretastatin A-4 with Potent Antiproliferative Activity. PLoS ONE, 2015, 10, e0128		1.1	16

#	Article	IF	CITATIONS
282	KPU-300, a Novel Benzophenone–Diketopiperazine–Type Anti-Microtubule Agent with a 2-Pyridyl Structure, Is a Potent Radiosensitizer That Synchronizes the Cell Cycle in Early M Phase. PLoS ONE, 2015, 10, e0145995.	1.1	6
283	Stabilizing versus Destabilizing the Microtubules: A Double-Edge Sword for an Effective Cancer Treatment Option?. Analytical Cellular Pathology, 2015, 2015, 1-19.	0.7	80
284	Cytotoxic Activity and Chemical Composition of the Root Extract from the Mexican Species <i>Linum scabrellum</i> : Mechanism of Action of the Active Compound 6-Methoxypodophyllotoxin. Evidence-based Complementary and Alternative Medicine, 2015, 2015, 1-11.	0.5	10
286	The design, synthesis, in vitro biological evaluation and molecular modeling of novel benzenesulfonate derivatives bearing chalcone moieties as potent anti-microtubulin polymerization agents. RSC Advances, 2015, 5, 23767-23777.	1.7	14
287	Development of a Novel Class of Tubulin Inhibitor from Desmosdumotin B with a Hydroxylated Bicyclic B-Ring. Journal of Medicinal Chemistry, 2015, 58, 2378-2389.	2.9	60
288	Emerging Microtubule Targets in Glioma Therapy. Seminars in Pediatric Neurology, 2015, 22, 49-72.	1.0	36
289	Recent Progress in The Synthetic Study of an Antitumor Marine Macrolide Aplyronine A and Related Molecules. Heterocycles, 2015, 91, 1137.	0.4	9
290	Heteroaromatic analogs of the resveratrol analog DMU-212 as potent anti-cancer agents. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 2763-2767.	1.0	18
291	Structural findings of phenylindoles as cytotoxic antimitotic agents in human breast cancer cell lines through multiple validated QSAR studies. Toxicology in Vitro, 2015, 29, 1392-1404.	1.1	32
292	ABC Transporter Modulatory Drugs from Marine Sources: A New Approach to Overcome Drug Resistance in Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 183-208.	0.1	2
293	Selected hybrid natural products as tubulin modulators. European Journal of Medicinal Chemistry, 2015, 94, 497-508.	2.6	16
294	Structures of potent anticancer compounds bound to tubulin. Protein Science, 2015, 24, 1164-1172.	3.1	20
295	Control of microtubule organization and dynamics: two ends in the limelight. Nature Reviews Molecular Cell Biology, 2015, 16, 711-726.	16.1	733
296	Synthesis and antitumor activity of 7-(triazol-1-yl)pyrroloallocolchicine derivatives. Russian Chemical Bulletin, 2015, 64, 1362-1368.	0.4	5
297	Antimitotic drugs in the treatment of cancer. Cancer Chemotherapy and Pharmacology, 2015, 76, 1101-1112.	1.1	147
298	Wogonin induces apoptosis and endoplasmic reticulum stress in HL-60 leukemia cells through inhibition of the PI3K-AKT signaling pathway. Oncology Reports, 2015, 33, 3146-3154.	1.2	37
299	Enhanced Efficacy of Pluronic Copolymer Micelle Encapsulated SCR7 against Cancer Cell Proliferation. Macromolecular Bioscience, 2015, 15, 521-534.	2.1	29
300	Microtubule Minus-End-Targeting Proteins. Current Biology, 2015, 25, R162-R171.	1.8	172

#	Article	IF	CITATIONS
301	Application of an ultra-performance liquid chromatography method with tandem mass spectrometry to pharmacokinetics, tissue distribution and excretion in the study of DAT-230, a novel tubulin-binding agent candidate, in rats. Journal of Pharmaceutical and Biomedical Analysis, 2015, 110, 49-57.	1.4	1
302	Role of tumor hypoxia in acquisition of resistance to microtubule-stabilizing drugs. Biochimica Et Biophysica Acta: Reviews on Cancer, 2015, 1855, 172-182.	3.3	15
303	Anticancer Drugs and Potential Anticancer Leads Inspired by Natural Products. Studies in Natural Products Chemistry, 2015, 44, 251-307.	0.8	11
304	Sep(t)arate or not – how some cells take septin-independent routes through cytokinesis. Journal of Cell Science, 2015, 128, 1877-1886.	1.2	41
305	Targeting the hallmarks of cancer with therapy-induced endoplasmic reticulum (ER) stress. Molecular and Cellular Oncology, 2015, 2, e975089.	0.3	58
306	Understanding the structural basis for controlling chromosome division. Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences, 2015, 373, 20130392.	1.6	10
307	The Unique Binding Mode of Laulimalide to Two Tubulin Protofilaments. Chemical Biology and Drug Design, 2015, 86, 190-199.	1.5	27
308	Formal total synthesis of (±)-rhazinal and its B-ring carbamate analogue. Tetrahedron, 2015, 71, 1276-1282.	1.0	13
309	3-(3-Hydroxy-4-methoxyphenyl)-4-(3,4,5-trimethoxyphenyl)-1,2,5-selenadiazole (G-1103), a novel combretastatin A-4 analog, induces G2/M arrest and apoptosis by disrupting tubulin polymerization in human cervical HeLa cells and fibrosarcoma HT-1080 cells. Chemico-Biological Interactions, 2015, 227, 7-17.	1.7	26
310	Synthesis of arylpyrazole linked benzimidazole conjugates as potential microtubule disruptors. Bioorganic and Medicinal Chemistry, 2015, 23, 1082-1095.	1.4	40
311	Biological targets and mechanisms of action of natural products from marine cyanobacteria. Natural Product Reports, 2015, 32, 478-503.	5.2	133
312	Design, synthesis and biological evaluation of novel pyrazoline-containing derivatives as potential tubulin assembling inhibitors. European Journal of Medicinal Chemistry, 2015, 94, 447-457.	2.6	50
313	Combined Molecular Docking, 3Dâ€≺scp>QSAR, and Pharmacophore Model: Design of Novel Tubulin Polymerization Inhibitors by Binding to Colchicineâ€binding Site. Chemical Biology and Drug Design, 2015, 86, 731-745.	1.5	17
314	Mechanistic Origin of Microtubule Dynamic Instability and Its Modulation by EB Proteins. Cell, 2015, 162, 849-859.	13.5	367
315	Introduction. Seminars in Pediatric Neurology, 2015, 22, 2-4.	1.0	2
316	Exploring the size adaptability of the B ring binding zone of theÂcolchicine site of tubulin with para-nitrogen substituted isocombretastatins. European Journal of Medicinal Chemistry, 2015, 100, 210-222.	2.6	27
317	Diaminothiazoles evade multidrug resistance in cancer cells and xenograft tumour models and develop transient specific resistance: understanding the basis of broad-spectrum versus specific resistance. Carcinogenesis, 2015, 36, 883-893.	1.3	11
318	Novel Anti-TM4SF1 Antibody–Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature. Molecular Cancer Therapeutics, 2015, 14, 1868-1876.	1.9	31

#	Article	IF	CITATIONS
319	βI-tubulin mutations in the laulimalide/peloruside binding site mediate drug sensitivity by altering drug–tubulin interactions and microtubule stability. Cancer Letters, 2015, 365, 251-260.	3.2	15
320	Photoswitchable Inhibitors of Microtubule Dynamics Optically Control Mitosis and Cell Death. Cell, 2015, 162, 403-411.	13.5	317
321	Pharmacokinetic synergy from the taxane extract of Taxus chinensis improves the bioavailability of paclitaxel. Phytomedicine, 2015, 22, 573-578.	2.3	22
322	Total Synthesis of Amphidinolide K, a Macrolide That Stabilizes F-Actin. Journal of Organic Chemistry, 2015, 80, 8511-8519.	1.7	9
323	MYC Is a Major Determinant of Mitotic Cell Fate. Cancer Cell, 2015, 28, 129-140.	7.7	110
324	Optical Control of Microtubule Dynamics in Time and Space. Cell, 2015, 162, 243-245.	13.5	19
325	Antitumor Effects of Sea Hare-Derived Compounds in Cancer. , 2015, , 701-739.		6
326	A short GC rich DNA derived from microbial origin targets tubulin/microtubules and induces apoptotic death of cancer cells. Chemical Communications, 2015, 51, 12024-12027.	2.2	11
327	Large-Scale Chemical Similarity Networks for Target Profiling of Compounds Identified in Cell-Based Chemical Screens. PLoS Computational Biology, 2015, 11, e1004153.	1.5	70
328	The design, synthesis and biological evaluation of conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase and microtubule inhibitors as potential antitumor agents. Bioorganic and Medicinal Chemistry, 2015, 23, 2408-2423.	1.4	32
329	Synthesis and activities towards resistant cancer cells of sulfone and sulfoxide griseofulvin derivatives. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 2078-2081.	1.0	15
330	Modeling the mitotic regulatory network identifies highly efficient anti-cancer drug combinations. Molecular BioSystems, 2015, 11, 497-505.	2.9	2
331	Systemic administration of epothilone B promotes axon regeneration after spinal cord injury. Science, 2015, 348, 347-352.	6.0	364
332	Cytotoxic activity and degradation patterns of structural proteins by corneal isolates of Acanthamoeba spp. Graefe's Archive for Clinical and Experimental Ophthalmology, 2015, 253, 65-75.	1.0	7
333	Design, synthesis and biological evaluation of di-substituted noscapine analogs as potent and microtubule-targeted anticancer agents. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 2133-2140.	1.0	11
334	The antimitotic pyrimido[4,5-c]quinolin-1(2H)-one scaffold: probing substituents at position 3. Medicinal Chemistry Research, 2015, 24, 2604-2611.	1.1	2
335	DNA Methylation of DKK3 Modulates Docetaxel Chemoresistance in Human Nonsmall Cell Lung Cancer Cell. Cancer Biotherapy and Radiopharmaceuticals, 2015, 30, 100-106.	0.7	19
336	Synthesis of a novel polycyclic ring scaffold with antimitotic properties via a selective domino Heck–Suzuki reaction. Chemical Science, 2015, 6, 390-396.	3.7	19

#	Article	IF	CITATIONS
337	De novo branching cascades for structural and functional diversity in small molecules. Nature Communications, 2015, 6, 6516.	5.8	62
338	Synthesis and biological evaluation of 2,3-diarylthiophene analogues of combretastatin A-4. MedChemComm, 2015, 6, 971-976.	3.5	17
339	Tubulin structure-based drug design for the development of novel 4î²-sulfur-substituted podophyllum tubulin inhibitors with anti-tumor activity. Scientific Reports, 2015, 5, 10172.	1.6	17
340	Targeted killing of rhabdomyosarcoma cells by a MAP-based human cytolytic fusion protein. Cancer Letters, 2015, 365, 149-155.	3.2	10
341	The newly synthesized 2-arylnaphthyridin-4-one, CSC-3436, induces apoptosis of non-small cell lung cancer cells by inhibiting tubulin dynamics and activating CDK1. Cancer Chemotherapy and Pharmacology, 2015, 75, 1303-1315.	1.1	15
342	Synthesis and biological evaluation of 5,6,7-trimethoxy-1-benzylidene-3,4-dihydro-naphthalen-2-one as tubulin-polymerization inhibitors. Chinese Chemical Letters, 2015, 26, 607-609.	4.8	5
343	A Chimeric Cetuximab-Functionalized Corona as a Potent Delivery System for Microtubule-Destabilizing Nanocomplexes to Hepatocellular Carcinoma Cells: A Focus on EGFR and Tubulin Intracellular Dynamics. Molecular Pharmaceutics, 2015, 12, 3908-3923.	2.3	10
344	Novel phase I study combining G1 phase, S phase, and G2/M phase cell cycle inhibitors in patients with advanced malignancies. Cell Cycle, 2015, 14, 3434-3440.	1.3	6
345	The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo. Journal of Hematology and Oncology, 2015, 8, 82.	6.9	69
346	Optimization of N-aryl-6-methoxy-1,2,3,4-tetrahydroquinolines as tubulin polymerization inhibitors. Bioorganic and Medicinal Chemistry, 2015, 23, 5740-5747.	1.4	21
347	Dietary flavonoid fisetin binds to β-tubulin and disrupts microtubule dynamics in prostate cancer cells. Cancer Letters, 2015, 367, 173-183.	3.2	56
348	Nitric oxide- and cisplatin-releasing silica nanoparticles for use against non-small cell lung cancer. Journal of Inorganic Biochemistry, 2015, 153, 23-31.	1.5	66
349	Synthesis of indole-derived allocolchicine congeners exhibiting pronounced anti-proliferative and apoptosis-inducing properties. MedChemComm, 2015, 6, 2158-2162.	3.5	16
350	Synthesis and biological evaluation of benzimidazole–oxindole conjugates as microtubule-targeting agents. Bioorganic Chemistry, 2015, 63, 72-84.	2.0	20
351	MicroRNA letâ€7b regulates genomic balance by targeting Aurora B kinase. Molecular Oncology, 2015, 9, 1056-1070.	2.1	21
352	Design and synthesis of pyrazole/isoxazole linked arylcinnamides as tubulin polymerization inhibitors and potential antiproliferative agents. Organic and Biomolecular Chemistry, 2015, 13, 10162-10178.	1.5	17
353	Synthesis, biological evaluation and molecular modeling of 1H-benzo[d]imidazole derivatives as novel anti-tubulin polymerization agents. RSC Advances, 2015, 5, 74425-74437.	1.7	5
354	Hexamethoxylated Monocarbonyl Analogues of Curcumin Cause G2/M Cell Cycle Arrest in NCI-H460 Cells via Michael Acceptor-Dependent Redox Intervention. Journal of Agricultural and Food Chemistry, 2015, 63, 7731-7742.	2.4	33

#	Article	IF	CITATIONS
355	Combined molecular dynamics and continuum solvent approaches (MM-PBSA/GBSA) to predict noscapinoid binding to γ-tubulin dimer. SAR and QSAR in Environmental Research, 2015, 26, 507-519.	1.0	15
356	Formal Synthesis of Premisakinolide A and C(19)–C(32) of Swinholide A via Site-Selective C–H Allylation and Crotylation of Unprotected Diols. Organic Letters, 2015, 17, 4686-4689.	2.4	11
357	A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models. Molecular Cancer Therapeutics, 2015, 14, 2463-2472.	1.9	25
358	Synthesis, Characterization, and Bioactivity of the Photoisomerizable Tubulin Polymerization Inhibitor azo-Combretastatin A4. Organic Letters, 2015, 17, 4546-4549.	2.4	71
359	An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer. Journal of Medicinal Chemistry, 2015, 58, 9309-9333.	2.9	47
360	Transcription factor NF-κB associates with microtubules and stimulates apoptosis in response to suppression of microtubule dynamics in MCF-7 cells. Biochemical Pharmacology, 2015, 93, 277-289.	2.0	35
361	Brazilin Isolated from <i>Caesalpinia sappan</i> Suppresses Nuclear Envelope Reassembly by Inhibiting Barrier-to-Autointegration Factor Phosphorylation. Journal of Pharmacology and Experimental Therapeutics, 2015, 352, 175-184.	1.3	24
362	Marine natural products that interfere with multiple cytoskeletal protein interactions. Natural Product Reports, 2015, 32, 534-542.	5.2	50
363	Microwave-assisted synthesis and biological evaluation of 3,4-diaryl maleic anhydride/N-substituted maleimide derivatives as combretastatin A-4 analogues. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 631-634.	1.0	31
364	Chemotherapy-induced peripheral neuropathy: What do we know about mechanisms?. Neuroscience Letters, 2015, 596, 90-107.	1.0	340
365	Synthesis and structure–activity relationships of pyridinyl-1H-1,2,3-triazolyldihydroisoxazoles as potent inhibitors of tubulin polymerization. European Journal of Medicinal Chemistry, 2015, 90, 603-619.	2.6	33
366	Synthesis and Biological Evaluation of Furanoallocolchicinoids. Journal of Medicinal Chemistry, 2015, 58, 692-704.	2.9	41
367	Synthesis and <scp>SAR</scp> studies of novel 6,7,8â€substituted 4â€substituted benzyloxyquinolinâ€2(1 <scp><i>H</i></scp>)â€one derivatives for anticancer activity. British Journal of Pharmacology, 2015, 172, 1195-1221.	2.7	17
368	Design and synthesis of pyrazole–oxindole conjugates targeting tubulin polymerization as new anticancer agents. European Journal of Medicinal Chemistry, 2015, 92, 501-513.	2.6	86
369	Nanoscale drug delivery for taxanes based on the mechanism of multidrug resistance of cancer. Biotechnology Advances, 2015, 33, 224-241.	6.0	35
370	Taking aim at a dynamic target: Noscapinoids as microtubule-targeted cancer therapeutics. Pharmacological Reports, 2015, 67, 56-62.	1.5	31
371	Effects for Sequential Treatment of siAkt and Paclitaxel on Gastric Cancer Cell Lines. International Journal of Medical Sciences, 2016, 13, 708-716.	1.1	5
372	Pre-clinical evaluation of a novel class of anti-cancer agents, the Pyrrolo-1, 5-benzoxazepines Journal of Cancer, 2016, 7, 2367-2377.	1.2	13

# 373	ARTICLE BubR1 alterations that reinforce mitotic surveillance act against aneuploidy and cancer. ELife, 2016, 5,	IF 2.8	Citations 15
374	Effects of Microtubule Stabilization by Epothilone B Depend on the Type and Age of Neurons. Neural Plasticity, 2016, 2016, 1-12.	1.0	24
375	Activity of Eribulin in a Primary Culture of Well-Differentiated/Dedifferentiated Adipocytic Sarcoma. Molecules, 2016, 21, 1662.	1.7	21
376	Antibody–Drug Conjugates for Cancer Therapy. Biomedicines, 2016, 4, 14.	1.4	77
377	The Interference of Selected Cytotoxic Alkaloids with the Cytoskeleton: An Insight into Their Modes of Action. Molecules, 2016, 21, 906.	1.7	27
378	Novel Natural Product- and Privileged Scaffold-Based Tubulin Inhibitors Targeting the Colchicine Binding Site. Molecules, 2016, 21, 1375.	1.7	58
379	Janus Compounds, 5-Chloro-N4-methyl-N4-aryl-9H-pyrimido[4,5-b]indole-2,4-diamines, Cause Both Microtubule Depolymerizing and Stabilizing Effects. Molecules, 2016, 21, 1661.	1.7	6
380	The Pharmacological Potential of Non-ribosomal Peptides from Marine Sponge and Tunicates. Frontiers in Pharmacology, 2016, 7, 333.	1.6	47
382	Low doses of paclitaxel enhance liver metastasis of breast cancer cells in the mouse model. FEBS Journal, 2016, 283, 2836-2852.	2.2	35
383	Flubendazole induces mitotic catastrophe and senescence in colon cancer cells <i>in vitro</i> . Journal of Pharmacy and Pharmacology, 2016, 68, 208-218.	1.2	35
384	Synthesis, anti-cancer evaluation of benzenesulfonamide derivatives as potent tubulin-targeting agents. European Journal of Medicinal Chemistry, 2016, 122, 488-496.	2.6	28
385	Diversity Oriented Synthesis of Allocolchicinoids with Fluoro and/or Oxygen Substituent(s) on the Câ€Ring from a Single Common Intermediate. European Journal of Organic Chemistry, 2016, 2016, 1562-1576.	1.2	14
386	Recent perspectives of epithelial ovarian carcinoma. Oncology Letters, 2016, 12, 3055-3058.	0.8	22
387	Dynamics of Microtubule Self-Assembly. , 2016, , 36-43.		Ο
388	Structural Determinants of the Dictyostatin Chemotype for Tubulin Binding Affinity and Antitumor Activity Against Taxane- and Epothilone-Resistant Cancer Cells. ACS Omega, 2016, 1, 1192-1204.	1.6	22
389	Delineating the Role of βIV-Tubulins in Pancreatic Cancer: βIVb-Tubulin Inhibition Sensitizes Pancreatic Cancer Cells to Vinca Alkaloids. Neoplasia, 2016, 18, 753-764.	2.3	18
390	CYLD – a deubiquitylase that acts to fine-tune microtubule properties and functions. Journal of Cell Science, 2016, 129, 2289-95.	1.2	26
391	Peloruside A, a microtubule-stabilizing agent, induces aneuploidy in ovarian cancer cells. Investigational New Drugs, 2016, 34, 424-438.	1.2	2

		CITATION RE	PORT	
#	Article		IF	CITATIONS
392	Anti-Microtubule Drugs. Methods in Molecular Biology, 2016, 1413, 403-421.		0.4	133
393	Early investigational tubulin inhibitors as novel cancer therapeutics. Expert Opinion on Investigational Drugs, 2016, 25, 917-936.		1.9	28
394	Design, Synthesis, and Evaluation of in Vitro and in Vivo Anticancer Activity of 4-Substi Coumarins: A Novel Class of Potent Tubulin Polymerization Inhibitors. Journal of Medic Chemistry, 2016, 59, 5721-5739.		2.9	85
395	Design, Synthesis, and Preclinical Evaluation of 4-Substituted-5-methyl-furo[2,3- <i>d<!--<br-->Microtubule Targeting Agents That Are Effective against Multidrug Resistant Cancer Co Medicinal Chemistry, 2016, 59, 5752-5765.</i>		2.9	29
396	Mitosis and mitochondrial priming for apoptosis. Biological Chemistry, 2016, 397, 595	-605.	1.2	10
397	Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy f cancer—a systematic review. Supportive Care in Cancer, 2016, 24, 3633-3650.	for breast	1.0	33
398	A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma. E Drug Safety, 2016, 15, 875-882.	xpert Opinion on	1.0	22
399	Molecular insight into the regulation and function of MCAK. Critical Reviews in Biocher Molecular Biology, 2016, 51, 228-245.	mistry and	2.3	36
400	Design, Synthesis, and Biological Evaluation of 1-Methyl-1,4-dihydroindeno[1,2- <i>cAnalogues as Potential Anticancer Agents Targeting Tubulin Colchicine Binding Site. Jo Medicinal Chemistry, 2016, 59, 5341-5355.</i>	>]pyrazole urnal of	2.9	72
401	[1,2]Oxazolo[5,4- e]isoindoles as promising tubulin polymerization inhibitors. Europe Medicinal Chemistry, 2016, 124, 840-851.	an Journal of	2.6	23
402	The Hidden Conundrum of Phosphoinositide Signaling in Cancer. Trends in Cancer, 202	16, 2, 378-390.	3.8	32
403	A microtubule inhibitor, ABT-751, induces autophagy and delays apoptosis in Huh-7 ce and Applied Pharmacology, 2016, 311, 88-98.	lls. Toxicology	1.3	19
404	Neue Ziele für die Photopharmakologie. Angewandte Chemie, 2016, 128, 11140-11	163.	1.6	105
405	Tools for the rational design of bivalent microtubule-targeting drugs. Biochemical and Research Communications, 2016, 479, 48-53.	Biophysical	1.0	10
406	Indole molecules as inhibitors of tubulin polymerization: potential new anticancer ager (2013–2015). Future Medicinal Chemistry, 2016, 8, 1291-1316.	ıts, an update	1.1	61
407	Cytoskeletal interference – A new mode of action for the anticancer drugs camptoth topotecan. European Journal of Pharmacology, 2016, 789, 265-274.	necin and	1.7	20
408	Structural and Biochemical Characterization of the Interaction of Tubulin with Potent N Analogues of Podophyllotoxin. Journal of Natural Products, 2016, 79, 2113-2121.	Natural	1.5	26
409	Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics. Drug Updates, 2016, 28, 65-81.	Resistance	6.5	147

#	Article	IF	CITATIONS
410	Inhibition of Bcl-xL sensitizes cells to mitotic blockers, but not mitotic drivers. Open Biology, 2016, 6, 160134.	1.5	28
411	Purine-Type Compounds Induce Microtubule Fragmentation and Lung Cancer Cell Death through Interaction with Katanin. Journal of Medicinal Chemistry, 2016, 59, 8521-8534.	2.9	29
412	Subtle Alterations in Microtubule Assembly Dynamics by Br-TMB-Noscapine Strongly Suppress Triple-Negative Breast Cancer Cell Viability Without Mitotic Arrest. ChemistrySelect, 2016, 1, 4313-4319.	0.7	8
413	Leiodermatolide, a novel marine natural product, has potent cytotoxic and antimitotic activity against cancer cells, appears to affect microtubule dynamics, and exhibits antitumor activity. International Journal of Cancer, 2016, 139, 2116-2126.	2.3	28
414	Fluorescent vinblastine probes for live cell imaging. Chemical Communications, 2016, 52, 9953-9956.	2.2	10
416	Emerging Targets in Photopharmacology. Angewandte Chemie - International Edition, 2016, 55, 10978-10999.	7.2	504
417	A general synthesis of arylindoles and (1-arylvinyl)carbazoles via a one-pot reaction from N-tosylhydrazones and 2-nitro-haloarenes and their potential application to colon cancer. Chemical Communications, 2016, 52, 13027-13030.	2.2	40
418	Pironetin reacts covalently with cysteine-316 of α-tubulin to destabilize microtubule. Nature Communications, 2016, 7, 12103.	5.8	83
419	The synthetic diazonamide DZ-2384 has distinct effects on microtubule curvature and dynamics without neurotoxicity. Science Translational Medicine, 2016, 8, 365ra159.	5.8	42
421	A Novel Nitrobenzoate Microtubule Inhibitor that Overcomes Multidrug Resistance Exhibits Antitumor Activity. Scientific Reports, 2016, 6, 31472.	1.6	23
422	Peripheral neuropathy with microtubule inhibitor containing antibody drug conjugates: Challenges and perspectives in translatability from nonclinical toxicology studies to the clinic. Regulatory Toxicology and Pharmacology, 2016, 82, 1-13.	1.3	33
423	Total Synthesis of Swinholide A: An Exposition in Hydrogen-Mediated C–C Bond Formation. Journal of the American Chemical Society, 2016, 138, 14246-14249.	6.6	47
424	Cytoskeletal reorganization and cell death in mitoxantrone-treated lung cancer cells. Acta Histochemica, 2016, 118, 784-796.	0.9	11
425	Gambogic Acid and Its Role in Chronic Diseases. Advances in Experimental Medicine and Biology, 2016, 928, 375-395.	0.8	22
427	Tubulin is a molecular target of the Wnt-activating chemical probe. BMC Biochemistry, 2016, 17, 9.	4.4	13
428	Recent advances of cytotoxic chalconoids targeting tubulin polymerization: Synthesis and biological activity. European Journal of Medicinal Chemistry, 2016, 121, 610-639.	2.6	78
429	Synthesis and biological evaluation of novel indole derivatives containing sulfonamide scaffold as potential tubulin inhibitor. MedChemComm, 2016, 7, 1759-1767.	3.5	15
430	ST-11: A New Brain-Penetrant Microtubule-Destabilizing Agent with Therapeutic Potential for Glioblastoma Multiforme. Molecular Cancer Therapeutics, 2016, 15, 2018-2029.	1.9	22

#	Article	IF	CITATIONS
431	Development of Novel Bis(indolyl)-hydrazide–Hydrazone Derivatives as Potent Microtubule-Targeting Cytotoxic Agents against A549 Lung Cancer Cells. Biochemistry, 2016, 55, 3020-3035.	1.2	50
432	HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naÃ⁻ve, HER2-positive, locally advanced/metastatic breast cancer. BMC Cancer, 2016, 16, 352.	1.1	122
433	N-(2-methyl-indol-1H-5-yl)-1-naphthalenesulfonamide: A novel reversible antimitotic agent inhibiting cancer cell motility. Biochemical Pharmacology, 2016, 115, 28-42.	2.0	7
434	Novel drug design for Chagas disease via targeting Trypanosoma cruzi tubulin: Homology modeling and binding pocket prediction on Trypanosoma cruzi tubulin polymerization inhibition by naphthoquinone derivatives. Bioorganic and Medicinal Chemistry, 2016, 24, 3849-3855.	1.4	16
435	The cytoskeleton as a novel target for treatment of renal fibrosis. , 2016, 166, 1-8.		19
436	Ethyl-2-amino-pyrrole-3-carboxylates are novel potent anticancer agents that affect tubulin polymerization, induce G2/M cell-cycle arrest, and effectively inhibit soft tissue cancer cell growth in vitro. Anti-Cancer Drugs, 2016, 27, 620-634.	0.7	15
437	Visualizing microtubule structural transitions and interactions with associated proteins. Current Opinion in Structural Biology, 2016, 37, 90-96.	2.6	51
438	Biological Characterization of an Improved Pyrrole-Based Colchicine Site Agent Identified through Structure-Based Design. Molecular Pharmacology, 2016, 89, 287-296.	1.0	9
439	Identification of gallic acid based glycoconjugates as a novel tubulin polymerization inhibitors. Organic and Biomolecular Chemistry, 2016, 14, 1338-1358.	1.5	25
440	Structural Insights into the Pharmacophore of Vinca Domain Inhibitors of Microtubules. Molecular Pharmacology, 2016, 89, 233-242.	1.0	61
441	Synthesis and biological evaluation of thiophene and benzo[b]thiophene analogs of combretastatin A-4 and isocombretastatin A-4: A comparison between the linkage positions of the 3,4,5-trimethoxystyrene unit. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 174-180.	1.0	22
442	A three dimensional micropatterned tumor model for breast cancer cell migration studies. Biomaterials, 2016, 81, 72-83.	5.7	114
443	Neoadjuvant Treatment of High-Risk, Clinically Localized Prostate Cancer Prior to Radical Prostatectomy. Current Urology Reports, 2016, 17, 37.	1.0	11
444	Peloruside A: a lead non-taxoid-site microtubule-stabilizing agent with potential activity against cancer, neurodegeneration, and autoimmune disease. Natural Product Reports, 2016, 33, 549-561.	5.2	34
445	Effects of Anticancer Drugs on Chromosome Instability and New Clinical Implications for Tumor-Suppressing Therapies. Cancer Research, 2016, 76, 902-911.	0.4	60
446	In vitro and in vivo biological characterization of the anti-proliferative potential of a cyclic trinuclear organotin(<scp>iv</scp>) complex. Molecular BioSystems, 2016, 12, 1015-1023.	2.9	17
447	New developments for antibody-drug conjugate-based therapeutic approaches. Current Opinion in Immunology, 2016, 40, 14-23.	2.4	225
448	Dynamic and Static Water Molecules Complement the TN16 Conformational Heterogeneity inside the Tubulin Cavity. Biochemistry, 2016, 55, 335-347.	1.2	15

#	Article	IF	CITATIONS
449	Treatment of taxane acute pain syndrome (TAPS) in cancer patients receiving taxane-based chemotherapy—a systematic review. Supportive Care in Cancer, 2016, 24, 1583-1594.	1.0	29
450	Actin-binding doliculide causes premature senescence in p53 wild type cells. Bioorganic and Medicinal Chemistry, 2016, 24, 123-129.	1.4	9
451	Potential anti-MDR agents based on the podophyllotoxin scaffold: synthesis and antiproliferative activity evaluation against chronic myeloid leukemia cells by activating MAPK signaling pathways. RSC Advances, 2016, 6, 2895-2903.	1.7	20
452	New Colchicine-Derived Triazoles and Their Influence on Cytotoxicity and Microtubule Morphology. ACS Medicinal Chemistry Letters, 2016, 7, 188-191.	1.3	37
453	The p53 inhibitor, pifithrin-α, disrupts microtubule organization, arrests growth, and induces polyploidy in the rainbow trout gill cell line, RTgill-W1. Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology, 2016, 179, 1-10.	1.3	9
454	Right Time, Right Place: Probing the Functions of Organelle Positioning. Trends in Cell Biology, 2016, 26, 121-134.	3.6	81
455	Genetic screening reveals a link between Wnt signaling and antitubulin drugs. Pharmacogenomics Journal, 2016, 16, 164-172.	0.9	9
456	Analysis of the binding mode of laulimalide to microtubules: Establishing a laulimalide–tubulin pharmacophore. Journal of Biomolecular Structure and Dynamics, 2016, 34, 1455-1469.	2.0	16
457	Relay Drug Delivery for Amplifying Targeting Signal and Enhancing Anticancer Efficacy. Advanced Materials, 2017, 29, 1605803.	11.1	56
458	Tissueâ€specific metabolite profiling of benzylisoquinoline alkaloids in the root of <scp><i>Macleaya cordata</i></scp> by combining laser microdissection with ultraâ€highâ€performance liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2017, 31, 397-410.	0.7	13
459	A Cytoplasmic RNA Virus Alters the Function of the Cell Splicing Protein SRSF2. Journal of Virology, 2017, 91, .	1.5	34
460	Application of 2D-HPLC coupled with principal component analysis to study an industrial opiate processing stream. Talanta, 2017, 166, 119-125.	2.9	7
461	Polymer conjugate of a microtubule destabilizer inhibits lung metastatic melanoma. Journal of Controlled Release, 2017, 249, 32-41.	4.8	9
462	Design, synthesis, biological evaluation and molecular modeling study of novel macrocyclic bisbibenzyl analogues as antitubulin agents. European Journal of Medicinal Chemistry, 2017, 129, 186-208.	2.6	7
463	Regulation of end-binding protein EB1 in the control of microtubule dynamics. Cellular and Molecular Life Sciences, 2017, 74, 2381-2393.	2.4	85
464	Structural Basis of Microtubule Stabilization by Discodermolide. ChemBioChem, 2017, 18, 905-909.	1.3	30
465	Non-kinase targets of protein kinase inhibitors. Nature Reviews Drug Discovery, 2017, 16, 424-440.	21.5	102
466	Novel anti-tubulin agents from plant and marine origins: insight from a molecular modeling and dynamics study. RSC Advances, 2017, 7, 15917-15925.	1.7	16

#	Article	IF	CITATIONS
467	Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention. Nature Communications, 2017, 8, 14683.	5.8	88
468	Discovery and Optimization of Novel 5-Indolyl-7-arylimidazo[1,2-a]pyridine-8-carbonitrile Derivatives as Potent Antitubulin Agents Targeting Colchicine-binding Site. Scientific Reports, 2017, 7, 43398.	1.6	12
469	Structural Basis of cis- and trans-Combretastatin Binding to Tubulin. CheM, 2017, 2, 102-113.	5.8	164
470	Use of substitute Nonidet P-40 nonionic detergents in intracellular tubulin polymerization assays for screening of microtubule targeting agents. Biochemistry and Cell Biology, 2017, 95, 379-384.	0.9	14
471	Enhanced stability of microtubules contributes in the development of colchicine resistance in MCF-7 cells. Biochemical Pharmacology, 2017, 132, 38-47.	2.0	19
472	G-1 Inhibits Breast Cancer Cell Growth via Targeting Colchicine-Binding Site of Tubulin to Interfere with Microtubule Assembly. Molecular Cancer Therapeutics, 2017, 16, 1080-1091.	1.9	31
473	Anti-leukemia effects of the novel synthetic 1-benzylindole derivative 21-900 in vitro and in vivo. Scientific Reports, 2017, 7, 42291.	1.6	4
474	An insight into the therapeutic potential of quinazoline derivatives as anticancer agents. MedChemComm, 2017, 8, 871-885.	3.5	128
475	Methyl 5-[(1H-indol-3-yl)selanyl]-1H-benzoimidazol-2-ylcarbamate (M-24), a novel tubulin inhibitor, causes G2/M arrest and cell apoptosis by disrupting tubulin polymerization in human cervical and breast cancer cells. Toxicology in Vitro, 2017, 42, 139-149.	1.1	11
476	Identification of novel 1-indolyl acetate-5-nitroimidazole derivatives of combretastatin A-4 as potential tubulin polymerization inhibitors. Biochemical Pharmacology, 2017, 137, 10-28.	2.0	15
477	Chalcone: A Privileged Structure in Medicinal Chemistry. Chemical Reviews, 2017, 117, 7762-7810.	23.0	938
478	Potential anticancer role of colchicine-based derivatives. Anti-Cancer Drugs, 2017, 28, 250-262.	0.7	66
479	One-pot synthesis and biological evaluation of N -(aminosulfonyl)-4-podophyllotoxin carbamates as potential anticancer agents. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2890-2894.	1.0	17
480	Brine shrimp toxicity of various polarities leaves and fruits crude fractions of Ziziphus jujuba native to Oman and their antimicrobial potency. Sustainable Chemistry and Pharmacy, 2017, 5, 122-126.	1.6	15
481	(Very) Early technology assessment and translation of predictive biomarkers in breast cancer. Cancer Treatment Reviews, 2017, 52, 117-127.	3.4	13
482	Ligand Binding Swaps between Soft Internal Modes of α,β-Tubulin and Alters Its Accessible Conformational Space. Journal of Physical Chemistry B, 2017, 121, 118-128.	1.2	11
483	Migrastatics—Anti-metastatic and Anti-invasion Drugs: Promises and Challenges. Trends in Cancer, 2017, 3, 391-406.	3.8	262
484	Evodiamine Prevents Glioma Growth, Induces Glioblastoma Cell Apoptosis and Cell Cycle Arrest through JNK Activation. The American Journal of Chinese Medicine, 2017, 45, 879-899.	1.5	36

Article	IF	CITATIONS
Modification of C-seco taxoids through ring tethering and substituent replacement leading to effective agents against tumor drug resistance mediated by βIII-Tubulin and P-glycoprotein (P-gp) overexpressions. European Journal of Medicinal Chemistry, 2017, 137, 488-503.	2.6	13
Mechanism of microtubule stabilization by taccalonolide AJ. Nature Communications, 2017, 8, 15787.	5.8	58
Structural insight into the role of Gln293Met mutation on the Peloruside A/Laulimalide association with αβ-tubulin from molecular dynamics simulations, binding free energy calculations and weak interactions analysis. Journal of Computer-Aided Molecular Design, 2017, 31, 643-652.	1.3	11
Activation of Phenyl 4-(2-Oxo-3-alkylimidazolidin-1-yl)benzenesulfonates Prodrugs by CYP1A1 as New Antimitotics Targeting Breast Cancer Cells. Journal of Medicinal Chemistry, 2017, 60, 4963-4982.	2.9	18
Benzimidazole Scaffold as Anticancer Agent: Synthetic Approaches and Structure–Activity Relationship. Archiv Der Pharmazie, 2017, 350, e201700040.	2.1	107
Design, synthesis, and structure–activity relationships of pyrimido[4,5- b]indole-4-amines as microtubule depolymerizing agents that are effective against multidrug resistant cells. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 3423-3430.	1.0	9
Oncolytic Herpes Simplex Virus Inhibits Pediatric Brain Tumor Migration and Invasion. Molecular Therapy - Oncolytics, 2017, 5, 75-86.	2.0	22
Synthesis, biological evaluation and molecular modeling of imidazo[1,2-a]pyridine derivatives as potent antitubulin agents. Bioorganic and Medicinal Chemistry, 2017, 25, 4088-4099.	1.4	14
Triazolopyrimidines Are Microtubule-Stabilizing Agents that Bind the Vinca Inhibitor Site of Tubulin. Cell Chemical Biology, 2017, 24, 737-750.e6.	2.5	58
Clinical Development of Anti-mitotic Drugs in Cancer. Advances in Experimental Medicine and Biology, 2017, 1002, 125-152.	0.8	22
Exploring the Boundaries of "Practical― De Novo Syntheses of Complex Natural Product-Based Drug Candidates. Chemical Reviews, 2017, 117, 11994-12051.	23.0	59
The small molecule inhibitor YK-4-279 disrupts mitotic progression of neuroblastoma cells, overcomes drug resistance and synergizes with inhibitors of mitosis. Cancer Letters, 2017, 403, 74-85.	3.2	32
Augmentation of the anticancer activity of CYT997 in human prostate cancer by inhibiting Src activity. Journal of Hematology and Oncology, 2017, 10, 118.	6.9	20
Anthelmintic drug albendazole arrests human gastric cancer cells at the mitotic phase and induces apoptosis. Experimental and Therapeutic Medicine, 2017, 13, 595-603.	0.8	32
Microtubule Targeting Agents in Cancer Therapy: Elucidating the Underlying Molecular Mechanisms. , 2017, , 15-65.		4
Differential involvement of the microtubule cytoskeleton in insulin receptor substrate 1 (IRS-1) and IRS-2 signaling to AKT determines the response to microtubule disruption in breast carcinoma cells. Journal of Biological Chemistry, 2017, 292, 7806-7816.	1.6	18
Antiproliferative Activity of Crocin Involves Targeting of Microtubules in Breast Cancer Cells. Scientific Reports, 2017, 7, 44984.	1.6	62

502	MPTOB002, a novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells. Investigational New Drugs, 2017, 35, 427-435.	1.2	5
-----	---	-----	---

#

#	Article	IF	CITATIONS
503	Synthesis and biological evaluation of novel indole-pyrimidine hybrids bearing morpholine and thiomorpholine moieties. European Journal of Medicinal Chemistry, 2017, 134, 110-118.	2.6	45
504	The apoptotic mechanisms of MT-6, a mitotic arrest inducer, in human ovarian cancer cells. Scientific Reports, 2017, 7, 46149.	1.6	Ο
505	Directed adenine functionalization for creating complex architectures for material and biological applications. Chemical Communications, 2017, 53, 4748-4758.	2.2	34
506	Strategies and challenges for the next generation of antibody–drug conjugates. Nature Reviews Drug Discovery, 2017, 16, 315-337.	21.5	1,527
507	Mechanisms of kinetic stabilization by the drugs paclitaxel and vinblastine. Molecular Biology of the Cell, 2017, 28, 1238-1257.	0.9	61
508	Developments and future clinical outlook of taxane nanomedicines. Journal of Controlled Release, 2017, 253, 137-152.	4.8	34
509	Development and Biological Evaluation of a Photoactivatable Small Molecule Microtubule-Targeting Agent. ACS Medicinal Chemistry Letters, 2017, 8, 395-400.	1.3	28
510	Exploring βâ€Tubulin Inhibitors from Plant Origin using Computational Approach. Phytochemical Analysis, 2017, 28, 230-241.	1.2	15
511	Patupilone-loaded poly(L-glutamic acid)- <i>graft</i> -methoxy-poly(ethylene glycol) micelle for oncotherapy. Journal of Biomaterials Science, Polymer Edition, 2017, 28, 394-414.	1.9	3
512	Induction of acetylation and bundling of cellular microtubules by 9-(4-vinylphenyl) noscapine elicits S-phase arrest in MDA-MB-231 cells. Biomedicine and Pharmacotherapy, 2017, 86, 74-80.	2.5	19
513	Structural Insights into the Inhibition of Tubulin by the Antitumor Agent 4î²-(1,2,4-triazol-3-ylthio)-4-deoxypodophyllotoxin. ACS Chemical Biology, 2017, 12, 746-752.	1.6	19
514	Microtubules in 3D cell motility. Journal of Cell Science, 2017, 130, 39-50.	1.2	102
515	Synthesis, in vitro and in vivo evaluation of new hybrids of millepachine and phenstatin as potent tubulin polymerization inhibitors. Organic and Biomolecular Chemistry, 2017, 15, 852-862.	1.5	16
516	Current Status and Perspectives in Marine Biodiscovery. Topics in Biodiversity and Conservation, 2017, , 29-50.	0.3	1
517	Novel mutations involving βl-, βlIA-, or βIVB-tubulin isotypes with functional resemblance to βIII-tubulin in breast cancer. Protoplasma, 2017, 254, 1163-1173.	1.0	22
518	Development of photoaffinity derivatives of the antitumor macrolide aplyronine A, a PPI-inducer between actin and tubulin. Bioorganic and Medicinal Chemistry, 2017, 25, 6322-6331.	1.4	11
519	Combined CRISPRi/a-Based Chemical Genetic Screens Reveal that Rigosertib Is a Microtubule-Destabilizing Agent. Molecular Cell, 2017, 68, 210-223.e6.	4.5	197
520	Synthesis and evaluation of anticancer activity of BOC26P, an ortho-aryl chalcone sodium phosphate as water-soluble prodrugs in vitro and in vivo. Biomedicine and Pharmacotherapy, 2017, 96, 551-562.	2.5	7

#	Article	IF	CITATIONS
521	Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel. Journal of Visualized Experiments, 2017, , .	0.2	7
522	Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells. Journal of Visualized Experiments, 2017, , .	0.2	10
523	A Stereocontrolled Annulation of the Taccalonolide Epoxy Lactone onto the Molecular Framework of <i>trans</i> -Androsterone. Organic Letters, 2017, 19, 4892-4895.	2.4	7
524	Pharmacological investigations on mast cell stabilizer and histamine receptor antagonists in vincristine-induced neuropathic pain. Naunyn-Schmiedeberg's Archives of Pharmacology, 2017, 390, 1087-1096.	1.4	18
525	Serial millisecond crystallography for routine room-temperature structure determination at synchrotrons. Nature Communications, 2017, 8, 542.	5.8	203
526	Design, synthesis and biological evaluation of 2-phenylquinoline-4-carboxamide derivatives as a new class of tubulin polymerization inhibitors. Bioorganic and Medicinal Chemistry, 2017, 25, 5939-5951.	1.4	13
527	Antibody–Drug Conjugates. Topics in Medicinal Chemistry, 2017, , 289-289.	0.4	1
528	Establishment and characterization of a triple negative basal-like breast cancer cell line with multi-drug resistance. Oncology Letters, 2017, 14, 5039-5045.	0.8	41
529	Tubulin inhibitors targeting the colchicine binding site: a perspective of privileged structures. Future Medicinal Chemistry, 2017, 9, 1765-1794.	1.1	119
530	Novel quinolone chalcones targeting colchicine-binding pocket kill multidrug-resistant cancer cells by inhibiting tubulin activity and MRP1 function. Scientific Reports, 2017, 7, 10298.	1.6	45
531	Design, synthesis and biological evaluation of 4-anilinoquinoline derivatives as novel potent tubulin depolymerization agents. European Journal of Medicinal Chemistry, 2017, 138, 1114-1125.	2.6	28
532	Chemoselective fluorination and chemoinformatic analysis of griseofulvin: Natural vs fluorinated fungal metabolites. Bioorganic and Medicinal Chemistry, 2017, 25, 5238-5246.	1.4	18
533	Novel Gomisin B analogues as potential cytotoxic agents: Design, synthesis, biological evaluation and docking studies. European Journal of Medicinal Chemistry, 2017, 139, 441-453.	2.6	19
534	Development and Biological Evaluation of Imidazothiazole propenones as Tubulin Inhibitors that Effectively Triggered Apoptotic Cell Death in Alveolar Lung Cancer Cell Line. ChemistrySelect, 2017, 2, 6480-6487.	0.7	8
535	The novel microtubule targeting agent BAL101553 in combination with radiotherapy in treatment-refractory tumor models. Radiotherapy and Oncology, 2017, 124, 433-438.	0.3	11
536	Interactome Analysis of Microtubule-targeting Agents Reveals Cytotoxicity Bases in Normal Cells. Genomics, Proteomics and Bioinformatics, 2017, 15, 352-360.	3.0	2
537	A small-molecule activator of kinesin-1 drives remodeling of the microtubule network. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 13738-13743.	3.3	57
538	Synthesis of the C(1)–C(13) Fragment of Leiodermatolide via Hydrogen-Mediated C–C Bond Formation. Organic Letters, 2017, 19, 6634-6637.	2.4	7

#	Article	IF	CITATIONS
539	Near-infrared remotely triggered drug-release strategies for cancer treatment. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 12419-12424.	3.3	64
541	Targeting cancer cell integrins using gold nanorods in photothermal therapy inhibits migration through affecting cytoskeletal proteins. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E5655-E5663.	3.3	151
542	Optomechanical proposal for monitoring microtubule mechanical vibrations. Physical Review E, 2017, 96, 012404.	0.8	8
543	Suppression of angiogenesis and tumour progression by combretastatin and derivatives. Cancer Letters, 2017, 403, 289-295.	3.2	31
544	Bortezomib induces neuropathic pain through protein kinase C-mediated activation of presynaptic NMDA receptors in the spinal cord. Neuropharmacology, 2017, 123, 477-487.	2.0	46
545	A Phase II Study of the c-Met Inhibitor Tivantinib in Combination with FOLFOX for the Treatment of Patients with Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction, or Stomach. Cancer Investigation, 2017, 35, 463-472.	0.6	23
546	Second-generation total synthesis of aplyronine A featuring Ni/Cr-mediated coupling reactions. Organic and Biomolecular Chemistry, 2017, 15, 124-131.	1.5	11
547	Identification of ginkgolide targets in brain by photoaffinity labeling. Chemical Biology and Drug Design, 2017, 89, 475-481.	1.5	3
548	Synthesis and cytotoxic activity of certain trisubstituted azetidin-2-one derivatives as a cis-restricted combretastatin A-4 analogues. Archives of Pharmacal Research, 2017, 40, 13-24.	2.7	9
549	Synthesis and cytostatic properties of polyfunctionalized furanoallocolchicinoids. European Journal of Medicinal Chemistry, 2017, 126, 432-443.	2.6	18
550	Synthesis, structure-activity relationships and biological evaluation ofÂ7-phenyl-pyrroloquinolinone 3-amide derivatives as potent antimitotic agents. European Journal of Medicinal Chemistry, 2017, 127, 643-660.	2.6	13
551	A Systematic Review of the Incidence and Risk Factors for Taxane Acute Pain Syndrome in Patients Receiving Taxane-Based Chemotherapy for Prostate Cancer. Clinical Genitourinary Cancer, 2017, 15, 1-6.	0.9	13
552	Back to the tubule: microtubule dynamics in Parkinson's disease. Cellular and Molecular Life Sciences, 2017, 74, 409-434.	2.4	114
553	Design and synthesis of imidazo[2,1-b]thiazole linked triazole conjugates: Microtubule-destabilizing agents. European Journal of Medicinal Chemistry, 2017, 126, 36-51.	2.6	48
554	Phytochemical Inhibition of Multidrug Resistance Protein-1 as a Therapeutic Strategy for Hemangioendothelioma. Antioxidants and Redox Signaling, 2017, 26, 1009-1019.	2.5	4
555	6α-Acetoxyanopterine: A Novel Structure Class of Mitotic Inhibitor Disrupting Microtubule Dynamics in Prostate Cancer Cells. Molecular Cancer Therapeutics, 2017, 16, 3-15.	1.9	20
556	Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers. Journal of Visualized Experiments, 2017, , .	0.2	2
558	Mitotic slippage and the subsequent cell fates after inhibition of Aurora B during tubulin-binding agent–induced mitotic arrest. Scientific Reports, 2017, 7, 16762.	1.6	32

#	Article	IF	Citations
π 559	NEUROPROTECTIVE EFFECTS OF GUARANA (PAULLINIA CUPANA MART.) AGAINST VINCRISTINE IN VITRO EXPOSURE. journal of prevention of Alzheimer's disease, The, 2017, 5, 1-6.	1.5	4
560	The therapeutic potential of cell cycle targeting in multiple myeloma. Oncotarget, 2017, 8, 90501-90520.	0.8	39
561	Harnessing Plant Biodiversity for the Discovery of Novel Anticancer Drugs Targeting Microtubules. Frontiers in Plant Science, 2017, 8, 720.	1.7	61
562	Laucysteinamide A, a Hybrid PKS/NRPS Metabolite from a Saipan Cyanobacterium, cf. Caldora penicillata. Marine Drugs, 2017, 15, 121.	2.2	18
563	Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy. Molecules, 2017, 22, 1281.	1.7	135
564	Zampanolide, a Microtubule-Stabilizing Agent, Is Active in Resistant Cancer Cells and Inhibits Cell Migration. International Journal of Molecular Sciences, 2017, 18, 971.	1.8	24
565	Microtubule Depolymerization by Kinase Inhibitors: Unexpected Findings of Dual Inhibitors. International Journal of Molecular Sciences, 2017, 18, 2508.	1.8	27
566	Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents. PLoS ONE, 2017, 12, e0182400.	1.1	19
567	Identification of pyrrolopyrimidine derivative PP-13 as a novel microtubule-destabilizing agent with promising anticancer properties. Scientific Reports, 2017, 7, 10209.	1.6	16
568	Immuno-Modulatory and Anti-Inflammatory Effects of Dihydrogracilin A, a Terpene Derived from the Marine Sponge Dendrilla membranosa. International Journal of Molecular Sciences, 2017, 18, 1643.	1.8	48
569	Human MAP Tau Based Targeted Cytolytic Fusion Proteins. Biomedicines, 2017, 5, 36.	1.4	12
570	Inhibitor of H3K27 demethylase JMJD3/UTX GSK-J4 is a potential therapeutic option for castration resistant prostate cancer. Oncotarget, 2017, 8, 62131-62142.	0.8	50
571	Drug-Clinical Agent Molecular Hybrid: Synthesis of Diaryl(trifluoromethyl)pyrazoles as Tubulin Targeting Anticancer Agents. ACS Omega, 2018, 3, 1955-1969.	1.6	33
572	Identification and characterization of SSE15206, a microtubule depolymerizing agent that overcomes multidrug resistance. Scientific Reports, 2018, 8, 3305.	1.6	21
573	Synthesis and Biological Evaluation of Selenium-Containing 4-Anilinoquinazoline Derivatives as Novel Antimitotic Agents. Journal of Medicinal Chemistry, 2018, 61, 2571-2588.	2.9	38
575	Analysis of Microtubule Dynamics Heterogeneity in Cell Culture. Methods in Molecular Biology, 2018, 1745, 181-204.	0.4	3
576	CRISPR/Cas9‒Mediated Tspo Gene Mutations Lead to Reduced Mitochondrial Membrane Potential and Steroid Formation in MA-10 Mouse Tumor Leydig Cells. Endocrinology, 2018, 159, 1130-1146.	1.4	42
577	Eribulin inhibits the growth of small cell lung cancer cell lines alone and with radiotherapy. Lung Cancer, 2018, 118, 148-154.	0.9	2

		CITATION REPORT		
#	Article		IF	Citations
578	Inhibition of Microtubule Depolymerization by Osmolytes. Biomacromolecules, 2018,	19, 2401-2408.	2.6	16
579	Structure based drug design and in vitro metabolism study: Discovery of N-(4-methylthiophenyl)-N,2-dimethyl-cyclopenta[d]pyrimidine as a potent microtubule Bioorganic and Medicinal Chemistry, 2018, 26, 2437-2451.	targeting agent.	1.4	11
580	Synthesis, biological evaluation and molecular docking studies of aminochalcone deriv potential anticancer agents by targeting tubulin colchicine binding site. Bioorganic Ch 78, 332-340.		2.0	41
581	Design, synthesis and evaluation of novel sulfonamides as potential anticancer agents Biology and Chemistry, 2018, 74, 294-303.	. Computational	1.1	47
582	Recent advances in trimethoxyphenyl (TMP) based tubulin inhibitors targeting the colo site. European Journal of Medicinal Chemistry, 2018, 151, 482-494.	hicine binding	2.6	162
583	Heterocyclic-Fused Pyrimidines as Novel Tubulin Polymerization Inhibitors Targeting th Binding Site: Structural Basis and Antitumor Efficacy. Journal of Medicinal Chemistry, 2 1704-1718.	e Colchicine 1018, 61,	2.9	84
584	Ultrasound-mediated synthesis, biological evaluation, docking and in vivo acute oral to novel indolin-2-one coupled pyrimidine derivatives. Research on Chemical Intermediate 3031-3059.	exicity study of es, 2018, 44,	1.3	8
585	Synthesis and biological evaluation of 4,6-diphenyl-2-(1H-pyrrol-1-yl)nicotinonitrile ana crolibulin and combretastatin A-4. European Journal of Medicinal Chemistry, 2018, 146	logues of 5, 185-193.	2.6	13
586	In vitro assessment of chemotherapy-induced neuronal toxicity. Toxicology in Vitro, 20	918, 50, 109-123.	1.1	16
587	Marine Invertebrate Natural Products that Target Microtubules. Journal of Natural Proc 81, 691-702.	lucts, 2018,	1.5	40
588	Microtubule dynamics: moving toward a multi-scale approach. Current Opinion in Cell 50, 8-13.	Biology, 2018,	2.6	19
589	Taccalonolide Microtubule Stabilizers Generated Using Semisynthesis Define the Effec Acyloxy Moieties at C-7 or C-15 and Disubstitutions at C-7 and C-25. Journal of Natura 81, 579-593.	ts of Mono I Products, 2018,	1.5	14
590	Immunogenicity considerations for antibody–drug conjugates: a focus on neutralizi assays. Bioanalysis, 2018, 10, 65-70.	ng antibody	0.6	5
591	Antibodyâ€drug conjugates: Promising and efficient tools for targeted cancer therapy. Cellular Physiology, 2018, 233, 6441-6457.	Journal of	2.0	67
592	Synthesis and Antiproliferative Activity Evaluation of Aryl(Hetaryl)Cyclopentenone Ana Combretastatin A-4. Pharmaceutical Chemistry Journal, 2018, 51, 867-872.	logs of	0.3	5
593	Biotin conjugated organic molecules and proteins for cancer therapy: A review. Europe Medicinal Chemistry, 2018, 145, 206-223.	an Journal of	2.6	90
594	ATP depletion during mitotic arrest induces mitotic slippage and APC/CCdh1-depender degradation. Experimental and Molecular Medicine, 2018, 50, 1-14.	nt cyclin B1	3.2	13
595	Radiosynthesis of microtubuleâ€targeted theranostic methyl <i>N</i> â€[5â€(3'â€radiohalobenzoyl)â€1 <i>H</i> â€benzimidazolâ€2â€yl]carbai and Radiopharmaceuticals, 2018, 61, 749-756.	mates. Journal of Labelled (Co ດາຄ ound	ls 5

#	Article	IF	CITATIONS
596	Real-time monitoring of tumor vascular disruption induced by radiofrequency assisted gadofullerene. Science China Materials, 2018, 61, 1101-1111.	3.5	11
597	Heterocyclic organobismuth (III) compounds containing an eight-membered ring: Inhibitory effects on cell cycle progression. Toxicology in Vitro, 2018, 50, 172-178.	1.1	7
598	Taxane acute pain syndrome (TAPS) in patients receiving chemotherapy for breast or prostate cancer: a prospective multi-center study. Supportive Care in Cancer, 2018, 26, 3073-3081.	1.0	12
599	High-affinity ligands of the colchicine domain in tubulin based on a structure-guided design. Scientific Reports, 2018, 8, 4242.	1.6	42
600	A Promising Microtubule Inhibitor Deoxypodophyllotoxin Exhibits Better Efficacy to Multidrug-Resistant Breast Cancer than Paclitaxel via Avoiding Efflux Transport. Drug Metabolism and Disposition, 2018, 46, 542-551.	1.7	18
601	Identification of Cdk1–LATS–Pin1 as a Novel Signaling Axis in Anti-tubulin Drug Response of Cancer Cells. Molecular Cancer Research, 2018, 16, 1035-1045.	1.5	17
602	Elucidation of the anticancer potential and tubulin isotype-specific interactions of β-sitosterol. Journal of Biomolecular Structure and Dynamics, 2018, 36, 195-208.	2.0	20
603	Optochemical Control of Biological Processes in Cells and Animals. Angewandte Chemie - International Edition, 2018, 57, 2768-2798.	7.2	331
604	Designed Tetrapeptide Interacts with Tubulin and Microtubule. Langmuir, 2018, 34, 1123-1132.	1.6	16
605	Optochemische Steuerung biologischer VorgÃ ¤ ge in Zellen und Tieren. Angewandte Chemie, 2018, 130, 2816-2848.	1.6	94
606	Discovery of thalicthuberine as a novel antimitotic agent from nature that disrupts microtubule dynamics and induces apoptosis in prostate cancer cells. Cell Cycle, 2018, 17, 652-668.	1.3	13
607	Effects of the Protonation State of Titratable Residues and the Presence of Water Molecules on Nocodazole Binding to βâ€ī ubulin. ChemMedChem, 2018, 13, 20-24.	1.6	15
608	Zampanolide Binding to Tubulin Indicates Cross-Talk of Taxane Site with Colchicine and Nucleotide Sites. Journal of Natural Products, 2018, 81, 494-505.	1.5	15
609	New (3-(1H-benzo[d]imidazol-2-yl))/(3-(3H-imidazo[4,5-b]pyridin-2-yl))-(1H-indol-5-yl)(3,4,5-trimethoxyphenyl)methanc conjugates as tubulin polymerization inhibitors. MedChemComm, 2018, 9, 275-281.	113225	11
610	A tripartite mode of action approach for investigating the impact of aneugens on tubulin polymerization. Environmental and Molecular Mutagenesis, 2018, 59, 188-201.	0.9	4
611	Aqueous extract of Triphala inhibits cancer cell proliferation through perturbation of microtubule assembly dynamics. Biomedicine and Pharmacotherapy, 2018, 98, 76-81.	2.5	17
612	Targeting tubulin polymerization by novel 7-aryl-pyrroloquinolinones: Synthesis, biological activity and SARs. European Journal of Medicinal Chemistry, 2018, 143, 244-258.	2.6	8
613	Podophyllotoxin extraction from <scp> <i>Linum usitatissimum </i> </scp> plant and its anticancer activity against HTâ€29, Aâ€549 and MDAâ€MBâ€231 cell lines with and without the presence of gold nanoparticles. Applied Organometallic Chemistry, 2018, 32, e4024.	1.7	11

#	Article	IF	CITATIONS
614	Synthesis and evaluation of C2 functionalized analogs of the α-tubulin-binding natural product pironetin. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2789-2793.	1.0	6
615	Podophyllotoxin derivatives as an excellent anticancer aspirant for future chemotherapy: A key current imminent needs. Bioorganic and Medicinal Chemistry, 2018, 26, 340-355.	1.4	123
616	Photoresponsive azo-combretastatin A-4 analogues. European Journal of Medicinal Chemistry, 2018, 143, 1-7.	2.6	44
617	Synthesis and biological evaluation of N-substituted 3-oxo-1,2,3,4-tetrahydro-quinoxaline-6-carboxylic acid derivatives as tubulin polymerization inhibitors. European Journal of Medicinal Chemistry, 2018, 143, 8-20.	2.6	23
618	Discovery of a Novel Microtubule Targeting Agent as an Adjuvant for Cancer Immunotherapy. BioMed Research International, 2018, 2018, 1-13.	0.9	10
619	Antiproliferative Activity and Molecular Docking of Novel Double-Modified Colchicine Derivatives. Cells, 2018, 7, 192.	1.8	27
620	A quantitative proteomic analysis of cofilin phosphorylation in myeloid cells and its modulation using the LIM kinase inhibitor Pyr1. PLoS ONE, 2018, 13, e0208979.	1.1	11
621	Microtubule-Based Control of Motor-Clutch System Mechanics in Glioma Cell Migration. Cell Reports, 2018, 25, 2591-2604.e8.	2.9	37
622	Measuring microtubule dynamics. Essays in Biochemistry, 2018, 62, 725-735.	2.1	55
623	MORAb-202, an Antibody–Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity. Molecular Cancer Therapeutics, 2018, 17, 2665-2675.	1.9	54
624	Alzheimer's disease (AD) therapeutics – 1: Repeated clinical failures continue to question the amyloid hypothesis of AD and the current understanding of AD causality. Biochemical Pharmacology, 2018, 158, 359-375.	2.0	59
625	Discovery of Novel 4-Arylisochromenes as Anticancer Agents Inhibiting Tubulin Polymerization. ACS Medicinal Chemistry Letters, 2018, 9, 974-979.	1.3	18
626	Tubulin's response to external electric fields by molecular dynamics simulations. PLoS ONE, 2018, 13, e0202141.	1.1	20
627	SAC3D1: a novel prognostic marker in hepatocellular carcinoma. Scientific Reports, 2018, 8, 15608.	1.6	46
628	Specific Targeting of Plant and Apicomplexa Parasite Tubulin through Differential Screening Using In Silico and Assay-Based Approaches. International Journal of Molecular Sciences, 2018, 19, 3085.	1.8	10
629	The Current Status of the Pharmaceutical Potential of Juniperus L. Metabolites. Medicines (Basel,) Tj ETQq1 1 0.7	7843 <u>1</u> 4 rg	BT/Overloc
630	MPT0B169 and MPT0B002, New Tubulin Inhibitors, Induce Growth Inhibition, G2/M Cell Cycle Arrest, and Apoptosis in Human Colorectal Cancer Cells. Pharmacology, 2018, 102, 262-271.	0.9	5
631	New 2-Oxoindolin Phosphonates as Novel Agents to Treat Cancer: A Green Synthesis and Molecular Modeling. Molecules, 2018, 23, 1981.	1.7	12

#	Article	IF	CITATIONS
632	Magnetic nanoparticle hyperthermia potentiates paclitaxel activity in sensitive and resistant breast cancer cells. International Journal of Nanomedicine, 2018, Volume 13, 4771-4779.	3.3	27
633	Phosphorylation state of Ser165 in α-tubulin is a toggle switch that controls proliferating human breast tumors. Cellular Signalling, 2018, 52, 74-82.	1.7	5
634	Substitution at the indole 3 position yields highly potent indolecombretastatins against human tumor cells. European Journal of Medicinal Chemistry, 2018, 158, 167-183.	2.6	16
635	Synthesis & antitumor activity of epothilones B and D and their analogs. Future Medicinal Chemistry, 2018, 10, 1483-1496.	1.1	14
636	Safety of Polysorbate 80 in the Oncology Setting. Advances in Therapy, 2018, 35, 754-767.	1.3	114
637	Synthesis, biological evaluation and molecular docking studies of a new series of chalcones containing naphthalene moiety as anticancer agents. Bioorganic Chemistry, 2018, 76, 249-257.	2.0	45
638	Synthesis and Evaluation of Linear and Macrocyclic Dolastatin 10 Analogues Containing Pyrrolidine Ring Modifications. ACS Omega, 2018, 3, 5212-5221.	1.6	13
639	SeaBioTech: From Seabed to Test-Bed: Harvesting the Potential of Marine Biodiversity for Industrial Biotechnology. Grand Challenges in Biology and Biotechnology, 2018, , 451-504.	2.4	4
640	Marine natural products for multi-targeted cancer treatment: A future insight. Biomedicine and Pharmacotherapy, 2018, 105, 233-245.	2.5	50
641	The inhibitory effect of kokusaginine on the growth of human breast cancer cells and MDR-resistant cells is mediated by the inhibition of tubulin assembly. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2490-2492.	1.0	9
642	Improving the Safety Profile of ADCs. Cancer Drug Discovery and Development, 2018, , 45-71.	0.2	1
643	Cellular Organization of the Gastrointestinal Tract. , 2018, , 107-199.		0
644	Changes in cell morphology guide identification of tubulin as the off-target for protein kinase inhibitors. Pharmacological Research, 2018, 134, 166-178.	3.1	8
645	Discovery of two-level modular organization from matched genomic data via joint matrix tri-factorization. Nucleic Acids Research, 2018, 46, 5967-5976.	6.5	27
646	Current Trends in the Clinical Development of Antibody-Drug Conjugates in Oncology. Pharmaceutical Medicine, 2018, 32, 259-273.	1.0	6
647	3-Aryl/Heteroaryl-5-amino-1-(3′,4′,5′-trimethoxybenzoyl)-1,2,4-triazoles as antimicrotubule agents. Desigr synthesis, antiproliferative activity and inhibition of tubulin polymerization. Bioorganic Chemistry, 2018, 80, 361-374.	1, 2.0	16
648	In vitro and in vivo pharmacokinetic and pharmacodynamic study of MBRI-001, a deuterium-substituted plinabulin derivative as a potent anti-cancer agent. Bioorganic and Medicinal Chemistry, 2018, 26, 4687-4692.	1.4	6
649	Development of a novel inducer of protein–protein interactions based on aplyronine A. Chemical Communications, 2018, 54, 9537-9540.	2.2	8

		CITATION REPORT		
#	Article		IF	Citations
650	Targeting the cell cycle in breast cancer: towards the next phase. Cell Cycle, 2018, 17, 1	371-1885.	1.3	108
651	The Novel Small Molecule STK899704 Promotes Senescence of the Human A549 NSCLC DNA Damage Responses and Cell Cycle Arrest. Frontiers in Pharmacology, 2018, 9, 163.	Cells by Inducing	1.6	13
652	A Novel Dual HDAC6 and Tubulin Inhibitor, MPT0B451, Displays Anti-tumor Ability in Hu Cells in Vitro and in Vivo. Frontiers in Pharmacology, 2018, 9, 205.	nan Cancer	1.6	22
653	Modes of cell death induced by tetrahydroisoquinoline-based analogs in MDA-MB-231 b lung cancer cell lines. Drug Design, Development and Therapy, 2018, Volume 12, 1881-1	east and A549 904.	2.0	7
654	Differential Morphological and Biochemical Recovery from Chemotherapy-Induced Peripl Neuropathy Following Paclitaxel, Ixabepilone, or Eribulin Treatment in Mouse Sciatic Ner Neurotoxicity Research, 2018, 34, 677-692.		1.3	17
655	Design, synthesis and preclinical evaluation of 5-methyl-N4-aryl-furo[2,3-d]pyrimidines as with combination chemotherapy potential. Bioorganic and Medicinal Chemistry Letters, 3085-3093.	s single agents 2018, 28,	1.0	11
656	An Indole–Chalcone Inhibits Multidrug-Resistant Cancer Cell Growth by Targeting Mic Molecular Pharmaceutics, 2018, 15, 3892-3900.	otubules.	2.3	36
657	Chemotherapeutic resistance: a nano-mechanical point of view. Biological Chemistry, 20 1433-1446.	18, 399,	1.2	18
658	Autophagy Governs Protumorigenic Effects of Mitotic Slippage–induced Senescence. Cancer Research, 2018, 16, 1625-1640.	Molecular	1.5	23
659	Cancer-Drug Interaction Network Construction and Drug Target Prediction Based on Mu Data. Lecture Notes in Computer Science, 2018, , 223-235.	lti-source	1.0	2
660	Endophytic Fungi—Alternative Sources of Cytotoxic Compounds: A Review. Frontiers ir Pharmacology, 2018, 9, 309.	1	1.6	185
661	Bifidenone: Structure–Activity Relationship and Advanced Preclinical Candidate. Journ Chemistry, 2018, 61, 6736-6747.	al of Medicinal	2.9	5
662	Novel nicotinoyl pyrazoline derivates bearing N-methyl indole moiety as antitumor agent synthesis and evaluation. European Journal of Medicinal Chemistry, 2018, 156, 722-737.		2.6	38
663	Autophagy blockade sensitizes human head and neck squamous cell carcinoma towards through enhancing excessively high reactive oxygen species-induced apoptosis. Journal o Medicine, 2018, 96, 929-938.	CYT997 f Molecular	1.7	21
664	Spatiotemporal oscillations of morphinan alkaloids in opium poppy. Journal of Bioscience 391-405.	2s, 2018, 43,	0.5	4
665	Mechanism of action of the third generation benzopyrans and evaluation of their broad activity in vitro and in vivo. Scientific Reports, 2018, 8, 5144.	anti-cancer	1.6	12
666	Apoptotic vesicles: deathly players in cancerâ€associated coagulation. Immunology and 2018, 96, 723-732.	Cell Biology,	1.0	7
667	Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cel modulating multiple cellular pathways. Scientific Reports, 2018, 8, 11926.	death by	1.6	74

#	Article	IF	CITATIONS
668	A Novel Microtubule Inhibitor Overcomes Multidrug Resistance in Tumors. Cancer Research, 2018, 78, 5949-5957.	0.4	18
669	Recent Advances and Perspectives in Cancer Drug Design. Anais Da Academia Brasileira De Ciencias, 2018, 90, 1233-1250.	0.3	38
670	Discovery of novel vinyl sulfone derivatives as anti-tumor agents with microtubule polymerization inhibitory and vascular disrupting activities. European Journal of Medicinal Chemistry, 2018, 157, 1068-1080.	2.6	26
671	NQO1 regulates mitotic progression and response to mitotic stress through modulating SIRT2 activity. Free Radical Biology and Medicine, 2018, 126, 358-371.	1.3	12
672	Interleukin-4 protects from chemotherapy-induced peripheral neuropathy in mice modal via the stimulation of IL-4/STAT6 signaling. Acta Cirurgica Brasileira, 2018, 33, 491-498.	0.3	16
673	Combretastatin-Inspired Heterocycles as Antitubulin Anticancer Agents. ACS Omega, 2018, 3, 9754-9769.	1.6	34
674	Genetics and Expression Profile of the Tubulin Gene Superfamily in Breast Cancer Subtypes and Its Relation to Taxane Resistance. Cancers, 2018, 10, 274.	1.7	83
675	Synthesis and biological evaluation of (1-aryl-1H-pyrazol-4-yl) (3,4,5-trimethoxyphenyl)methanone derivatives as tubulin inhibitors. European Journal of Medicinal Chemistry, 2018, 156, 137-147.	2.6	11
676	Microtubule-Targeting Agents: Strategies To Hijack the Cytoskeleton. Trends in Cell Biology, 2018, 28, 776-792.	3.6	340
677	Molecular basis of resistance to the microtubule-depolymerizing antitumor compound plocabulin. Scientific Reports, 2018, 8, 8616.	1.6	9
678	Alkaloid rich fraction of Datura alba Rumph. ex Nees leaves possesses antitumor and antimitotic activity. South African Journal of Botany, 2018, 117, 282-287.	1.2	5
679	Separating the effects of nucleotide and EB binding on microtubule structure. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E6191-E6200.	3.3	113
680	Synthesis and Evaluations of "1,4â€Triazolyl Combretacoumarins―and Desmethoxy Analogs. European Journal of Organic Chemistry, 2019, 2019, 5610-5623.	1.2	7
681	Reversible and Irreversible Modulation of Tubulin Selfâ€Assembly by Intense Nanosecond Pulsed Electric Fields. Advanced Materials, 2019, 31, 1903636.	11.1	29
682	DF2726A, a new IL-8 signalling inhibitor, is able to counteract chemotherapy-induced neuropathic pain. Scientific Reports, 2019, 9, 11729.	1.6	20
683	Design, synthesis and biological evaluation of novel vicinal diaryl-substituted 1H-Pyrazole analogues of combretastatin A-4 as highly potent tubulin polymerization inhibitors. European Journal of Medicinal Chemistry, 2019, 181, 111577.	2.6	22
684	4(1H)-quinolone derivatives overcome acquired resistance to anti-microtubule agents by targeting the colchicine site of β-tubulin. European Journal of Medicinal Chemistry, 2019, 181, 111584.	2.6	10
685	TUBB4B Downregulation Is Critical for Increasing Migration of Metastatic Colon Cancer Cells. Cells, 2019, 8, 810.	1.8	25

	Сітатіо	n Report	
#	Article	IF	CITATIONS
686	Heliopsis longipes S.F. Blake (Asteraceae) extract causes cell cycle arrest and induces caspase dependent apoptosis against cancer cell lines. South African Journal of Botany, 2019, 125, 251-260.	1.2	9
687	Bioorthogonal labeling with tetrazine-dyes for super-resolution microscopy. Communications Biology, 2019, 2, 261.	2.0	101
688	Neuroprotective Approach of Anti-Cancer Microtubule Stabilizers Against Tauopathy Associated Dementia: Current Status of Clinical and Preclinical Findings. Journal of Alzheimer's Disease Reports, 2019, 3, 179-218.	1.2	16
689	Inhibition of DNA Repair Mechanisms and Induction of Apoptosis in Triple Negative Breast Cancer Cells Expressing the Human Herpesvirus 6 U94. Cancers, 2019, 11, 1006.	1.7	13
690	Emerging Alkaloids Against Cancer: A Peep into Factors, Regulation, and Molecular Mechanisms. , 2019, , 37-60.		1
691	Synthesis and biological evaluation of 7-methoxy-1-(3,4,5-trimethoxyphenyl)-4,5-dihydro-2H-benzo[e]indazoles as new colchicine site inhibitors. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 2632-2634.	1.0	10
692	Chromosomal Instability in Tumor Initiation and Development. Cancer Research, 2019, 79, 3995-4002.	0.4	67
693	Coherent diffractive imaging of microtubules using an X-ray laser. Nature Communications, 2019, 10, 2589.	5.8	22
694	C12, a combretastatin-A4 analog, exerts anticancer activity by targeting microtubules. Biochemical Pharmacology, 2019, 170, 113663.	2.0	13
695	Pentagamavunon-1 (PGV-1) inhibits ROS metabolic enzymes and suppresses tumor cell growth by inducing M phase (prometaphase) arrest and cell senescence. Scientific Reports, 2019, 9, 14867.	1.6	20
696	Eribulin Suppressed Cisplatinum- and Doxorubicin-resistant Recurrent Lung Metastatic Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model. Anticancer Research, 2019, 39, 4775-4779.	0.5	16
697	Antiangiogenesis-Combined Photothermal Therapy in the Second Near-Infrared Window at Laser Powers Below the Skin Tolerance Threshold. Nano-Micro Letters, 2019, 11, 93.	14.4	22
698	The Natural Compound Withaferin A Covalently Binds to Cys239 of <i>β</i> -Tubulin to Promote Tubulin Degradation. Molecular Pharmacology, 2019, 96, 711-719.	1.0	18
699	Photoswitching off the Antiproliferative Activity of Combretastatin A-4 Analogues. Organic Letters, 2019, 21, 9608-9612.	2.4	17
700	Pimozide suppresses cancer cell migration and tumor metastasis through binding to ARPC2, a subunit of the Arp2/3 complex. Cancer Science, 2019, 110, 3788-3801.	1.7	34
701	Design, synthesis, and biological evaluation of 1-substituted -2-aryl imidazoles targeting tubulin polymerization as potential anticancer agents. European Journal of Medicinal Chemistry, 2019, 184, 111732.	2.6	28
702	Selective Inhibition of Spindle Microtubules by a Tubulin-Binding Quinazoline Derivative. Molecular Pharmacology, 2019, 96, 609-618.	1.0	4
703	In vitro wound healing of tumor cells: inhibition of cell migration by selected cytotoxic alkaloids. BMC Pharmacology & Toxicology, 2019, 20, 4.	1.0	73

#	Article	IF	CITATIONS
704	Shikonin potentiates paclitaxel antitumor efficacy in esophageal cancer cells via the apoptotic pathway. Oncology Letters, 2019, 18, 3195-3201.	0.8	9
705	Eribulin rapidly inhibits TGF-β-induced Snail expression and can induce Slug expression in a Smad4-dependent manner. British Journal of Cancer, 2019, 121, 611-621.	2.9	16
706	Highlights in Resistance Mechanism Pathways for Combination Therapy. Cells, 2019, 8, 1013.	1.8	51
707	Design, synthesis, and biological evaluation of novel benzodiazepine derivatives as anticancer agents through inhibition of tubulin polymerization inÂvitro and inÂvivo. European Journal of Medicinal Chemistry, 2019, 182, 111670.	2.6	19
708	Tumor-Targeted Drug Conjugates as an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC). Cancers, 2019, 11, 1297.	1.7	21
709	Novel [1,2,4]triazolo[1,5-a]pyrimidine derivatives as potent antitubulin agents: Design, multicomponent synthesis and antiproliferative activities. Bioorganic Chemistry, 2019, 92, 103260.	2.0	57
710	Design and synthesis of (2-(phenylamino)thieno[3,2-d]pyrimidin-4-yl)(3,4,5-trimethoxyphenyl)methanone analogues as potent anti-tubulin polymerization agents. European Journal of Medicinal Chemistry, 2019, 183, 111679.	2.6	22
711	Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985). European Journal of Medicinal Chemistry, 2019, 183, 111682.	2.6	102
712	Design, synthesis and biological evaluation of resveratrol-cinnamoyl derivates as tubulin polymerization inhibitors targeting the colchicine binding site. Bioorganic Chemistry, 2019, 93, 103319.	2.0	15
713	GEF-H1 Signaling upon Microtubule Destabilization Is Required for Dendritic Cell Activation and Specific Anti-tumor Responses. Cell Reports, 2019, 28, 3367-3380.e8.	2.9	37
714	Molecular Mechanisms Underlying Yatein-Induced Cell-Cycle Arrest and Microtubule Destabilization in Human Lung Adenocarcinoma Cells. Cancers, 2019, 11, 1384.	1.7	10
715	Structure, Thermodynamics, and Kinetics of Plinabulin Binding to Two Tubulin Isotypes. CheM, 2019, 5, 2969-2986.	5.8	33
716	Multiscale Computational Modeling of Tubulin-Tubulin Lateral Interaction. Biophysical Journal, 2019, 117, 1234-1249.	0.2	16
717	Employment of enhanced permeability and retention effect (EPR): Nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer. Materials Science and Engineering C, 2019, 98, 1252-1276.	3.8	536
718	Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity. , 2019, 197, 122-152.		83
719	Next generation diversity-oriented synthesis: a paradigm shift from chemical diversity to biological diversity. Organic and Biomolecular Chemistry, 2019, 17, 1608-1623.	1.5	41
720	Identification of the Metabolic Profile of the α-Tubulin-Binding Natural Product (â^')–Pironetin. Journal of Medicinal Chemistry, 2019, 62, 1684-1689.	2.9	11
721	Antitumor effect of XCT790, an ERRα inverse agonist, on ERα-negative endometrial cancer cells. Cellular Oncology (Dordrecht), 2019, 42, 223-235.	2.1	8

ARTICLE IF CITATIONS Crocin, a carotenoid, suppresses spindle microtubule dynamics and activates the mitotic checkpoint by 722 2.0 15 binding to tubulin. Biochemical Pharmacology, 2019, 163, 32-45. Synthesis of substituted biphenyl methylene indolinones as apoptosis inducers and tubulin 723 polymerization inhibitors. Bioorganic Chemistry, 2019, 86, 210-223. Synthesis, inÂvitro and inÂvivo biological evaluation of substituted 724 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones as new potent anticancer agents. European 2.6 4 Journal of Medicinal Chemistry, 2019, 166, 514-530. Class III Î²-tubulin Expression in Colorectal Neoplasms Is a Potential Predictive Biomarker for Paclitaxel 0.5 Response. Anticancer Research, 2019, 39, 655-662. Multicomponent access to novel proline/cyclized cysteine tethered monastrol conjugates as 726 2.4 21 potential anticancer agents. Journal of Saudi Chemical Society, 2019, 23, 503-513. Tubulin-VDAC Interaction: Molecular Basis for Mitochondrial Dysfunction in Chemotherapy-Induced 1.3 Peripheral Neuropathy. Frontiers in Physiology, 2019, 10, 671. 2-Phenylindole derivatives as anticancer agents: synthesis and screening against murine melanoma, 728 1.1 8 human lung and breast cancer cell lines. Synthetic Communications, 2019, 49, 2258-2269. Targeted Polypeptideâ& Microtubule Aggregation with Cucurbit [8] uril for Enhanced Cell Apoptosis. 729 1.6 Angewandte Chemie, 2019, 131, 10663-10667. Synthesis of 1,2,3-Triazolo-Fused Allocolchicine Analogs via Intramolecular Oxidative Biaryl Coupling. 730 2.4 13 Órganic Letters, 2019, 21, 5002-5005. Microtubule minus-end regulation at a glance. Journal of Cell Science, 2019, 132, . 1.2 Synthesis and biological evaluation of indole-2-carbohydrazides and 732 thiazolidinyl-indole-2-carboxamides as potent tubulin polymerization inhibitors. Computational 1.1 11 Biology and Chemistry, 2019, 80, 512-523. Targeted Polypeptideâ& Microtubule Aggregation with Cucurbit [8] uril for Enhanced Cell Apoptosis. 46 Angewandte Chemie - International Edition, 2019, 58, 10553-10557. Synthesis and biological evaluation of novel 4,7-dihydroxycoumarin derivatives as anticancer agents. 734 1.0 20 Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1819-1824. Evaluation of anticancer activity <i>in vitro</i> and <i>in vivo</i> of iridium(<scp>iii</scp>) polypyridyl complexes. New Journal of Chemistry, 2019, 43, 8566-8579. 1.4 Revisiting microtubule targeting agents: α-Tubulin and the pironetin binding site as unexplored targets 736 1.0 46 for cancer therapeutics. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1865-1873. 1-Phenyl-dihydrobenzoindazoles as novel colchicine site inhibitors: Structural basis and antitumor efficacý. European Journal of Medicinal Chemistry, 2019, 177, 448-456. Systematic Review on Cytotoxic and Anticancer Potential of N-Substituted Isatins as Novel Class of 738 Compounds Useful in Multidrug-Resistant Cancer Therapy: In Silico and In Vitro Analysis. Topics in 3.025 Current Chemistry, 2019, 377, 15. Tubulin heterogeneity regulates functions and dynamics of microtubules and plays a role in the 739 development of drug resistance in cancer. Biochemical Journal, 2019, 476, 1359-1376.

#	Article	IF	CITATIONS
740	Dual-Arm Nanocapsule Targets Neuropilin-1 Receptor and Microtubule: A Potential Nanomedicine Platform. Molecular Pharmaceutics, 2019, 16, 2522-2531.	2.3	13
741	Synthesis and biological evaluation of 3-functionalized 2-phenyl- and 2-alkylbenzo[b]furans as antiproliferative agents against human melanoma cell line. Bioorganic Chemistry, 2019, 88, 102930.	2.0	10
742	Colchicine Binding Site Agent DJ95 Overcomes Drug Resistance and Exhibits Antitumor Efficacy. Molecular Pharmacology, 2019, 96, 73-89.	1.0	23
743	Non-linear Dose Response of Lymphocyte Cell Lines to Microtubule Inhibitors. Frontiers in Pharmacology, 2019, 10, 436.	1.6	8
744	Metabolomics-Driven Exploration of the Chemical Drug Space to Predict Combination Antimicrobial Therapies. Molecular Cell, 2019, 74, 1291-1303.e6.	4.5	57
745	Semisynthetic aurones inhibit tubulin polymerization at the colchicine-binding site and repress PC-3 tumor xenografts in nude mice and myc-induced T-ALL in zebrafish. Scientific Reports, 2019, 9, 6439.	1.6	15
746	Regulating the BCL2 Family to Improve Sensitivity to Microtubule Targeting Agents. Cells, 2019, 8, 346.	1.8	42
747	Design, synthesis and antitumour and anti-angiogenesis evaluation of 22 moscatilin derivatives. Bioorganic and Medicinal Chemistry, 2019, 27, 2657-2665.	1.4	10
748	<i>In Situ</i> Ring Contraction and Transformation of the Rhizoxin Macrocycle through an Abiotic Pathway. Journal of Natural Products, 2019, 82, 886-894.	1.5	2
749	Conformational Properties of the Chemotherapeutic Drug Analogue Epothilone A: How to Model a Flexible Protein Ligand Using Scarcely Available Experimental Data. Journal of Chemical Information and Modeling, 2019, 59, 2218-2230.	2.5	4
750	Hybrid cis-stilbene Molecules: Novel Anticancer Agents. International Journal of Molecular Sciences, 2019, 20, 1300.	1.8	31
751	Microtubule-Targeting Drugs: More than Antimitotics. Journal of Natural Products, 2019, 82, 680-685.	1.5	65
752	Pocket similarity identifies selective estrogen receptor modulators as microtubule modulators at the taxane site. Nature Communications, 2019, 10, 1033.	5.8	22
753	Design and Synthesis of Novel Cytotoxic Indoleâ€Thiosemicarbazone Derivatives: Biological Evaluation and Docking Study. Chemistry and Biodiversity, 2019, 16, e1800470.	1.0	14
754	Influence of 2â€Methoxyestradiol and Sex on Hypoxiaâ€Induced Pulmonary Hypertension and Hypoxiaâ€Inducible Factorâ€Iâ€I±. Journal of the American Heart Association, 2019, 8, e011628.	1.6	33
755	In Silico Repurposing of Cell Cycle Modulators for Cancer Treatment. , 2019, , 255-279.		0
756	Polymorphs, co-crystal structure and pharmacodynamics study of MBRI-001, a deuterium-substituted plinabulin derivative as a tubulin polymerization inhibitor. Bioorganic and Medicinal Chemistry, 2019, 27, 1836-1844.	1.4	5
757	Diphenyl ether derivatives occupy the expanded binding site of cyclohexanedione compounds at the colchicine site in tubulin by movement of the αT5 loop. European Journal of Medicinal Chemistry, 2019, 171, 195-208.	2.6	5

#	Article	IF	CITATIONS
758	Rapid and inefficient kinetics of sickle hemoglobin fiber growth. Science Advances, 2019, 5, eaau1086.	4.7	21
759	Phenethyl Isothiocyanate and Cisplatin Co-Encapsulated in a Liposomal Nanoparticle for Treatment of Non-Small Cell Lung Cancer. Molecules, 2019, 24, 801.	1.7	25
760	Anti-tubulin agents of natural origin: Targeting taxol, vinca, and colchicine binding domains. European Journal of Medicinal Chemistry, 2019, 171, 310-331.	2.6	127
761	Tubulin mRNA stability is sensitive to change in microtubule dynamics caused by multiple physiological and toxic cues. PLoS Biology, 2019, 17, e3000225.	2.6	49
762	Plinabulin, an inhibitor of tubulin polymerization, targets KRAS signaling through disruption of endosomal recycling. Biomedical Reports, 2019, 10, 218-224.	0.9	19
763	Characterization of Disulfide Bond Rebridged Fab–Drug Conjugates Prepared Using a Dual Maleimide Pyrrolobenzodiazepine Cytotoxic Payload. ChemMedChem, 2019, 14, 1185-1195.	1.6	15
764	Molecular modeling study on the differential microtubuleâ€stabilizing effect in singly―and doublyâ€bonded complexes with peloruside A and paclitaxel. Proteins: Structure, Function and Bioinformatics, 2019, 87, 668-678.	1.5	6
765	Photo-control of cancer cell growth by benzodiazo N-substituted pyrrole derivatives. Journal of Photochemistry and Photobiology A: Chemistry, 2019, 377, 109-118.	2.0	12
766	Covalent modification of Cys-239 in β-tubulin by small molecules as a strategy to promote tubulin heterodimer degradation. Journal of Biological Chemistry, 2019, 294, 8161-8170.	1.6	35
767	Antiproliferative Aspidosperma-Type Monoterpenoid Indole Alkaloids from Bousigonia mekongensis Inhibit Tubulin Polymerization. Molecules, 2019, 24, 1256.	1.7	15
768	Design, synthesis and biological evaluation of pyridine-chalcone derivatives as novel microtubule-destabilizing agents. European Journal of Medicinal Chemistry, 2019, 173, 1-14.	2.6	47
769	Emerging roles of allosteric modulators in the regulation of proteinâ€protein interactions (PPIs): A new paradigm for PPI drug discovery. Medicinal Research Reviews, 2019, 39, 2314-2342.	5.0	77
770	Antibody-Drug Conjugates for the Therapy of Thoracic Malignancies. Journal of Thoracic Oncology, 2019, 14, 358-376.	0.5	11
771	Activated Plateletsâ€Targeting Micelles with Controlled Drug Release for Effective Treatment of Primary and Metastatic Triple Negative Breast Cancer. Advanced Functional Materials, 2019, 29, 1806620.	7.8	43
772	Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy. Medicinal Research Reviews, 2019, 39, 1398-1426.	5.0	98
773	Molecular, Biological and Structural Features of VL CDR-1 Rb44 Peptide, Which Targets the Microtubule Network in Melanoma Cells. Frontiers in Oncology, 2019, 9, 25.	1.3	3
774	Polymer "ruthenium-cyclopentadienyl―conjugates - New emerging anti-cancer drugs. European Journal of Medicinal Chemistry, 2019, 168, 373-384.	2.6	26
775	Synthesis and bioevaluation of diarylpyrazoles as antiproliferative agents. European Journal of Medicinal Chemistry, 2019, 171, 1-10.	2.6	17

#	ARTICLE	IF	CITATIONS
776	CETSA-based target engagement of taxanes as biomarkers for efficacy and resistance. Scientific Reports, 2019, 9, 19384.	1.6	22
777	The Masked Polar Group Incorporation (MPGI) Strategy in Drug Design: Effects of Nitrogen Substitutions on Combretastatin and Isocombretastatin Tubulin Inhibitors. Molecules, 2019, 24, 4319.	1.7	15
778	Topological properties and inÂvitro identification of essential nodes of the Paclitaxel and Vincristine interactomes in PC-3 cells. Biomedical Journal, 2019, 42, 307-316.	1.4	4
779	Complex Formation with Monomeric α-Tubulin and Importin 13 Fosters c-Jun Protein Stability and Is Required for c-Jun's Nuclear Translocation and Activity. Cancers, 2019, 11, 1806.	1.7	6
780	3,5-Diaryl-1H-pyrazolo[3,4-b]pyridines as potent tubulin polymerization inhibitors: Rational design, synthesis and biological evaluation. European Journal of Medicinal Chemistry, 2019, 168, 426-435.	2.6	33
781	Bioelectronics of The Cellular Cytoskeleton: Monitoring Cytoskeletal Conductance Variation for Sensing Drug Resistance. ACS Sensors, 2019, 4, 353-362.	4.0	13
782	Synthesis, molecular properties prediction and biological evaluation of indole-vinyl sulfone derivatives as novel tubulin polymerization inhibitors targeting the colchicine binding site. Bioorganic Chemistry, 2019, 85, 49-59.	2.0	31
783	A class of novel tubulin polymerization inhibitors exert effective anti-tumor activity via mitotic catastrophe. European Journal of Medicinal Chemistry, 2019, 163, 896-910.	2.6	31
784	Vincristine Impairs Microtubules and Causes Neurotoxicity in Cerebral Organoids. Neuroscience, 2019, 404, 530-540.	1.1	30
785	Zerumbone, a cyclic sesquiterpene, exerts antimitotic activity in HeLa cells through tubulin binding and exhibits synergistic activity with vinblastine and paclitaxel. Cell Proliferation, 2019, 52, e12558.	2.4	19
786	Synthesis of Thicolchicineâ€Based Conjugates: Investigation towards Bivalent Tubulin/Microtubules Binders. ChemPlusChem, 2019, 84, 98-102.	1.3	9
787	Power of Tyrosine Assembly in Microtubule Stabilization and Neuroprotection Fueled by Phenol Appendages. ACS Chemical Neuroscience, 2019, 10, 1506-1516.	1.7	5
788	Anti-mitotic therapies in cancer. Journal of Cell Biology, 2019, 218, 10-11.	2.3	67
789	Antibody–drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes. Journal of Cellular Physiology, 2019, 234, 5628-5642.	2.0	157
790	Non-mitotic effect of albendazole triggers apoptosis of human leukemia cells via SIRT3/ROS/p38 MAPK/TTP axis-mediated TNF-α upregulation. Biochemical Pharmacology, 2019, 162, 154-168.	2.0	34
791	Discovery and optimization of 3,4,5-trimethoxyphenyl substituted triazolylthioacetamides as potent tubulin polymerization inhibitors. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 22-27.	1.0	14
792	Synthesis, biological evaluation, and molecular docking investigation of 3-amidoindoles as potent tubulin polymerization inhibitors. European Journal of Medicinal Chemistry, 2019, 162, 525-533.	2.6	30
793	6-MOMIPP, a novel brain-penetrant anti-mitotic indolyl-chalcone, inhibits glioblastoma growth and viability. Cancer Chemotherapy and Pharmacology, 2019, 83, 237-254.	1.1	13

#	Article	IF	CITATIONS
794	Intracellular reduction in <scp>ATP</scp> levels contributes to <scp>CYT</scp> 997â€induced suppression of metastasis of head and neck squamous carcinoma. Journal of Cellular and Molecular Medicine, 2019, 23, 1174-1182.	1.6	8
795	Synthesis and biological evaluation of quinoxaline derivatives as tubulin polymerization inhibitors that elevate intracellular <scp>ROS</scp> and triggers apoptosis via mitochondrial pathway. Chemical Biology and Drug Design, 2019, 93, 617-627.	1.5	10
796	Polyester Nanoparticle Encapsulation Mitigates Paclitaxel-Induced Peripheral Neuropathy. ACS Chemical Neuroscience, 2019, 10, 1801-1812.	1.7	8
797	Synthesis, molecular modelling and anticancer evaluation of new pyrrolo[1,2- <i>b</i>]pyridazine and pyrrolo[2,1- <i>a</i>]phthalazine derivatives. Journal of Enzyme Inhibition and Medicinal Chemistry, 2019, 34, 230-243.	2.5	24
798	MSC-Delivered Soluble TRAIL and Paclitaxel as Novel Combinatory Treatment for Pancreatic Adenocarcinoma. Theranostics, 2019, 9, 436-448.	4.6	39
799	Hemithioindigos for Cellular Photopharmacology: Desymmetrised Molecular Switch Scaffolds Enabling Design Control over the Isomerâ€Đependency of Potent Antimitotic Bioactivity. ChemBioChem, 2019, 20, 1305-1314.	1.3	48
800	Antitubulin sulfonamides: The successful combination of an established drug class and a multifaceted target. Medicinal Research Reviews, 2019, 39, 775-830.	5.0	25
801	Discovery of novel quinazolines as potential anti-tubulin agents occupying three zones of colchicine domain. Bioorganic Chemistry, 2019, 83, 380-390.	2.0	34
802	1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase. European Journal of Medicinal Chemistry, 2019, 162, 612-630.	2.6	32
803	Synthesis and biological evaluation of 1-benzyl-N-(2-(phenylamino)pyridin-3-yl)-1H-1,2,3-triazole-4-carboxamides as antimitotic agents. Bioorganic Chemistry, 2019, 83, 535-548.	2.0	15
804	Structure-activity relationships, biological evaluation and structural studies of novel pyrrolonaphthoxazepines as antitumor agents. European Journal of Medicinal Chemistry, 2019, 162, 290-320.	2.6	31
805	Inhibition of the formation of autophagosome but not autolysosome augments ABTâ€751â€induced apoptosis in <i>TP53</i> â€deficient Hepâ€3B cells. Journal of Cellular Physiology, 2019, 234, 9551-9563.	2.0	5
806	Mitosis inhibitors in anticancer therapy: When blocking the exit becomes a solution. Cancer Letters, 2019, 440-441, 64-81.	3.2	60
807	Discovery of Novel Quinoline–Chalcone Derivatives as Potent Antitumor Agents with Microtubule Polymerization Inhibitory Activity. Journal of Medicinal Chemistry, 2019, 62, 993-1013.	2.9	84
808	The pyrrolopyrimidine colchicine-binding site agent PP-13 reduces the metastatic dissemination of invasive cancer cells in vitro and in vivo. Biochemical Pharmacology, 2019, 160, 1-13.	2.0	17
809	Effects of carbendazim and astaxanthin co-treatment on the proliferation of MCF-7 breast cancer cells. In Vitro Cellular and Developmental Biology - Animal, 2019, 55, 113-119.	0.7	29
810	Conformational States of E7010 Is Complemented by Microclusters of Water Inside the α,β-Tubulin Core. Journal of Chemical Information and Modeling, 2019, 59, 2274-2286.	2.5	9
811	The human allicin-proteome: S-thioallylation of proteins by the garlic defence substance allicin and its biological effects. Free Radical Biology and Medicine, 2019, 131, 144-153.	1.3	61

ARTICLE IF CITATIONS Predictive factors for taxane acute pain syndrome determined by ordered logistic regression analysis. 812 1.0 6 Supportive Care in Cancer, 2019, 27, 2673-2677. Synthesis and Microtubuleâ€Destabilizing Activity of N â€Cyclopropylâ€4â€((3,4â€dihydroquinolinâ€1(2 H) Tj ETQq1 1 0.784314 rgl Computer-aided molecular design of (E)-N-Aryl-2-ethene-sulfonamide analogues as microtubule 814 2.3 4 targeted agents in prostate cancer. Arabian Journal of Chemistry, 2019, 12, 2150-2165. Pharmacophore modeling, 3D-QSAR, docking study and ADME prediction of acyl 1,3,4-thiadiazole amides and sulfonamides as antitubulin agents. Arabian Journal of Chemistry, 2019, 12, 5000-5018. Synthesis, characterization, and application of griseofulvin surface molecularly imprinted polymers as the selective solid phase extraction sorbent in rat plasma samples. Arabian Journal of Chemistry, 816 2.3 11 2020, 13, 4082-4091. Potential drugs used in the antibody–drug conjugate (ADC) architecture for cancer therapy. Journal of Cellular Physiology, 2020, 235, 31-64. 818 Control of the Cell Cycle., 2020, , 56-73.e5. 1 Tubulin colchicine site binding agent LL01 displays potent antitumor efficiency both in vitro and in 1.2 vivo with suitable drug-like properties. Investigational New Drugs, 2020, 38, 29-38. Structural insights into the design of indole derivatives as tubulin polymerization inhibitors. FEBS Letters, 2020, 594, 199-204. 820 1.3 8 A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors. Investigational New 1.2 Drugs, 2020, 38, 1067-1076. Synthesis of d-ring modified acid hydrazide derivatives of podophyllotoxin and their anticancer 822 12 2.0 studies as Tubulin inhibiting agents. Bioorganic Chemistry, 2020, 94, 103384. Synthesis and biological evaluation of 1-(benzofuran-3-yl)-4-(3,4,5-trimethoxyphenyl)-1H-1,2,3-triazole derivatives as tubulin polymerization inhibitors. Bioorganic Chemistry, 2020, 94, 103392. The RepID–CRL4 ubiquitin ligase complex regulates metaphase to anaphase transition via BUB3 824 5.8 26 degradation. Nature Communications, 2020, 11, 24. A proficient microwave synthesis with structure elucidation and the exploitation of the biological behavior of the newly halogenated 3-amino-1H-benzo[f]chromene molecules, targeting dual inhibition of topoisomerase II and microtubules. Bioorganic Chemistry, 2020, 95, 103549. 16 The stilbene and dibenzo[b,f]oxepine derivatives as anticancer compounds. Biomedicine and 826 2.58 Pharmacotherapy, 2020, 123, 109781. Thiazole-containing compounds as therapeutic targets for cancer therapy. European Journal of 203 Medicinal Chemistry, 2020, 188, 112016. Structureâ€"Activity Relationship Study of Novel 6-Aryl-2-benzoyl-pyridines as Tubulin Polymerization 828 2.9 37 Inhibitors with Potent Antiproliferative Properties. Journal of Medicinal Chemistry, 2020, 63, 827-846. Synthesis, biological evaluation, and molecular modelling of new naphthalene-chalcone derivatives as potential anticancer agents on MCF-7 breast cancer cells by targeting tubulin colchicine binding 829 site. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 139-144.

#	Article	IF	CITATIONS
830	Design, synthesis and biological evaluation of novel indole-based oxalamide and aminoacetamide derivatives as tubulin polymerization inhibitors. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 126816.	1.0	19
831	An Orally Available Tubulin Inhibitor, VERU-111, Suppresses Triple-Negative Breast Cancer Tumor Growth and Metastasis and Bypasses Taxane Resistance. Molecular Cancer Therapeutics, 2020, 19, 348-363.	1.9	28
832	Taxanes convert regions of perturbed microtubule growth into rescue sites. Nature Materials, 2020, 19, 355-365.	13.3	44
833	Development of Surface Molecularly Imprinted Polymers as Dispersive Solid Phase Extraction Coupled with HPLC Method for the Removal and Detection of Griseofulvin in Surface Water. International Journal of Environmental Research and Public Health, 2020, 17, 134.	1.2	9
834	Computational modeling and target synthesis of monomethoxy-substituted o-diphenylisoxazoles with unexpectedly high antimitotic microtubule destabilizing activity. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127608.	1.0	9
835	Development of triazolothiadiazine derivatives as highly potent tubulin polymerization inhibitors: Structure-activity relationship, inÂvitro and inÂvivo study. European Journal of Medicinal Chemistry, 2020, 208, 112847.	2.6	35
836	Tumor Therapeutic Modes. , 2020, , 135-229.		1
837	Chromosomal instability reducing effect of paclitaxel and lapatinib in mouse embryonic stem cells with chromosomal abnormality. Molecular Biology Reports, 2020, 47, 8605-8614.	1.0	1
838	A stereotetrad-centered approach toward pironetin: Dead ends, Detour, and evolution of the synthetic strategy. Tetrahedron, 2020, 76, 131660.	1.0	5
839	Folate-Targeted Cholesterol-Grafted Lipo-Polymeric Nanoparticles for Chemotherapeutic Agent Delivery. AAPS PharmSciTech, 2020, 21, 280.	1.5	17
840	Photosensitizer-stabilized self-assembling nanoparticles potentiate chemo/photodynamic efficacy of patient-derived melanoma. Journal of Controlled Release, 2020, 328, 325-338.	4.8	31
841	The investigation and bioorthogonal anticancer activity enhancement of a triphenylphosphine-labile prodrug of seleno-combretastatin-4. Chemical Communications, 2020, 56, 14495-14498.	2.2	4
842	A novel orally active microtubule destabilizing agent S-40 targets the colchicine-binding site and shows potent antitumor activity. Cancer Letters, 2020, 495, 22-32.	3.2	12
843	Synthesis, and biological evaluation of 3,6-diaryl-[1,2,4]triazolo[4,3-a]pyridine analogues as new potent tubulin polymerization inhibitors. European Journal of Medicinal Chemistry, 2020, 204, 112625.	2.6	35
844	SAR Investigation and Discovery of Water-Soluble 1-Methyl-1,4-dihydroindeno[1,2- <i>c</i>]pyrazoles as Potent Tubulin Polymerization Inhibitors. Journal of Medicinal Chemistry, 2020, 63, 14840-14866.	2.9	18
845	Nanomechanics in Monitoring the Effectiveness of Drugs Targeting the Cancer Cell Cytoskeleton. International Journal of Molecular Sciences, 2020, 21, 8786.	1.8	25
846	A Multipronged Approach Establishes Covalent Modification of β-Tubulin as the Mode of Action of Benzamide Anti-cancer Toxins. Journal of Medicinal Chemistry, 2020, 63, 14054-14066.	2.9	9
847	Discovery of noscapine derivatives as potential Î ² -tubulin inhibitors. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127489.	1.0	9

#	Article	IF	CITATIONS
848	Chemometric and Transcriptomic Profiling, Microtubule Disruption and Cell Death Induction by Secalonic Acid in Tumor Cells. Molecules, 2020, 25, 3224.	1.7	7
849	Recent applications of the Wittig reaction in alkaloid synthesis. The Alkaloids Chemistry and Biology, 2020, 84, 201-334.	0.8	16
850	Biology of Glioblastoma Multiforme—Exploration of Mitotic Catastrophe as a Potential Treatment Modality. International Journal of Molecular Sciences, 2020, 21, 5324.	1.8	16
851	Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours. British Journal of Cancer, 2020, 123, 1360-1369.	2.9	10
852	Cytotoxic substituted indolizines as new colchicine site tubulin polymerisation inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 1581-1595.	2.5	11
853	Antibody-Drug Conjugates: The New Frontier of Chemotherapy. International Journal of Molecular Sciences, 2020, 21, 5510.	1.8	83
854	Diaryl Ether: A Privileged Scaffold for Drug and Agrochemical Discovery. Journal of Agricultural and Food Chemistry, 2020, 68, 9839-9877.	2.4	70
855	<p>Analysis of Differential Expression Proteins of Paclitaxel-Treated Lung Adenocarcinoma Cell A549 Using Tandem Mass Tag-Based Quantitative Proteomics</p> . OncoTargets and Therapy, 2020, Volume 13, 10297-10313.	1.0	7
856	Mechanical Force and Actin Dynamics during Cutaneous Squamous Cell Carcinoma (cSCC) Progression: Opportunities for Novel Treatment Modalities. , 2020, , .		1
857	Synthetic and medicinal chemistry of phthalazines: Recent developments, opportunities and challenges. Bioorganic Chemistry, 2020, 105, 104425.	2.0	18
858	Natural and Semisynthetic Chalcones as Dual FLT3 and Microtubule Polymerization Inhibitors. Journal of Natural Products, 2020, 83, 3111-3121.	1.5	19
859	Design, synthesis, and anticancer evaluation of benzophenone derivatives bearing naphthalene moiety as novel tubulin polymerization inhibitors. Bioorganic Chemistry, 2020, 104, 104265.	2.0	21
860	Photoswitchable paclitaxel-based microtubule stabilisers allow optical control over the microtubule cytoskeleton. Nature Communications, 2020, 11, 4640.	5.8	52
861	Intrinsic and Extrinsic Factors Affecting Microtubule Dynamics in Normal and Cancer Cells. Molecules, 2020, 25, 3705.	1.7	38
862	Two Antagonistic Microtubule Targeting Drugs Act Synergistically to Kill Cancer Cells. Cancers, 2020, 12, 2196.	1.7	7
863	Molecular targets and anticancer activity of quinoline–chalcone hybrids: literature review. RSC Advances, 2020, 10, 31139-31155.	1.7	74
864	Is Crocin a Potential Anti-tumor Candidate Targeting Microtubules? Computational Insights From Molecular Docking and Dynamics Simulations. Frontiers in Molecular Biosciences, 2020, 7, 586970.	1.6	4
865	Platinum(IV) complexes conjugated with chalcone analogs as dual targeting anticancer agents: In vitro and in vivo studies. Bioorganic Chemistry, 2020, 105, 104430.	2.0	17

#	Article	IF	CITATIONS
866	A New Quantitative Cell-Based Assay Reveals Unexpected Microtubule Stabilizing Activity of Certain Kinase Inhibitors, Clinically Approved or in the Process of Approval. Frontiers in Pharmacology, 2020, 11, 543.	1.6	10
867	Potent colchicine-site ligands with improved intrinsic solubility by replacement of the 3,4,5-trimethoxyphenyl ring with a 2-methylsulfanyl-6-methoxypyridine ring. Bioorganic Chemistry, 2020, 98, 103755.	2.0	13
868	Colchicine Alkaloids and Synthetic Analogues: Current Progress and Perspectives. Journal of Medicinal Chemistry, 2020, 63, 10618-10651.	2.9	64
869	NMK-BH2, a novel microtubule-depolymerising bis (indolyl)-hydrazide-hydrazone, induces apoptotic and autophagic cell death in cervical cancer cells by binding to tubulin at colchicine – site. Biochimica Et Biophysica Acta - Molecular Cell Research, 2020, 1867, 118762.	1.9	14
870	The strategic combination of trastuzumab emtansine with oncolytic rhabdoviruses leads to therapeutic synergy. Communications Biology, 2020, 3, 254.	2.0	11
871	The emerging role of antibody-drug conjugates in urothelial carcinoma. Expert Review of Anticancer Therapy, 2020, 20, 551-561.	1.1	23
872	Albendazole-Induced SIRT3 Upregulation Protects Human Leukemia K562 Cells from the Cytotoxicity of MCL1 Suppression. International Journal of Molecular Sciences, 2020, 21, 3907.	1.8	8
873	Pharmacology Profile of Recently Developed Multiâ€Functional Azoles; SARâ€Based Predictive Structural Modification. ChemistrySelect, 2020, 5, 6730-6758.	0.7	3
874	Novel dibenzoxanthenes compounds inhibit human gastric cancer SGC-7901 cell growth by apoptosis. Journal of Molecular Structure, 2020, 1220, 128588.	1.8	2
875	Genomewide Metaâ€Analysis Validates a Role for <i>S1PR1</i> in Microtubule Targeting Agentâ€Induced Sensory Peripheral Neuropathy. Clinical Pharmacology and Therapeutics, 2020, 108, 625-634.	2.3	25
876	Centrocountins—synthesis and chemical biology of nature inspired indoloquinolizines. , 2020, , 247-265.		1
877	Design, synthesis and biological evaluation of a novel tubulin inhibitor SKLB0565 targeting the colchicine binding site. Bioorganic Chemistry, 2020, 97, 103695.	2.0	11
878	Drp1 modulates mitochondrial stress responses to mitotic arrest. Cell Death and Differentiation, 2020, 27, 2620-2634.	5.0	18
879	CAMSAP2-mediated noncentrosomal microtubule acetylation drives hepatocellular carcinoma metastasis. Theranostics, 2020, 10, 3749-3766.	4.6	16
880	Structure-based design and synthesis of novel furan-diketopiperazine-type derivatives as potent microtubule inhibitors for treating cancer. Bioorganic and Medicinal Chemistry, 2020, 28, 115435.	1.4	12
881	Destruction of a Microtubule-Bound MYC Reservoir during Mitosis Contributes to Vincristine's Anticancer Activity. Molecular Cancer Research, 2020, 18, 859-872.	1.5	10
882	Beta3-Tubulin Is Critical for Microtubule Dynamics, Cell Cycle Regulation, and Spontaneous Release of Microvesicles in Human Malignant Melanoma Cells (A375). International Journal of Molecular Sciences, 2020, 21, 1656.	1.8	15
883	Design, synthesis and biological evaluation of novel 5,6,7-trimethoxy-N-aryl-2-styrylquinolin-4-amines as potential anticancer agents and tubulin polymerization inhibitors. Bioorganic Chemistry, 2020, 98, 103711.	2.0	44

#	Article	IF	CITATIONS
884	Synthesis and biological evaluation of benzofuran-based 3,4,5-trimethoxybenzamide derivatives as novel tubulin polymerization inhibitors. Bioorganic Chemistry, 2020, 102, 104076.	2.0	25
885	Dynamic and asymmetric fluctuations in the microtubule wall captured by high-resolution cryoelectron microscopy. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 16976-16984.	3.3	49
886	Katanin P60: a potential biomarker for lymph node metastasis and prognosis for non-small cell lung cancer. World Journal of Surgical Oncology, 2020, 18, 157.	0.8	6
887	Mitochondrial ROS accumulation inhibiting JAK2/STAT3 pathway is a critical modulator of CYT997-induced autophagy and apoptosis in gastric cancer. Journal of Experimental and Clinical Cancer Research, 2020, 39, 119.	3.5	51
888	Butterfly Structure: A Privileged Scaffold Targeting Tubulin-Colchicine Binding Site. Current Topics in Medicinal Chemistry, 2020, 20, 1505-1508.	1.0	4
889	Novel piperidine derivatives as colchicine binding site inhibitors induce apoptosis and inhibit epithelial-mesenchymal transition against prostate cancer PC3 cells. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 1403-1413.	2.5	11
890	Predicting and affecting response to cancer therapy based on pathway-level biomarkers. Nature Communications, 2020, 11, 3296.	5.8	55
891	Characterization of Tâ€DM1â€resistant breast cancer cells. Pharmacology Research and Perspectives, 2020, 8, e00617.	1.1	9
892	Systematic functional identification of cancer multi-drug resistance genes. Genome Biology, 2020, 21, 27.	3.8	26
893	Discovery of T-1101 tosylate as a first-in-class clinical candidate for Hec1/Nek2 inhibition in cancer therapy. European Journal of Medicinal Chemistry, 2020, 191, 112118.	2.6	8
894	From Seabed to Bedside: A Review on Promising Marine Anticancer Compounds. Biomolecules, 2020, 10, 248.	1.8	34
895	Discovery of isopenicin A, a meroterpenoid as a novel inhibitor of tubulin polymerization. Biochemical and Biophysical Research Communications, 2020, 525, 303-307.	1.0	8
896	Antitumor Activity of Asperphenin A, a Lipopeptidyl Benzophenone from Marine-Derived Aspergillus sp. Fungus, by Inhibiting Tubulin Polymerization in Colon Cancer Cells. Marine Drugs, 2020, 18, 110.	2.2	17
897	Unraveling the molecular mechanism of BNC105, a phase II clinical trial vascular disrupting agent, provides insights into drug design. Biochemical and Biophysical Research Communications, 2020, 525, 148-154.	1.0	7
898	Neoadjuvant Approaches Prior To Radical Prostatectomy. Cancer Journal (Sudbury, Mass), 2020, 26, 2-12.	1.0	5
899	Fibronectin-targeted dual-acting micelles for combination therapy of metastatic breast cancer. Signal Transduction and Targeted Therapy, 2020, 5, 12.	7.1	41
900	Antihepatoma activity of multifunctional polymeric nanoparticles via inhibition of microtubules and tyrosine kinases. Nanomedicine, 2020, 15, 381-396.	1.7	5
901	DHPAC, a novel microtubule depolymerizing agent, suppresses angiogenesis and vasculogenic mimicry formation of human nonâ€small cell lung cancer. Journal of Cellular Biochemistry, 2020, 121, 4756-4771.	1.2	8

#	Article	IF	CITATIONS
902	Elaeocarpus reticulatus fruit extracts reduce viability and induce apoptosis in pancreatic cancer cells in vitro. Molecular Biology Reports, 2020, 47, 2073-2084.	1.0	5
903	β-Lactams with antiproliferative and antiapoptotic activity in breast and chemoresistant colon cancer cells. European Journal of Medicinal Chemistry, 2020, 189, 112050.	2.6	25
904	SIRT3, PP2A and TTP protein stability in the presence of TNFâ€Ì± on vincristineâ€induced apoptosis of leukaemia cells. Journal of Cellular and Molecular Medicine, 2020, 24, 2552-2565.	1.6	11
905	Antibody Conjugates-Recent Advances and Future Innovations. Antibodies, 2020, 9, 2.	1.2	75
906	Epothilone D alters normal growth, viability and microtubule dependent intracellular functions of cortical neurons in vitro. Scientific Reports, 2020, 10, 918.	1.6	13
907	Effects of microtubule-inhibiting small molecule and antibody-drug conjugate treatment on differentially-sized A431 squamous carcinoma spheroids. Scientific Reports, 2020, 10, 907.	1.6	13
908	Synthesis and biological evaluation of novel shikonin-benzo[b]furan derivatives as tubulin polymerization inhibitors targeting the colchicine binding site. European Journal of Medicinal Chemistry, 2020, 190, 112105.	2.6	29
909	Cytoskeletal Proteins in Cancer and Intracellular Stress: A Therapeutic Perspective. Cancers, 2020, 12, 238.	1.7	70
910	The microtubule targeting agents eribulin and paclitaxel activate similar signaling pathways and induce cell death predominantly in a caspase-independent manner. Cell Cycle, 2020, 19, 464-478.	1.3	15
911	Kinesin family member 11 is a potential therapeutic target and is suppressed by microRNAâ€30a in breast cancer. Molecular Carcinogenesis, 2020, 59, 908-922.	1.3	10
912	Synthesis of C-29-phosphonium derivatives of 3,28-diacetoxylup-20(29)-en-30-oic acid. Russian Chemical Bulletin, 2020, 69, 487-491.	0.4	5
913	AQ-4, a deuterium-containing molecule, acts as a microtubule-targeting agent for cancer treatment. European Journal of Pharmacology, 2020, 877, 173093.	1.7	2
914	Design, synthesis and anticancer properties of isocombretapyridines as potent colchicine binding site inhibitors. European Journal of Medicinal Chemistry, 2020, 197, 112308.	2.6	13
915	CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110. Journal of Hematology and Oncology, 2020, 13, 32.	6.9	13
916	A novel benzodiazepine derivative that suppresses microtubules dynamics and impairs mitotic progression. Journal of Cell Science, 2020, 133, .	1.2	3
917	In silico design of peptide inhibitors of tubulin: amyloid-β as a lead compound. Journal of Biomolecular Structure and Dynamics, 2021, 39, 2189-2198.	2.0	3
918	Cyclic bridged analogs of isoCA-4: Design, synthesis and biological evaluation. European Journal of Medicinal Chemistry, 2021, 209, 112873.	2.6	16
919	Synthesis of Morpholineâ€Based Analogues of (â^)â€Zampanolide and Their Biological Activity. Chemistry - A European Journal, 2021, 27, 5936-5943.	1.7	7

#	Article	IF	CITATIONS
920	Target identification of a novel unsymmetrical 1,3,4â€oxadiazole derivative with antiproliferative properties. Journal of Cellular Physiology, 2021, 236, 3789-3799.	2.0	4
921	Predicting and Overcoming Taxane Chemoresistance. Trends in Molecular Medicine, 2021, 27, 138-151.	3.5	16
922	Methylsulfanylpyridine based diheteroaryl isocombretastatin analogs as potent anti-proliferative agents. European Journal of Medicinal Chemistry, 2021, 209, 112933.	2.6	5
923	Phase I Dose-Escalation Study of SCB01A, a Microtubule Inhibitor with Vascular Disrupting Activity, in Patients with Advanced Solid Tumors. Oncologist, 2021, 26, e567-e579.	1.9	3
924	Design, synthesis, and biological evaluation of new series of pyrrol-2(3H)-one and pyridazin-3(2H)-one derivatives as tubulin polymerization inhibitors. Bioorganic Chemistry, 2021, 107, 104522.	2.0	8
925	High-resolution X-ray structure of three microtubule-stabilizing agents in complex with tubulin provide a rationale for drug design. Biochemical and Biophysical Research Communications, 2021, 534, 330-336.	1.0	10
926	Microtubule-targeting agents and neurodegeneration. Drug Discovery Today, 2021, 26, 604-615.	3.2	16
927	Development of novel derivatives of stilbene and macrocyclic compounds as potent of anti-microtubule factors. Biomedicine and Pharmacotherapy, 2021, 133, 110973.	2.5	12
928	Quantitative self-assembly of photoactivatable small molecular prodrug cocktails for safe and potent cancer chemo-photodynamic therapy. Nano Today, 2021, 36, 101030.	6.2	52
929	Tubulin inhibitory activity of a novel colchicine-binding compounds based on a dinaphthospiropyranran scaffold. Bioorganic and Medicinal Chemistry, 2021, 29, 115874.	1.4	1
930	The 3-D conformational shape of N-naphthyl-cyclopenta[d]pyrimidines affects their potency as microtubule targeting agents and their antitumor activity. Bioorganic and Medicinal Chemistry, 2021, 29, 115887.	1.4	5
931	Cyclization of Polarized Divinyl Ketones under Aqueous and Ambient Conditions. Advanced Synthesis and Catalysis, 2021, 363, 251-258.	2.1	3
932	Congeners Derived from Microtubule-Active Phenylpyrimidines Produce a Potent and Long-Lasting Paralysis of <i>Schistosoma mansoni</i> In Vitro. ACS Infectious Diseases, 2021, 7, 1089-1103.	1.8	6
933	Marine sponges: source of novel biotechnological substances. , 2021, , 363-379.		0
934	Self-assembled supramolecular nanomicelles from a bile acid–docetaxel conjugate are highly tolerable with improved therapeutic efficacy. Biomaterials Science, 2021, 9, 5626-5639.	2.6	4
935	Light-driven photoswitching of quinazoline analogues of combretastatin A-4 as an effective approach for targeting skin cancer cells. Organic and Biomolecular Chemistry, 2021, 19, 7670-7677.	1.5	3
936	Methoxy and bromo scans on <i>N</i> -(5-methoxyphenyl) methoxybenzenesulphonamides reveal potent cytotoxic compounds, especially against the human breast adenocarcinoma MCF7 cell line. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 1029-1047.	2.5	4
937	Microtubule destabilization is a critical checkpoint of chemotaxis and transendothelial migration in melanoma cells but not in T cells. Cell Adhesion and Migration, 2021, 15, 166-179.	1.1	3

#	Article	IF	CITATIONS
938	ABT-751 Induces Multiple Anticancer Effects in Urinary Bladder Urothelial Carcinoma-Derived Cells: Highlighting the Induction of Cytostasis through the Inhibition of SKP2 at Both Transcriptional and Post-Translational Levels. International Journal of Molecular Sciences, 2021, 22, 945.	1.8	4
939	Dual Inhibition of γ-Tubulin and Plk1 Induces Mitotic Cell Death. Frontiers in Pharmacology, 2020, 11, 620185.	1.6	4
940	Identified the novel resistant biomarkers for taxane-based therapy for triple-negative breast cancer. International Journal of Medical Sciences, 2021, 18, 2521-2531.	1.1	11
941	A bifunctional molecule-based strategy for the development of theranostic antibody-drug conjugate. Theranostics, 2021, 11, 2550-2563.	4.6	15
942	Structural insights into targeting of the colchicine binding site by ELR510444 and parbendazole to achieve rational drug design. RSC Advances, 2021, 11, 18938-18944.	1.7	3
943	CEP55 Inhibitor: Extensive Computational Approach Defining a New Target of Cell Cycle Machinery Agent. Advanced Pharmaceutical Bulletin, 2021, 12, 191-199.	0.6	0
944	Synthesis, biological evaluation and molecular docking investigation of new sulphonamide derivatives bearing naphthalene moiety as potent tubulin polymerisation inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 1401-1409.	2.5	2
945	The Development of Antibody-Drug Conjugates for Urothelial Carcinoma Treatment. The Korean Journal of Urological Oncology, 2021, 19, 30-39.	0.1	0
946	Histone Deacetylase Inhibitors and Microtubule Inhibitors Induce Apoptosis in Feline Luminal Mammary Carcinoma Cells. Animals, 2021, 11, 502.	1.0	6
947	Taccalonolides: A Novel Class of Microtubule-Stabilizing Anticancer Agents. Cancers, 2021, 13, 920.	1.7	9
949	Microtubule Destabilizing Sulfonamides as an Alternative to Taxane-Based Chemotherapy. International Journal of Molecular Sciences, 2021, 22, 1907.	1.8	7
950	Insight on [1,3]thiazolo[4,5-e]isoindoles as tubulin polymerization inhibitors. European Journal of Medicinal Chemistry, 2021, 212, 113122.	2.6	30
951	Synthesis and bioevaluation of N-(3,4,5-trimethoxyphenyl)-1H-pyrazolo[3,4-b]pyridin-3-amines as tubulin polymerization inhibitors with anti-angiogenic effects. Bioorganic and Medicinal Chemistry, 2021, 31, 115985.	1.4	17
953	Discovery of novel indoleâ€1,2,4â€ŧriazole derivatives as tubulin polymerization inhibitors. Drug Development Research, 2021, 82, 1008-1020.	1.4	9
954	Microtubule-Targeted Self-Assembly Triggers Prometaphase–Metaphase Oscillations Suppressing Tumor Growth. Nano Letters, 2021, 21, 3052-3059.	4.5	10
955	A facile synthesis of diaryl pyrroles led to the discovery of potent colchicine site antimitotic agents. European Journal of Medicinal Chemistry, 2021, 214, 113229.	2.6	13
956	Synthesis and cytotoxic evaluation of novel simplified plinabulin-quinoline derivatives. Mendeleev Communications, 2021, 31, 213-215.	0.6	5
957	Recent Advances in the Molecular Design and Applications of Multispecific Biotherapeutics. Antibodies, 2021, 10, 13.	1.2	21

#	Article	IF	CITATIONS
958	LMTK3 inhibition affects microtubule stability. Molecular Cancer, 2021, 20, 53.	7.9	6
959	The Dolaflexin-based Antibody–Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b. Molecular Cancer Therapeutics, 2021, 20, 896-905.	1.9	25
960	Identification of a novel Bax–Cdk1 signalling complex that links activation of the mitotic checkpoint to apoptosis. Journal of Cell Science, 2021, 134, .	1.2	4
961	Oxocrebanine: A Novel Dual Topoisomerase inhibitor, Suppressed the Proliferation of Breast Cancer Cells MCF-7 by Inducing DNA Damage and Mitotic Arrest. Phytomedicine, 2021, 84, 153504.	2.3	6
962	Azobenzene derivatives show anti-cancer activity against pancreatic cancer cells only under nutrient starvation conditions via G0/G1 cell cycle arrest. Tetrahedron, 2021, 85, 132077.	1.0	3
963	Progress of tubulin polymerization activity detection methods. Bioorganic and Medicinal Chemistry Letters, 2021, 37, 127698.	1.0	22
964	Discovery of novel N-benzylbenzamide derivatives as tubulin polymerization inhibitors with potent antitumor activities. European Journal of Medicinal Chemistry, 2021, 216, 113316.	2.6	15
965	Association between Low-Grade Chemotherapy-Induced Peripheral Neuropathy (CINP) and Survival in Patients with Metastatic Adenocarcinoma of the Pancreas. Journal of Clinical Medicine, 2021, 10, 1846.	1.0	4
966	EB2 promotes hepatocellular carcinoma proliferation and metastasis via MAPK/ERK pathway by modulating microtubule dynamics. Clinical Science, 2021, 135, 847-864.	1.8	7
967	Imaging methods in mechanosensing: a historical perspective and visions for the future. Molecular Biology of the Cell, 2021, 32, 842-854.	0.9	8
968	Synthesis and Preclinical Evaluation of Indole Triazole Conjugates as Microtubule Targeting Agents that are Effective against MCF-7 Breast Cancer Cell Lines. Anti-Cancer Agents in Medicinal Chemistry, 2021, 21, 1047-1055.	0.9	8
969	Colchicine Blocks Tubulin Heterodimer Recycling by Tubulin Cofactors TBCA, TBCB, and TBCE. Frontiers in Cell and Developmental Biology, 2021, 9, 656273.	1.8	14
970	Cytoskeletal proteins as glioblastoma biomarkers and targets for therapy: A systematic review. Critical Reviews in Oncology/Hematology, 2021, 160, 103283.	2.0	17
971	Combretastatin A-4 sulfur-containing heterocyclic derivatives: Synthesis, antiproliferative activities and molecular docking studies. European Journal of Medicinal Chemistry, 2021, 215, 113275.	2.6	7
972	Crocetin and Its Glycoside Crocin, Two Bioactive Constituents From Crocus sativus L. (Saffron), Differentially Inhibit Angiogenesis by Inhibiting Endothelial Cytoskeleton Organization and Cell Migration Through VEGFR2/SRC/FAK and VEGFR2/MEK/ERK Signaling Pathways. Frontiers in Pharmacology, 2021, 12, 675359.	1.6	6
973	Comprehensive Analysis of Binding Sites in Tubulin. Angewandte Chemie - International Edition, 2021, 60, 13331-13342.	7.2	44
974	Comprehensive Analysis of Binding Sites in Tubulin. Angewandte Chemie, 2021, 133, 13443-13454.	1.6	7
975	STMN2 mediates nuclear translocation of Smad2/3 and enhances TGFÎ ² signaling by destabilizing microtubules to promote epithelial-mesenchymal transition in hepatocellular carcinoma. Cancer Letters, 2021, 506, 128-141.	3.2	11

ARTICLE IF CITATIONS Cinnamide derived pyrimidine-benzimidazole hybrids as tubulin inhibitors: Synthesis, in silico and cell 976 2.0 41 growth inhibition studies. Bioorganic Chemistry, 2021, 110, 104765. Small-molecule probe reveals a kinase cascade that links stress signaling to TCF/LEF and Wnt 2.5 responsiveness. Cell Chemical Biology, 2021, 28, 625-635.e5. RIP3/MLKL pathwayâ€regulated necroptosis: A new mechanism of paclitaxelâ€induced peripheral 979 1.4 12 neuropathy. Journal of Biochemical and Molecular Toxicology, 2021, 35, e22834. Synthesis and structure–activity relationships of 5-phenyloxazole-2-carboxylic acid derivatives as novel inhibitors of tubulin polymerization. Bioorganic and Medicinal Chemistry Letters, 2021, 40, 1.0 127968 Synthesis and biological evaluation of novel 1,3-diphenylurea quinoxaline derivatives as potent 981 1.1 2 anticancer agents. Medicinal Chemistry Research, 2021, 30, 1496-1511. Simple Thalidomide Analogs in Melanoma: Synthesis and Biological Activity. Applied Sciences (Switzerland), 2021, 11, 5823. 1.3 Discovery of an indole-substituted furanone with tubulin polymerization inhibition activity. 983 1.0 7 Bioorganic and Medicinal Chemistry Letters, 2021, 41, 127991. Eribulin and Paclitaxel Differentially Alter Extracellular Vesicles and Their Cargo from 984 1.7 Triple-Negative Breast Cancer Cells. Cancers, 2021, 13, 2783. The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively. Cancer Medicine, 2021, 10, 4677-4696. 985 25 1.3 Efficient Synthesis and Bioevaluation of Novel Dual Tubulin/Histone Deacetylase 3 Inhibitors as Potential Ánticancer Agents. Journal of Medicinal Chemistry, 2021, 64, 8447-8473. Anti-Tumoral Effects of a (1H-Pyrrol-1-yl)Methyl-1H-Benzoimidazole Carbamate Ester Derivative on Head 987 1.7 6 and Neck Squamous Carcinoma Cell Lines. Pharmaceuticals, 2021, 14, 564. Size-Dependent Biodistribution of Fluorescent Furano-Allocolchicinoid-Chitosan Formulations in 988 Mice. Polymers, 2021, 13, 2045. Recent Progress on Tubulin Inhibitors with Dual Targeting Capabilities for Cancer Therapy. Journal of 989 2.9 69 Medicinal Chemistry, 2021, 64, 7963-7990. Thiolated-Polymer-Based Nanoparticles as an Avant-Garde Approach for Anticancer 990 16 Therapiesâ€" Reviewing Thiomers from Chitosan and Hyaluronic Acid. Pharmaceutics, 2021, 13, 854. Discovery of novel tubulin inhibitors targeting taxanes site by virtual screening, molecular dynamic 991 1.2 4 simulation, and biological evaluation. Journal of Cellular Biochemistry, 2021, 122, 1609-1624. Second-Generation Antimitotics in Cancer Clinical Trials. Pharmaceutics, 2021, 13, 1011. 992 Fluorine Substituted Proline Enhances the Tubulin Binding Potential of a Tetrapeptide at the GTP Binding Pocket Causing the Inhibition of Microtubule Motility and an Antimitotic Effect. Journal of 993 1.2 3 Physical Chemistry B, 2021, 125, 8768-8780. Total Synthesis of Leiodermatolide A via Transfer Hydrogenative Allylation, Crotylation, and Propargylation: Polyketide Construction beyond Discrete Allyl- or Allenylmetal Reagents. Journal of 994 6.6 the American Chemical Society, 2021, 143, 10590-10595.

#	Article	IF	CITATIONS
995	Integration of NMR studies, computational predictions, and in vitro assays in the search of marine diterpenes with antitumor activity. Chemical Biology and Drug Design, 2021, 98, 507-521.	1.5	3
996	Design, Synthesis, and <i>inâ€vitro</i> Evaluation of Tubulinâ€Targeting Dibenzothiazines with Antiproliferative Activity as a Novel Heterocycle Building Block. ChemMedChem, 2021, 16, 3003-3016.	1.6	6
997	Preclinical and clinical studies into the bioactivity of low-dose naltrexone (LDN) for oncotherapy. International Immunopharmacology, 2021, 96, 107714.	1.7	6
998	Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin—a novel tumor checkpoint controller targeting microtubules. Neuro-Oncology, 2022, 24, 384-395.	0.6	7
999	One-Pot Multi-Component Synthesis and Biological Evaluation of Novel Indole-Pyrimidine Derivatives as Potent Anti-Cancer and Anti-Microbial Agents. Russian Journal of Bioorganic Chemistry, 2021, 47, 954-962.	0.3	4
1000	Eribulin Activates the cGAS-STING Pathway via the Cytoplasmic Accumulation of Mitochondrial DNA. Molecular Pharmacology, 2021, 100, 309-318.	1.0	17
1001	Design, Synthesis, and Biological Evaluation of Stable Colchicine-Binding Site Tubulin Inhibitors 6-Aryl-2-benzoyl-pyridines as Potential Anticancer Agents. Journal of Medicinal Chemistry, 2021, 64, 12049-12074.	2.9	33
1002	1H-benzimidazole-2-yl hydrazones as tubulin-targeting agents: Synthesis, structural characterization, anthelmintic activity and antiproliferative activity against MCF-7 breast carcinoma cells and molecular docking studies. Chemico-Biological Interactions, 2021, 345, 109540.	1.7	20
1003	The X-ray structure of tubulysin analogue TGL in complex with tubulin and three possible routes for the development of next-generation tubulysin analogues. Biochemical and Biophysical Research Communications, 2021, 565, 29-35.	1.0	3
1004	The Phytochemical Scoulerine Inhibits Aurora Kinase Activity to Induce Mitotic and Cytokinetic Defects. Journal of Natural Products, 2021, 84, 2312-2320.	1.5	6
1005	C3 ester side chain plays a pivotal role in the antitumor activity of Maytansinoids. Biochemical and Biophysical Research Communications, 2021, 566, 197-203.	1.0	6
1006	Modulation of Microtubule Properties and Functions by Encapsulation of Nanomaterials Using a Tau-Derived Peptide. Bulletin of the Chemical Society of Japan, 2021, 94, 2100-2112.	2.0	25
1007	X-ray Crystallography-Guided Design, Antitumor Efficacy, and QSAR Analysis of Metabolically Stable Cyclopenta-Pyrimidinyl Dihydroquinoxalinone as a Potent Tubulin Polymerization Inhibitor. Journal of Medicinal Chemistry, 2021, 64, 13072-13095.	2.9	13
1008	Identification of novel microtubule inhibitors effective in fission yeast and human cells and their effects on breast cancer cell lines. Open Biology, 2021, 11, 210161.	1.5	2
1009	Design, synthesis and biological evaluation of novel acridine and quinoline derivatives as tubulin polymerization inhibitors with anticancer activities. Bioorganic and Medicinal Chemistry, 2021, 46, 116376.	1.4	14
1010	The Design, Synthesis, and Biological Activities of Pyrrole-Based Carboxamides: The Novel Tubulin Inhibitors Targeting the Colchicine-Binding Site. Molecules, 2021, 26, 5780.	1.7	12
1011	Discovery of Dolastatinol: A Synthetic Analog of Dolastatin 10 and Low Nanomolar Inhibitor of Tubulin Polymerization. ACS Medicinal Chemistry Letters, 2021, 12, 1596-1604.	1.3	3
1012	Design, synthesis, biological evaluation, and molecular docking of new benzofuran and indole derivatives as tubulin polymerization inhibitors. Drug Development Research, 2022, 83, 485-500.	1.4	6

#	Article	IF	CITATIONS
1013	Inhibition of microtubule assembly and cytotoxic effect of graphene oxide on human colorectal carcinoma cell HCT116. Archives of Biochemistry and Biophysics, 2021, 708, 108940.	1.4	12
1014	Phosphoproteomics Provides Novel Insights into the Response of Primary Acute Lymphoblastic Leukemia Cells to Microtubule Depolymerization in G1 Phase of the Cell Cycle. ACS Omega, 2021, 6, 24949-24959.	1.6	0
1015	PICT1 is critical for regulating the Rps27a-Mdm2-p53 pathway by microtubule polymerization inhibitor against cervical cancer. Biochimica Et Biophysica Acta - Molecular Cell Research, 2021, 1868, 119084.	1.9	9
1016	Pathomechanisms of Paclitaxel-Induced Peripheral Neuropathy. Toxics, 2021, 9, 229.	1.6	65
1017	Bifunctional chiral selenium-containing 1,4-diarylazetidin-2-ones with potent antitumor activities by disrupting tubulin polymerization and inducing reactive oxygen species production. European Journal of Medicinal Chemistry, 2021, 221, 113531.	2.6	13
1018	Synthesis and biological evaluation of chalcone-polyamine conjugates as novel vectorized agents in colorectal and prostate cancer chemotherapy. European Journal of Medicinal Chemistry, 2021, 222, 113586.	2.6	21
1019	A review on the role of tau and stathmin in gastric cancer metastasis. European Journal of Pharmacology, 2021, 908, 174312.	1.7	8
1020	Design, synthesis, anticancer activity and molecular docking analysis of novel dinitrophenylpyrazole bearing 1,2,3-triazoles. Journal of Molecular Structure, 2021, 1243, 130865.	1.8	26
1021	Design, structure-activity relationship study and biological evaluation of the thieno[3,2-c]isoquinoline scaffold as a potential anti-cancer agent. Bioorganic and Medicinal Chemistry Letters, 2021, 52, 128327.	1.0	3
1022	βIII-tubulin overexpression in cancer: Causes, consequences, and potential therapies. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188607.	3.3	21
1023	Ion channels as key partners of cytoskeleton in cancer disease. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188627.	3.3	5
1024	Mitosis Inhibitors and Medicinal Plants: Neurotoxicity and Neuroprotection. , 2021, , 1-35.		0
1025	Nrf2 overexpression increases risk of high tumor mutation burden in acute myeloid leukemia by inhibiting MSH2. Cell Death and Disease, 2021, 12, 20.	2.7	29
1026	Design, synthesis and biological evaluation of novel thiazole-naphthalene derivatives as potential anticancer agents and tubulin polymerisation inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 1693-1701.	2.5	17
1027	Discovery of novel quinoline-based analogues of combretastatin A-4 as tubulin polymerisation inhibitors with apoptosis inducing activity and potent anticancer effect. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 802-818.	2.5	15
1028	Conformers, Properties of the Anticancer Drug Plocabulin, and its Binding Mechanism with p-Glycoprotein: DFT and MD Studies. Australian Journal of Chemistry, 2021, 74, 529.	0.5	0
1029	Application of ensemble pharmacophore-based virtual screening to the discovery of novel antimitotic tubulin inhibitors. Computational and Structural Biotechnology Journal, 2021, 19, 4360-4372.	1.9	14
1030	Stiffening of DU145 prostate cancer cells driven by actin filaments – microtubule crosstalk conferring resistance to microtubule-targeting drugs. Nanoscale, 2021, 13, 6212-6226.	2.8	21

#	Article	IF	CITATIONS
1031	2-APCAs, the Novel Microtubule Targeting Agents Active against Distinct Cancer Cell Lines. Molecules, 2021, 26, 616.	1.7	8
1032	Allosteric Modulators of Protein–Protein Interactions (PPIs). Advances in Experimental Medicine and Biology, 2019, 1163, 313-334.	0.8	23
1033	Polymethoxyflavones from Gardenia oudiepe (Rubiaceae) induce cytoskeleton disruption-mediated apoptosis and sensitize BRAF-mutated melanoma cells to chemotherapy. Chemico-Biological Interactions, 2020, 325, 109109.	1.7	7
1034	Computational assessment of MCM2 transcriptional expression and identification of the prognostic biomarker for human breast cancer. Heliyon, 2020, 6, e05087.	1.4	34
1035	Target identification and validation of natural products with label-free methodology: A critical review from 2005 to 2020. , 2020, 216, 107690.		25
1036	Synthesis and antiproliferative activity of 2-aryl-4-(3,4,5-trimethoxybenzoyl)-1,2,3-triazol derivatives as microtubule-destabilizing agents. RSC Advances, 2017, 7, 29103-29111.	1.7	10
1039	Design, Synthesis and Biological Evaluation of Novel 4-(4-Methoxynaphthalen-1-yl)-5-arylpyrimidin-2-amines as Tubulin Polymerization Inhibitors. Chemical and Pharmaceutical Bulletin, 2020, 68, 1184-1192.	0.6	3
1040	Current progress and future perspectives in the development of anti-polo-like kinase 1 therapeutic agents. F1000Research, 2017, 6, 1024.	0.8	22
1041	Pretubulysin: From Hypothetical Biosynthetic Intermediate to Potential Lead in Tumor Therapy. PLoS ONE, 2012, 7, e37416.	1.1	34
1042	A Synthetic Podophyllotoxin Derivative Exerts Anti-Cancer Effects by Inducing Mitotic Arrest and Pro-Apoptotic ER Stress in Lung Cancer Preclinical Models. PLoS ONE, 2013, 8, e62082.	1.1	32
1043	Virtual and Biophysical Screening Targeting the γ-Tubulin Complex – A New Target for the Inhibition of Microtubule Nucleation. PLoS ONE, 2013, 8, e63908.	1.1	13
1044	An Antimitotic and Antivascular Agent BPR0L075 Overcomes Multidrug Resistance and Induces Mitotic Catastrophe in Paclitaxel-Resistant Ovarian Cancer Cells. PLoS ONE, 2013, 8, e65686.	1.1	24
1045	Laulimalide Induces Dose-Dependent Modulation of Microtubule Behaviour in the C. elegans Embryo. PLoS ONE, 2013, 8, e71889.	1.1	8
1046	Suprafenacine, an Indazole-Hydrazide Agent, Targets Cancer Cells Through Microtubule Destabilization. PLoS ONE, 2014, 9, e110955.	1.1	10
1047	MPTOB169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells. PLoS ONE, 2016, 11, e0148093.	1.1	4
1048	Discovery of a Series of Acridinones as Mechanism-Based Tubulin Assembly Inhibitors with Anticancer Activity. PLoS ONE, 2016, 11, e0160842.	1.1	9
1049	Technical Insights into Highly Sensitive Isolation and Molecular Characterization of Fixed and Live Circulating Tumor Cells for Early Detection of Tumor Invasion. PLoS ONE, 2017, 12, e0169427.	1.1	62
1050	Anticancer activity of a novel small molecule tubulin inhibitor STK899704. PLoS ONE, 2017, 12, e0173311.	1.1	32

#	Article	IF	CITATIONS
1051	Synthesis and bioevaluation of N,4-diaryl-1,3-thiazole-2-amines as tubulin inhibitors with potent antiproliferative activity. PLoS ONE, 2017, 12, e0174006.	1.1	20
1052	Investigation of Targetin, a Microtubule Binding Agent which Regresses the Growth of Pediatric High and Low Grade Gliomas. Journal of Pediatric Oncology, 2013, 1, 32-40.	0.1	4
1053	Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma. Oncotarget, 2016, 7, 86594-86607.	0.8	19
1054	Mitotic cell death induction by targeting the mitotic spindle with tubulin-inhibitory indole derivative molecules. Oncotarget, 2017, 8, 19738-19759.	0.8	19
1055	An oral quinoline derivative, MPT0B392, causes leukemic cells mitotic arrest and overcomes drug resistant cancer cells. Oncotarget, 2017, 8, 27772-27785.	0.8	6
1056	Pygopus2 inhibits the efficacy of paclitaxel-induced apoptosis and induces multidrug resistance in human glioma cells. Oncotarget, 2017, 8, 27915-27928.	0.8	7
1057	The tubulin inhibitor MG-2477 induces autophagy-regulated cell death, ROS accumulation and activation of FOXO3 in neuroblastoma. Oncotarget, 2017, 8, 32009-32026.	0.8	13
1058	Microtubule inhibitor, SP-6-27 inhibits angiogenesis and induces apoptosis in ovarian cancer cells. Oncotarget, 2017, 8, 67017-67028.	0.8	20
1059	WX-132-18B, a novel microtubule inhibitor, exhibits promising anti-tumor effects. Oncotarget, 2017, 8, 71782-71796.	0.8	27
1060	AG488 as a therapy against gliomas. Oncotarget, 2017, 8, 71833-71844.	0.8	3
1060 1061	AG488 as a therapy against gliomas. Oncotarget, 2017, 8, 71833-71844. Structural recognition of tubulysin B derivatives by multidrug resistance efflux transporters in human cancer cells. Oncotarget, 2017, 8, 49973-49987.	0.8 0.8	3
	Structural recognition of tubulysin B derivatives by multidrug resistance efflux transporters in		
1061	Structural recognition of tubulysin B derivatives by multidrug resistance efflux transporters in human cancer cells. Oncotarget, 2017, 8, 49973-49987. ROS-mediated EB1 phosphorylation through Akt/GSK3î ² pathway: implication in cancer cell response to	0.8	7
1061 1062	Structural recognition of tubulysin B derivatives by multidrug resistance efflux transporters in human cancer cells. Oncotarget, 2017, 8, 49973-49987. ROS-mediated EB1 phosphorylation through Akt/GSK3î ² pathway: implication in cancer cell response to microtubule-targeting agents. Oncotarget, 2014, 5, 3408-3423. Phase I clinical trial of AXL1717 for treatment of relapsed malignant astrocytomas: analysis of dose	0.8 0.8	7 39
1061 1062 1063	Structural recognition of tubulysin B derivatives by multidrug resistance efflux transporters in human cancer cells. Oncotarget, 2017, 8, 49973-49987. ROS-mediated EB1 phosphorylation through Akt/CSK3î² pathway: implication in cancer cell response to microtubule-targeting agents. Oncotarget, 2014, 5, 3408-3423. Phase I clinical trial of AXL1717 for treatment of relapsed malignant astrocytomas: analysis of dose and response. Oncotarget, 2017, 8, 81501-81510. Microtubins: a novel class of small synthetic microtubule targeting drugs that inhibit cancer cell	0.8 0.8 0.8	7 39 27
1061 1062 1063 1064	Structural recognition of tubulysin B derivatives by multidrug resistance efflux transporters in human cancer cells. Oncotarget, 2017, 8, 49973-49987. ROS-mediated EB1 phosphorylation through Akt/GSK3î ² pathway: implication in cancer cell response to microtubule-targeting agents. Oncotarget, 2014, 5, 3408-3423. Phase I clinical trial of AXL1717 for treatment of relapsed malignant astrocytomas: analysis of dose and response. Oncotarget, 2017, 8, 81501-81510. Microtubins: a novel class of small synthetic microtubule targeting drugs that inhibit cancer cell proliferation. Oncotarget, 2017, 8, 104007-104021. The small molecule SI113 synergizes with mitotic spindle poisons in arresting the growth of human	0.8 0.8 0.8 0.8	7 39 27 7
1061 1062 1063 1064 1065	Structural recognition of tubulysin B derivatives by multidrug resistance efflux transporters in human cancer cells. Oncotarget, 2017, 8, 49973-49987. ROS-mediated EB1 phosphorylation through Akt/GSK3Î ² pathway: implication in cancer cell response to microtubule-targeting agents. Oncotarget, 2014, 5, 3408-3423. Phase I clinical trial of AXL1717 for treatment of relapsed malignant astrocytomas: analysis of dose and response. Oncotarget, 2017, 8, 81501-81510. Microtubins: a novel class of small synthetic microtubule targeting drugs that inhibit cancer cell proliferation. Oncotarget, 2017, 8, 104007-104021. The small molecule SI113 synergizes with mitotic spindle poisons in arresting the growth of human glioblastoma multiforme. Oncotarget, 2017, 8, 110743-110755. Picropodophyllin causes mitotic arrest and catastrophe by depolymerizing microtubules via	0.8 0.8 0.8 0.8 0.8	7 39 27 7 20

#	Article	IF	CITATIONS
1069	Low-dose eribulin reduces lung metastasis of osteosarcoma <i>in vitro</i> and <i>in vivo</i> . Oncotarget, 2019, 10, 161-174.	0.8	9
1070	IPP51, a chalcone acting as a microtubule inhibitor with <i>in vivo</i> antitumor activity against bladder carcinoma. Oncotarget, 2015, 6, 14669-14686.	0.8	35
1071	Mitotic centromere-associated kinesin (MCAK): a potential cancer drug target. Oncotarget, 2011, 2, 935-947.	0.8	66
1072	Mitotic entry: Non-genetic heterogeneity exposes the requirement for Plk1. Oncotarget, 2015, 6, 36472-36488.	0.8	11
1073	Mcl-1 dynamics influence mitotic slippage and death in mitosis. Oncotarget, 2016, 7, 5176-5192.	0.8	59
1074	Multiplicity of acquired cross-resistance in paclitaxel-resistant cancer cells is associated with feedback control of TUBB3 via FOXO3a-mediated ABCB1 regulation. Oncotarget, 2016, 7, 34395-34419.	0.8	29
1075	Antivascular and antitumor properties of the tubulin-binding chalcone TUB091. Oncotarget, 2017, 8, 14325-14342.	0.8	50
1076	Resistance to anti-tubulin agents: From vinca alkaloids to epothilones. , 2019, 2, 82-106.		13
1077	Microtubule targeting agents in glioma. Translational Cancer Research, 2016, 5, S54-S60.	0.4	19
1078	Pyridine Based Antitumour Compounds Acting at the Colchicine Site. Current Medicinal Chemistry, 2016, 23, 1100-1130.	1.2	42
1079	Recent Progress of Benzimidazole Hybrids for Anticancer Potential. Current Medicinal Chemistry, 2020, 27, 5970-6014.	1.2	41
1080	Tubulin Maytansine Site Binding Ligands and their Applications as MTAs and ADCs for Cancer Therapy. Current Medicinal Chemistry, 2020, 27, 4567-4576.	1.2	9
1081	Tubulins as Therapeutic Targets in Cancer: from Bench to Bedside. Current Pharmaceutical Design, 2012, 18, 2778-2792.	0.9	90
1082	ADCs, as Novel Revolutionary Weapons for Providing a Step Forward in Targeted Therapy of Malignancies. Current Drug Delivery, 2020, 17, 23-51.	0.8	16
1083	Alkaloids as Anticancer Agents: A Review of Chinese Patents in Recent 5 Years. Recent Patents on Anti-Cancer Drug Discovery, 2020, 15, 2-13.	0.8	12
1084	The Interactions of Anticancer Agents with Tea Catechins: Current Evidence from Preclinical Studies. Anti-Cancer Agents in Medicinal Chemistry, 2014, 14, 1343-1350.	0.9	9
1085	Role of crocin in several cancer cell lines: An updated review. Iranian Journal of Basic Medical Sciences, 2020, 23, 3-12.	1.0	25
1086	The Synergistic Effect of Doxorubicin and Ethanolic Extracts of Caesalpinia sappan L. Wood and Ficus septica Burm. f. Leaves on Viability, Cell Cycle Progression, and Apoptosis Induction of MCFÂ7 Cells. Indonesian Journal of Biotechnology, 2017, 21, 29.	0.1	3

\sim			<u> </u>		
	ΙΤΔΤ	ION	RE	DO	DT
<u> </u>	והו		IVL	. 0	

#	Article	IF	CITATIONS
1087	Endophytic bacteria of Catharanthus roseus as an alternative source of Vindoline and application of response surface methodology to enhance its production. Archives of Biological Sciences, 2019, 71, 27-38.	0.2	14
1088	An overview of microtubule targeting agents for cancer therapy. Arhiv Za Higijenu Rada I Toksikologiju, 2019, 70, 160-172.	0.4	32
1089	Structure–Activity Relationship Study of Gatastatin Based on the Topliss Tree Approach. Heterocycles, 2019, 99, 238.	0.4	3
1090	Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors. Cancer Research and Treatment, 2016, 48, 28-36.	1.3	20
1091	Developing New Small Molecular Drugs for Prostate Cancer Therapy. Journal of Cancer Therapy, 2013, 04, 86-90.	0.1	2
1092	Efficacy of Nab-Paclitaxel Plus Gemcitabine and Prognostic Value of Peripheral Neuropathy in Patients with Metastatic Pancreatic Cancer. Gut and Liver, 2018, 12, 728-735.	1.4	8
1093	Target Identification and Mode of Action Studies of an Antitumor Compound Aplyronine A by Using Photoaffinity Derivatives. Yuki Gosei Kagaku Kyokaishi/Journal of Synthetic Organic Chemistry, 2015, 73, 151-160.	0.0	4
1094	Microtubule-Targeting Agents Enter the Central Nervous System (CNS): Double-edged Swords for Treating CNS Injury and Disease. International Neurourology Journal, 2014, 18, 171.	0.5	13
1095	Osteosarcoma of the Breast in a Patient Derived Orthotopic Xenograft (PDOX) Mouse Model Is Arrested by both Cisplatinum and Eribulin. In Vivo, 2021, 35, 3107-3110.	0.6	4
1096	Synthesis and Investigations of Building Blocks with Dibenzo[b,f] Oxepine for Use in Photopharmacology. International Journal of Molecular Sciences, 2021, 22, 11033.	1.8	4
1097	Identification and optimization of biphenyl derivatives as novel tubulin inhibitors targeting colchicine-binding site overcoming multidrug resistance. European Journal of Medicinal Chemistry, 2022, 228, 113930.	2.6	5
1098	Preparation and biological evaluation of new antimicrotubule agents: Modification of the imidazolidinâ€2â€one moiety of phenyl 4â€{2â€oxoimidazolidinâ€1â€yl)benzenesulfonates. Chemical Biology an Drug Design, 2022, 99, 187-196.	d1.5	1
1099	Antiâ€microtubule activity of the traditional Chinese medicine herb Northern Ban Lan (<i>lsatis) Tj ETQq0 0 0 rgB</i>	T /Overloo 4.1	ck 10 Tf 50 2
1100	Characterization of Microtubule Destabilizing Drugs: A Quantitative Cell-Based Assay That Bridges the Gap between Tubulin Based- and Cytotoxicity Assays. Cancers, 2021, 13, 5226.	1.7	7
1101	Discovery of a Series of Hydroxamic Acid-Based Microtubule Destabilizing Agents with Potent Antitumor Activity. Journal of Medicinal Chemistry, 2021, 64, 15379-15401.	2.9	8
1102	Discovery of a Dual Tubulin and Poly(ADP-Ribose) Polymerase-1 Inhibitor by Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking, and Biological Evaluation. Journal of Medicinal Chemistry, 2021, 64, 15702-15715.	2.9	22
1103	Inhibiting microcephaly genes as alternative to microtubule targeting agents to treat brain tumors. Cell Death and Disease, 2021, 12, 956.	2.7	10
1104	CLIP-170S is a microtubuleÂ+TIP variant that confers resistance to taxanes by impairing drug-target engagement. Developmental Cell, 2021, 56, 3264-3275.e7.	3.1	5

		CITATION RE	PORT	
#	Article		IF	CITATIONS
1105	Synthesis, Computational Analysis, and Antiproliferative Activity of Novel Benzimidazo Acrylonitriles as Tubulin Polymerization Inhibitors: Part 2. Pharmaceuticals, 2021, 14, 1	le .052.	1.7	6
1106	Radioresistance of Human Cancers: Clinical Implications of Genetic Expression Signatu in Oncology, 2021, 11, 761901.	res. Frontiers	1.3	11
1107	Inhibiting parasite proliferation using a rationally designed antiâ€ŧubulin agent. EMBO Medicine, 2021, 13, e13818.	Molecular	3.3	14
1108	Microtubules, Drug Resistance, and Tumorigenesis. , 2012, , 223-240.			1
1109	Plant Compounds Acting on the Cytoskeleton. Plant Cell Monographs, 2014, , 301-32	3.	0.4	0
1110	Control of the Cell Cycle. , 2014, , 52-68.e6.			3
1112	PPMP, a novel tubulin-depolymerizing agent against esophageal cancer in patient-deriv xenografts. Oncotarget, 2016, 7, 30977-30989.	ved tumor	0.8	4
1114	5-(Furan-2-yl)-4-(3,4,5-trimethoxyphenyl)-3H-1,2-dithiol-3- one oxime (6f), a new synth causes human fibrosarcoma HT-1080 cell apoptosis by disrupting tubulin polymerisatio G2/M arrest. International Journal of Oncology, 2017, 50, 2069-2078.	etic compound, on and inducing	1.4	1
1115	On the Chemistry and Biology of the Marine Macrolides Zampanolide and Dactylolide.	, 2017, , 555-599.		0
1116	On the Chemistry and Biology of the Marine Macrolides Zampanolide and Dactylolide.	, 2017, , 555-599.		0
1118	Colchicine-, Vinblastine-, Taxol- and Eribulin-based Payloads for Antibody–Drug Conjı RSC Drug Discovery Series, 2019, , 117-136.	Jgates (ADCs).	0.2	1
1121	Secreted amphiregulin promotes vincristine resistance in oral squamous cell carcinoma International Journal of Oncology, 2019, 55, 949-959.	a.	1.4	8
1123	Integration of Phytochemicals and Phytotherapy into Cancer Precision Medicine. Huma in Health Sciences and Technology, 2020, , 355-392.	an Perspectives	0.2	1
1124	A High-Throughput Cellular Screening Assay for Small-Molecule Inhibitors and Activato Cytoplasmic Dynein-1-Based Cargo Transport. SLAS Discovery, 2020, 25, 985-999.	rs of	1.4	4
1126	Amentoflavone triggers cell cycle G2/M arrest by interfering with microtubule dynamic DNA damage in SKOV3 cells. Oncology Letters, 2020, 20, 1-1.	s and inducing	0.8	7
1127	Securinine induces mitotic block in cancer cells by binding to tubulin and inhibiting mi assembly: A possible mechanistic basis for its anticancer activity. Life Sciences, 2021, 2		2.0	5
1128	Dynamics of Serum Thymidine Kinase 1 at the First Cycle of Neoadjuvant Chemothera Outcome of Disease in Estrogen-Receptor-Positive Breast Cancer. Cancers, 2021, 13, 5		1.7	1
1129	Synthesis, Molecular Docking, and Biological Evaluation of 2,3-Diphenylquinoxaline De Tubulin's Colchicine Binding Site Inhibitor Based on Primary Virtual Screening. Ant Medicinal Chemistry, 2021, 21, .	rivatives as a -Cancer Agents in	0.9	1

#	Article	IF	CITATIONS
1130	Chapter 2: Challenges and Considerations in the Design of Antibody-Drug Conjugates. AAPS Advances in the Pharmaceutical Sciences Series, 2020, , 27-48.	0.2	0
1131	Calibrated liposomal release of the anti-mitotic agent BI-2536 increases the targeting of mitotic tumor cells. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 157, 183-190.	2.0	1
1132	Antibody-Based Targeted Interventions for the Diagnosis and Treatment of Skin Cancers. Anti-Cancer Agents in Medicinal Chemistry, 2020, 21, 162-186.	0.9	2
1133	MNBDR: A Module Network Based Method for Drug Repositioning. Genes, 2021, 12, 25.	1.0	6
1134	Design and synthesis of a new series of 3,5-disubstituted-1,2,4-oxadiazoles as potential colchicine binding site inhibitors: antiproliferative activity, molecular docking, and SAR studies. New Journal of Chemistry, 2021, 45, 21657-21669.	1.4	23
1135	Design, synthesis and biological evaluation of novel 2-phenyl-4,5,6,7-tetrahydro-1H-‫indole derivatives as potential anticancer agents and tubulin polymerization inhibitors. Arabian Journal of Chemistry, 2022, 15, 103504.	2.3	7
1136	Discovery and Use of Natural Products and Derivatives as Chemical Probes. Chemical Biology, 2020, , 124-149.	0.1	1
1137	Kanakugiol, a Compound Isolated from Lindera erythrocarpa, Promotes Cell Death by Inducing Mitotic Catastrophe after Cell Cycle Arrest. Journal of Microbiology and Biotechnology, 2020, 30, 279-286.	0.9	4
1139	Lead optimization of novel quinolone chalcone compounds by a structure–activity relationship (SAR) study to increase efficacy and metabolic stability. Scientific Reports, 2021, 11, 21576.	1.6	3
1140	Generating Paclitaxel-Resistant in Cervical Cancer HeLa Cell Line. Indonesian Journal of Cancer Chemoprevention, 2020, 11, 90.	0.3	1
1142	Synthesis, molecular docking, and saturation-transfer difference NMR spectroscopy of longipinane derivatives as novel microtubule stabilizers. Journal of Molecular Structure, 2020, 1218, 128519.	1.8	2
1143	Could microtubule inhibitors be the best choice of therapy in gastric cancer with high immune activity: mutant DYNC1H1 as a biomarker. Aging, 2020, 12, 25101-25119.	1.4	7
1144	The effect of the crocus sativus L. Carotenoid, crocin, on the polymerization of microtubules, in vitro. Iranian Journal of Basic Medical Sciences, 2013, 16, 101-7.	1.0	19
1145	Breast Cancer Cell Lines Exhibit Differential Sensitivities to Microtubule-targeting Drugs Independent of Doubling Time. Anticancer Research, 2015, 35, 5845-50.	0.5	31
1146	A novel microtubule inhibitor, MT3-037, causes cancer cell apoptosis by inducing mitotic arrest and interfering with microtubule dynamics. American Journal of Cancer Research, 2016, 6, 747-63.	1.4	2
1147	Vincristine-induced peripheral neuropathy in pediatric cancer patients. American Journal of Cancer Research, 2016, 6, 2416-2430.	1.4	47
1148	Expression of the Class II and III Beta-Tubulin in Neoplastic and Non-Neoplastic Lymphoid Tissues. Asian Pacific Journal of Cancer Prevention, 2017, 18, 1045-1050.	0.5	1
1149	Quetiapine reverses paclitaxel-induced neuropathic pain in mice: Role of alpha2- adrenergic receptors. Iranian Journal of Basic Medical Sciences, 2017, 20, 1182-1188.	1.0	7

#	Article	IF	CITATIONS
1150	Potent and broad anticancer activities of leaf extracts from L. of the subtropical Okinawa islands. American Journal of Cancer Research, 2020, 10, 581-594.	1.4	2
1151	3D-QSAR-Based Pharmacophore Modeling, Virtual Screening, and Molecular Docking Studies for Identification of Tubulin Inhibitors with Potential Anticancer Activity. BioMed Research International, 2021, 2021, 6480804.	0.9	1
1152	Clinical and preclinical features of eribulin-related peripheral neuropathy. Experimental Neurology, 2022, 348, 113925.	2.0	3
1153	Combretastatin Derivatives as Microtubule Inhibitors of Colchicines Binding Site. Anti-Infective Agents, 2022, 20, .	0.1	0
1154	BP-M345, a New Diarylpentanoid with Promising Antimitotic Activity. Molecules, 2021, 26, 7139.	1.7	8
1155	The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy. Pharmaceutics, 2021, 13, 1974.	2.0	6
1156	A Matteson Homologationâ€Based Synthesis of Doliculide and Derivatives. European Journal of Organic Chemistry, 2021, 2021, 6459-6471.	1.2	18
1157	Tubulin alpha 1c promotes aerobic glycolysis and cell growth through upregulation of yes association protein expression in breast cancer. Anti-Cancer Drugs, 2022, 33, 132-141.	0.7	7
1158	Dysregulation of Microtubule Nucleating Proteins in Cancer Cells. Cancers, 2021, 13, 5638.	1.7	10
1159	TH588 and Low-Dose Nocodazole Impair Chromosome Congression by Suppressing Microtubule Turnover within the Mitotic Spindle. Cancers, 2021, 13, 5995.	1.7	7
1160	Eribulin activity in soft tissue sarcoma monolayer and three-dimensional cell line models: could the combination with other drugs improve its antitumoral effect?. Cancer Cell International, 2021, 21, 646.	1.8	6
1161	Design, synthesis, docking study and anticancer evaluation of new trimethoxyphenyl pyridine derivatives as tubulin inhibitors and apoptosis inducers. RSC Advances, 2021, 11, 39728-39741.	1.7	6
1162	Design, Synthesis, and Biological Evaluation of 5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidines as Microtubule Targeting Agents. Molecules, 2022, 27, 321.	1.7	3
1163	Design, synthesis and evaluation of novel bis-substituted aromatic amide dithiocarbamate derivatives as colchicine site tubulin polymerization inhibitors with potent anticancer activities. European Journal of Medicinal Chemistry, 2022, 229, 114069.	2.6	34
1164	Indole derivatives as tubulin polymerization inhibitors for the development of promising anticancer agents. Bioorganic and Medicinal Chemistry, 2022, 55, 116597.	1.4	21
1165	Exploration of benzimidazoles as potential microtubule modulators: An insight in the synthetic and therapeutic evolution. Journal of Molecular Structure, 2022, 1253, 132251.	1.8	7
1166	3D-QSAR-Based Pharmacophore Modeling, Virtual Screening, and Molecular Docking Studies for Identification of Tubulin Inhibitors with Potential Anticancer Activity. BioMed Research International, 2021, 2021, 1-20.	0.9	3
1167	Impact of the ferrocenyl group on cytotoxicity and KSP inhibitory activity of ferrocenyl monastrol conjugates. Dalton Transactions, 2022, 51, 491-508.	1.6	6

#	Article	IF	CITATIONS
1168	Recent development of imidazole derivatives as potential anticancer agents. ChemistrySelect, 2023, 8, 2903-2941.	0.7	0
1169	Structure-Based Design and Synthesis of N-Substituted 3-Amino-Î ² -Carboline Derivatives as Potent $\hat{I}\pm\hat{I}^2$ -Tubulin Degradation Agents. Journal of Medicinal Chemistry, 2022, 65, 2675-2693.	2.9	13
1170	Fused pyrrolo-pyridines and pyrrolo-(iso)quinoline as anticancer agents. ChemistrySelect, 2023, 8, 2583-2645.	0.7	2
1171	Synthesis and Biological Investigation of Bile Acid-Paclitaxel Hybrids. Molecules, 2022, 27, 471.	1.7	11
1172	Synthesis and evaluation of <scp> 2â€arylâ€1 <i>H</i> </scp> â€benzo[d]imidazole derivatives as potential microtubule targeting agents. Drug Development Research, 2022, , .	1.4	4
1173	Novel Pyrazolines and Benzothiazepines as Tubulin Polymerization Inhibitors: Synthesis, Biological Evaluation, and Molecular Docking. Heterocycles, 2022, 104, 447.	0.4	3
1174	Docetaxel-triggered SIDT2/NOX4/JNK/HuR signaling axis is associated with TNF-α-mediated apoptosis of cancer cells. Biochemical Pharmacology, 2022, 195, 114865.	2.0	10
1176	Antiviral, Anticancer and Hypotensive Potential of Diphyllin Glycosides and their Mechanisms of Action. Mini-Reviews in Medicinal Chemistry, 2022, 22, .	1.1	0
1177	Cytotoxic mechanism of tioconazole involves cell cycle arrest at mitosis through inhibition of microtubule assembly. Cytotechnology, 2022, 74, 141-162.	0.7	4
1178	The phytochemical, corynoline, diminishes Aurora kinase B activity to induce mitotic defect and polyploidy. Biomedicine and Pharmacotherapy, 2022, 147, 112645.	2.5	5
1179	Destruction of tumor vasculature by vascular disrupting agents in overcoming the limitation of EPR effect. Advanced Drug Delivery Reviews, 2022, 183, 114138.	6.6	33
1180	The effects of estrogen on targeted cancer therapy drugs. Pharmacological Research, 2022, 177, 106131.	3.1	7
1181	IMB5476, a novel microtubule inhibitor, induces mitotic catastrophe and overcomes multidrug resistance in tumors. European Journal of Pharmacology, 2022, 919, 174802.	1.7	3
1182	Spatiotemporal oscillations of morphinan alkaloids in opium poppy. Journal of Biosciences, 2018, 43, 391-405.	0.5	0
1183	Synthesis and evaluation of new chalcones and oximes as anticancer agents. RSC Advances, 2022, 12, 10307-10320.	1.7	13
1184	Structure–activity relationship studies on an antitumor marine macrolide using aplyronine a–swinholide A hybrid. Organic and Biomolecular Chemistry, 2022, 20, 2922-2938.	1.5	1
1185	A comparative evaluation of monomethoxy substituted o-diarylazoles as antiproliferative microtubule destabilizing agents. Mendeleev Communications, 2022, 32, 120-122.	0.6	6
1186	In silico and In vitro Antitubercular Studies for Nitrogen Rich Hybrids of homopiperazine-pyrimidine-Pyrazole Adducts. Asian Journal of Chemistry, 2022, 34, 562-568.	0.1	0

#	Article	IF	CITATIONS
1187	A Novel Targeted Delivery of Valeric Acid Using Liposomal Nanoparticles in Treatment of Lung Cell Carcinoma. Journal of Biomedical Nanotechnology, 2022, 18, 211-217.	0.5	4
1188	Discovery of Novel Coumarin-Indole Derivatives ÂAs Tubulin Polymerization Inhibitors with Potent Anti-Gastric Cancer Activities. SSRN Electronic Journal, 0, , .	0.4	0
1189	A low molecular weight multifunctional theranostic molecule for the treatment of prostate cancer. Theranostics, 2022, 12, 2335-2350.	4.6	7
1190	Indole-Based Tubulin Inhibitors: Binding Modes and SARs Investigations. Molecules, 2022, 27, 1587.	1.7	16
1191	Discovery of Novel 3,4-Dihydro-2(1H)-Quinolinone Sulfonamide Derivatives as New Tubulin Polymerization Inhibitors with Anti-Cancer Activity. Molecules, 2022, 27, 1537.	1.7	1
1192	Computational Study on E-Hooks of Tubulins in the Binding Process with Kinesin. International Journal of Molecular Sciences, 2022, 23, 2035.	1.8	1
1193	Design, synthesis, characterization and cytotoxic activity of new ortho-hydroxy and indole-chalcone derivatives against breast cancer cells (MCF-7). Medicinal Chemistry Research, 2022, 31, 517-532.	1.1	7
1194	A Concise Synthesis of Triazole Analogues of Lavendustin A via Click Chemistry Approach and Preliminary Evaluation of Their Antiparasitic Activity Against <i>Trypanosoma cruzi</i> . ChemistrySelect, 2022, 7, .	0.7	3
1195	Recent Approaches to the Identification of Novel Microtubule-Targeting Agents. Frontiers in Molecular Biosciences, 2022, 9, 841777.	1.6	15
1196	Microtubules as Regulators of Neural Network Shape and Function: Focus on Excitability, Plasticity and Memory. Cells, 2022, 11, 923.	1.8	4
1197	Targeted Delivery of Chemotherapeutic Agents for Osteosarcoma Treatment. Frontiers in Oncology, 2022, 12, 843345.	1.3	9
1198	PI3K/AKT Signaling Tips the Balance of Cytoskeletal Forces for Cancer Progression. Cancers, 2022, 14, 1652.	1.7	23
1199	2â€Aminoâ€4â€arylâ€5â€oxoâ€4,5â€dihydropyrano[3,2â€ <i>c</i>]chromeneâ€3â€carbonitriles with Microtubu Centrosomeâ€Declustering, and Antiangiogenic Effects <i>inâ€vitro</i> and <i>inâ€vivo</i> . ChemMedChem 2022, 17, .		ptive, 4
1200	DNA Nanobots – Emerging Customized Nanomedicine in Oncology. Current Drug Delivery, 2023, 20, 111-126.	0.8	4
1201	Investigation of benzimidazole anthelmintics as oral anticancer agents. Bulletin of the Korean Chemical Society, 0, , .	1.0	5
1202	Assessment of Pharmacological Interactions between SIRT2 Inhibitor AGK2 and Paclitaxel in Different Molecular Subtypes of Breast Cancer Cells. Cells, 2022, 11, 1211.	1.8	8
1203	Selective Delivery of Clinically Approved Tubulin Binding Agents through Covalent Conjugation to an Active Targeting Moiety. Current Medicinal Chemistry, 2022, 29, 5179-5211.	1.2	1
1204	Triggered azobenzene-based prodrugs and drug delivery systems. Journal of Controlled Release, 2022, 345, 475-493.	4.8	51

#	Article	IF	CITATIONS
1205	Indazole-based microtubule-targeting agents as potential candidates for anticancer drugs discovery. Bioorganic Chemistry, 2022, 122, 105735.	2.0	14
1206	Lattice defects induced by microtubule-stabilizing agents exert a long-range effect on microtubule growth by promoting catastrophes. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	24
1207	Modified FOLFIRINOX versus sequential chemotherapy (FOLFIRI/FOLFOX) as a secondâ€line treatment regimen for unresectable pancreatic cancer: A realâ€world analysis. Cancer Medicine, 2022, 11, 1088-1098.	1.3	4
1209	VTT-006, an anti-mitotic compound, binds to the Ndc80 complex and suppresses cancer cell growth in vitro. Oncoscience, 2021, 8, 134-153.	0.9	1
1210	The BH3-only protein NOXA serves as an independent predictor of breast cancer patient survival and defines susceptibility to microtubule targeting agents. Cell Death and Disease, 2021, 12, 1151.	2.7	11
1211	Morphological profiling by means of the Cell Painting assay enables identification of tubulin-targeting compounds. Cell Chemical Biology, 2022, 29, 1053-1064.e3.	2.5	22
1212	The Tubulin Code and Tubulin-Modifying Enzymes in Autophagy and Cancer. Cancers, 2022, 14, 6.	1.7	13
1213	Female Oncofertility: Current Understandings, Therapeutic Approaches, Controversies, and Future Perspectives. Journal of Clinical Medicine, 2021, 10, 5690.	1.0	7
1214	Primary acute lymphoblastic leukemia cells are susceptible to microtubule depolymerization in G1 and M phases through distinct cell death pathways*. Journal of Biological Chemistry, 2022, , 101939.	1.6	0
1215	The Interplay of Microtubules with Mitochondria–ER Contact Sites (MERCs) in Glioblastoma. Biomolecules, 2022, 12, 567.	1.8	5
1229	5-arylalkynyl-2-benzoyl thiophene: a novel microtubule inhibitor exhibits antitumor activity without neurological toxicity American Journal of Cancer Research, 2022, 12, 229-246.	1.4	0
1230	Monitoring the Disruptive Effects of Tubulin-Binding Agents on Cellular Microtubules. Methods in Molecular Biology, 2022, 2430, 431-448.	0.4	6
1231	Crystallization Systems for the High-Resolution Structural Analysis of Tubulin–Ligand Complexes. Methods in Molecular Biology, 2022, 2430, 349-374.	0.4	3
1232	Electro-Modulation of Tubulin Properties and Function. Methods in Molecular Biology, 2022, 2430, 61-70.	0.4	0
1233	Risk Factors for Nab-Paclitaxel and Gemcitabine-Induced Peripheral Neuropathy in Patients with Pancreatic Cancer. Oncology, 2022, 100, 384-391.	0.9	1
1234	Colchicine-Binding Site Agent CH-2-77 as a Potent Tubulin Inhibitor Suppressing Triple-Negative Breast Cancer. Molecular Cancer Therapeutics, 2022, 21, 1103-1114.	1.9	5
1235	Structural insight into SSE15206 in complex with tubulin provides a rational design for pyrazolinethioamides as tubulin polymerization inhibitors. Future Medicinal Chemistry, 2022, 14, 785-794.	1.1	1
1236	KIF22 Promotes Development of Pancreatic Cancer by Regulating the MEK/ERK/P21 Signaling Axis. BioMed Research International, 2022, 2022, 1-10.	0.9	4

~			n		
(T	TAT	ION	- K F	-P(ากา

#	Article	IF	CITATIONS
1237	Aerosol delivery of star polymer-siRNA nanoparticles as a therapeutic strategy to inhibit lung tumor growth. Biomaterials, 2022, 285, 121539.	5.7	14
1238	Dual-functional antitumor conjugates improving the anti-metastasis effect of combretastatin A4 by targeting tubulin polymerization and matrix metalloproteinases. European Journal of Medicinal Chemistry, 2022, 238, 114439.	2.6	5
1239	Actividad analgésica y antiinflamatoria de derivados de podofilotoxina. Revista De InvestigaciÓn De La Universidad Norbert Wiener, 2022, 2, 93-102.	0.0	0
1240	Identification and validation of novel microtubule suppressors with an imidazopyridine scaffold through structure-based virtual screening and docking. RSC Medicinal Chemistry, 2022, 13, 929-943.	1.7	6
1242	Photopharmacology of Antimitotic Agents. International Journal of Molecular Sciences, 2022, 23, 5657.	1.8	13
1243	Discovery of novel coumarin-indole derivatives as tubulin polymerization inhibitors with potent anti-gastric cancer activities. European Journal of Medicinal Chemistry, 2022, 238, 114467.	2.6	27
1244	Anticancer mechanism of 7-α-hydroxyfrullanolide on microtubules and computational prediction of its target binding in triple-negative breast cancer cells. PeerJ, 0, 10, e13508.	0.9	0
1245	Cytotoxicity of phenylpironetin analogs and the metabolic fate of pironetin and phenylpironetin. Bioorganic Chemistry, 2022, 125, 105915.	2.0	2
1246	Cancer therapeutic drug guide. , 2023, , 451-506.		0
1247	Navitoclax Enhances the Therapeutic Effects of PLK1 Targeting on Lung Cancer Cells in 2D and 3D Culture Systems. Pharmaceutics, 2022, 14, 1209.	2.0	3
1248	Domino Semipinacol/Iterative Aldol/Iso-Nazarov Cyclization to Triaryl-cyclopentenone: Enantioselective Synthesis of Combretastatin A-4 Analogues. Organic Letters, 2022, 24, 4240-4245.	2.4	4
1249	A potent estrogen receptor and microtubule specific purine-benzothiazole-based fluorescent molecular probe induces apoptotic death of breast cancer cells. Scientific Reports, 2022, 12, .	1.6	3
1250	Iron-Sensitive Prodrugs That Trigger Active Ferroptosis in Drug-Tolerant Pancreatic Cancer Cells. Journal of the American Chemical Society, 2022, 144, 11536-11545.	6.6	29
1251	Obstacles to Glioblastoma Treatment Two Decades after Temozolomide. Cancers, 2022, 14, 3203.	1.7	23
1252	LIM Kinases, Promising but Reluctant Therapeutic Targets: Chemistry and Preclinical Validation In Vivo. Cells, 2022, 11, 2090.	1.8	6
1253	Intestinal obstruction from calcium polystyrene sulfonate in pediatric cancer patients. Pediatric Hematology Oncology Journal, 2022, , .	0.1	1
1254	Radiation Cleaved Drug-Conjugate Linkers Enable Local Payload Release. Bioconjugate Chemistry, 2022, 33, 1474-1484.	1.8	7
1255	Multistage and transmission-blocking tubulin targeting potent antimalarial discovered from the open access MMV pathogen box. Biochemical Pharmacology, 2022, 203, 115154.	2.0	5

#	Article	IF	CITATIONS
1256	Nrf2 overexpression increases the resistance of acute myeloid leukemia to cytarabine by inhibiting replication factor C4. Cancer Gene Therapy, 2022, 29, 1773-1790.	2.2	6
1257	Discovery of N-benzylarylamide derivatives as novel tubulin polymerization inhibitors capable of activating the Hippo pathway. European Journal of Medicinal Chemistry, 2022, 240, 114583.	2.6	20
1258	Synthesis and Antitumor Activity of 2,3â€Diphenylâ€2 <i>H</i> â€indazole Derivatives as Potent Antitubulin Agents. ChemistrySelect, 2022, 7, .	0.7	1
1259	Single-nucleotide polymorphismÂassociations with efficacy and toxicity in metastatic castration-resistant prostate cancer treated with cabazitaxel. Pharmacogenomics, 0, , .	0.6	0
1260	In Vitro Evaluation of NLS-DTX Activity in Triple-Negative Breast Cancer. Molecules, 2022, 27, 4920.	1.7	3
1261	Quantification of Engagement of Microtubules by Small Molecules in Living Cells by Flow Cytometry. ACS Bio & Med Chem Au, 2022, 2, 529-537.	1.7	3
1262	Triple negative breast cancer: approved treatment options and their mechanisms of action. Journal of Cancer Research and Clinical Oncology, 2023, 149, 3701-3719.	1.2	13
1263	Design, Synthesis and Biological Investigation of 2-Anilino Triazolopyrimidines as Tubulin Polymerization Inhibitors with Anticancer Activities. Pharmaceuticals, 2022, 15, 1031.	1.7	5
1264	Applicability of atomic force microscopy to determine cancer-related changes in cells. Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences, 2022, 380, .	1.6	5
1265	Spectrin: an alternate target for cytoskeletal drugs. Journal of Biomolecular Structure and Dynamics, 2023, 41, 6534-6545.	2.0	1
1266	Protective effect of selenium on vincristine-induced peripheral neuropathy in PC12 cell line. Cytotechnology, 0, , .	0.7	0
1267	Insight into the Tubulin-Targeted Anticancer Potential of Noscapine and its Structural Analogs. Anti-Cancer Agents in Medicinal Chemistry, 2022, 22, .	0.9	1
1268	Radiosynthesis and evaluation of [11C]AG-488, a dual anti-angiogenetic and anti-tubulin PET ligand. Bioorganic and Medicinal Chemistry Letters, 2022, 74, 128941.	1.0	0
1269	SKLB-14b, a novel oral microtubule-destabilizing agent based on hydroxamic acid with potent anti-tumor and anti-multidrug resistance activities. Bioorganic Chemistry, 2022, 128, 106053.	2.0	3
1270	Synthesis and screening of novel 4-N-heterocyclic-2-aryl-6,7,8-trimethoxyquinazolines as antiproliferative and tubulin polymerization inhibitors. Bioorganic and Medicinal Chemistry, 2022, 72, 116976.	1.4	7
1271	Discovery of a 2,6-diarylpyridine-based hydroxamic acid derivative as novel histone deacetylase 8 and tubulin dual inhibitor for the treatment of neuroblastoma. Bioorganic Chemistry, 2022, 128, 106112.	2.0	5
1272	Light-induced stabilization of microtubules by photo-crosslinking of a Tau-derived peptide. Chemical Communications, 2022, 58, 9190-9193.	2.2	8
1273	Hybrid Histone Deacetylase Inhibitor: An Effective Strategy for Cancer Therapy. Current Medicinal Chemistry, 2023, 30, 2267-2311.	1.2	1

#	Article	IF	CITATIONS
1275	Pyridine Heterocycles in the Therapy of Oncological Diseases. , 0, , .		0
1276	Synthesis and antitumor activity of litseaone B analogues as tubulin polymerisation inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 2530-2539.	2.5	0
1277	The microtubule cytoskeleton: An old validated target for novel therapeutic drugs. Frontiers in Pharmacology, 0, 13, .	1.6	15
1278	A Perspective Study on the RTK, PI3K, Bâ€Raf, CDK and the Multiâ€Protein Targeting in Medicinal Chemistry. Chemistry and Biodiversity, 2022, 19, .	1.0	2
1280	Photostability and Antiproliferative Activity of Furan Analogues of Combretastatin A-4. Chemical Research in Toxicology, 2022, 35, 2014-2024.	1.7	2
1281	The protective effects of sonicated Bordetella bronchiseptica bacterin on the immunosuppression of spleen cells induced by anti-cancer drugs (5-fluorouracil, doxorubicin, and vincristine). Korean Journal of Veterinary Research, 2022, 62, e20.	0.1	0
1282	Boosting ferroptosis and microtubule inhibition for antitumor therapy via a carrier-free supermolecule nanoreactor. Journal of Pharmaceutical Analysis, 2023, 13, 99-109.	2.4	10
1283	How does plasticity of migration help tumor cells to avoid treatment: Cytoskeletal regulators and potential markers. Frontiers in Pharmacology, 0, 13, .	1.6	2
1284	Synthesis,characterization and biological activities of nitrogen-containing Combretastatin A-4 derivatives. Medicinal Chemistry Research, 0, , .	1.1	0
1285	Synthesis and bioactive evaluation of <i>N</i> -((1-methyl-1 <i>H</i> -indol-3-yl)methyl)- <i>N</i> -(3,4,5-trimethoxyphenyl)acetamide derivatives as agents for inhibiting tubulin polymerization. RSC Medicinal Chemistry, 2023, 14, 113-121.	1.7	5
1286	Chemotherapeutic Protocols for the Treatment of Breast Cancer. , 2022, , 79-123.		0
1287	Benzotriazole Substituted 2-Phenylquinazolines as Anticancer Agents: Synthesis, Screening, Antiproliferative and Tubulin Polymerization Inhibition Activity. Current Cancer Drug Targets, 2022, 23, .	0.8	1
1288	Sabizabulin, a Potent Orally Bioavailable Colchicine Binding Site Agent, Suppresses HER2+ Breast Cancer and Metastasis. Cancers, 2022, 14, 5336.	1.7	8
1289	Anticancer Tetrahydrocarbazoles: A Wide Journey from 2000 Till Date. Letters in Drug Design and Discovery, 2024, 21, 421-439.	0.4	0
1290	Drug resistance dependent on allostery: A P-loop rigor Eg5 mutant exhibits resistance to allosteric inhibition by STLC. Frontiers in Oncology, 0, 12, .	1.3	1
1291	Identification of novel aza-analogs of TN-16 as disrupters of microtubule dynamics through a multicomponent reaction. European Journal of Medicinal Chemistry, 2023, 245, 114895.	2.6	1
1292	Synthesis, biological evaluation and molecular docking studies of a new series of bis-chalcones. Research on Chemical Intermediates, 2023, 49, 273-287.	1.3	0
1294	Tirbanibulin for Actinic Keratosis: Insights into the Mechanism of Action. Clinical, Cosmetic and Investigational Dermatology, 0, Volume 15, 2495-2506.	0.8	10

#	Article	IF	CITATIONS
1295	Novel amino analogs of the trimethoxyphenyl ring in potent colchicine site ligands improve solubility by the masked polar group incorporation (MPGI) strategy. Bioorganic Chemistry, 2023, 131, 106282.	2.0	2
1296	Dynamics of Microtubule Self-Assembly. , 2016, , 201-210.		0
1297	Antitumor activity of NMS-P937, specific small-molecule polo-like kinase 1 inhibitor, in PC3 human prostate cancer, HeLa cervical cancer, and SKOV-3 ovarian cancer cell lines. Ahi Evran Medical Journal, 0, , .	0.1	0
1298	An efficient five-lncRNA signature for lung adenocarcinoma prognosis, with AL606489.1 showing sexual dimorphism. Frontiers in Genetics, 0, 13, .	1.1	1
1299	Myotoxin-3 from the Pacific Rattlesnake Crotalus oreganus oreganus Venom Is a New Microtubule-Targeting Agent. Molecules, 2022, 27, 8241.	1.7	2
1300	α-Tubulin detyrosination links the suppression of MCAK activity with taxol cytotoxicity. Journal of Cell Biology, 2023, 222, .	2.3	7
1301	Cytotoxic Cancer Drugs. , 2023, , 1-16.		0
1302	Screening Key Pathogenic Genes and Small Molecule Compounds for PNET. Journal of Pediatric Hematology/Oncology, 0, Publish Ahead of Print, .	0.3	0
1303	Discovery of Novel Acridane-Based Tubulin Polymerization Inhibitors with Anticancer and Potential Immunomodulatory Effects. Journal of Medicinal Chemistry, 2023, 66, 627-640.	2.9	10
1304	Optimization of Benzamide Derivatives as Potent and Orally Active Tubulin Inhibitors Targeting the Colchicine Binding Site. Journal of Medicinal Chemistry, 2022, 65, 16372-16391.	2.9	11
1305	Discovery of Novel <i>N</i> -Heterocyclic-Fused Deoxypodophyllotoxin Analogues as Tubulin Polymerization Inhibitors Targeting the Colchicine-Binding Site for Cancer Treatment. Journal of Medicinal Chemistry, 2022, 65, 16774-16800.	2.9	9
1307	Anticancer effects of the HDAC inhibitor, 3β,6β‑dihydroxyurs‑12‑en‑27‑oic acid, in MCF‑7 breast ca via the inhibition of Akt/mTOR pathways. Oncology Reports, 2023, 49, .	nçer cells 1.2	0
1308	Xanthatin and 8-epi-xanthatin as new potential colchicine binding site inhibitors: a computational study. Journal of Molecular Modeling, 2023, 29, .	0.8	0
1309	Discovery and biological evaluation of 4,6-pyrimidine analogues with potential anticancer agents as novel colchicine binding site inhibitors. European Journal of Medicinal Chemistry, 2023, 248, 115085.	2.6	3
1310	Synthesis and Antiproliferative Activity of Steroidal Diaryl Ethers. Molecules, 2023, 28, 1196.	1.7	4
1311	Identification of Inhibitors of Tubulin Polymerization Using a CRISPR-Edited Cell Line with Endogenous Fluorescent Tagging of β-Tubulin and Histone H1. Biomolecules, 2023, 13, 249.	1.8	6
1312	Discovery of Podofilox as a Potent cGAMP–STING Signaling Enhancer with Antitumor Activity. Cancer Immunology Research, 2023, 11, 583-599.	1.6	3
1313	Resveratrol Improves Paclitaxel-Induced Cognitive Impairment in Mice by Activating SIRT1/PGC-1α Pathway to Regulate Neuronal State and Microglia Cell Polarization. Drug Design, Development and Therapy, 0, Volume 17, 1125-1138.	2.0	4

#	Article	IF	CITATIONS
1314	Impact of Benzimidazole containing scaffolds as Anticancer Agents through diverse modes of action. Current Bioactive Compounds, 2023, 19, .	0.2	0
1315	Overcoming Cancer Multi-drug Resistance (MDR): Reasons, mechanisms, nanotherapeutic solutions, and challenges. Biomedicine and Pharmacotherapy, 2023, 162, 114643.	2.5	26
1316	Mechanisms of chromosomal instability (CIN) tolerance in aggressive tumors: surviving the genomic chaos. Chromosome Research, 2023, 31, .	1.0	4
1318	Synthesis of <i>cis</i> -stilbene-based 1,2,4-triazole/1,3,4-oxadiazole conjugates as potential cytotoxic and tubulin polymerization inhibitors. New Journal of Chemistry, 2023, 47, 4687-4697.	1.4	2
1319	Drug–Drug Interactions of Cannabidiol with Standard-of-Care Chemotherapeutics. International Journal of Molecular Sciences, 2023, 24, 2885.	1.8	5
1320	An update on the recent advances and discovery of novel tubulin colchicine binding inhibitors. Future Medicinal Chemistry, 2023, 15, 73-95.	1.1	9
1321	Emerging application of magnetic nanoparticles for breast cancer therapy. European Polymer Journal, 2023, 187, 111898.	2.6	28
1322	The emerging role of microtubules in invasion plasticity. Frontiers in Oncology, 0, 13, .	1.3	2
1323	Design, Synthesis, and Biological Evaluation of Heterocyclic-Fused Pyrimidine Chemotypes Guided by X-ray Crystal Structure with Potential Antitumor and Anti-multidrug Resistance Efficacy Targeting the Colchicine Binding Site. Journal of Medicinal Chemistry, 2023, 66, 3588-3620.	2.9	12
1324	Simple monocyclic pyrimidine analogs as microtubule targeting agents binding to the colchicine site. Bioorganic and Medicinal Chemistry, 2023, 82, 117217.	1.4	4
1325	Bench-to-Bedside Studies of Arginine Deprivation in Cancer. Molecules, 2023, 28, 2150.	1.7	9
1326	Response of Therapy in Cell-Cycle Regulatory Genes in Breast Cancer. , 2023, , 335-353.		0
1327	New Combretastatin Analogs as Anticancer Agents: Design, Synthesis, Microtubules Polymerization Inhibition, and Molecular Docking Studies. Chemistry and Biodiversity, 2023, 20, .	1.0	2
1328	Target-Based Anticancer Indole Derivatives for the Development of Anti-Glioblastoma Agents. Molecules, 2023, 28, 2587.	1.7	6
1329	Discovery of novel N-benzylarylamide-dithiocarbamate based derivatives as dual inhibitors of tubulin polymerization and LSD1 that inhibit gastric cancers. European Journal of Medicinal Chemistry, 2023, 252, 115281.	2.6	12
1330	Reversible Photocontrol of Microtubule Stability by Spiropyran onjugated Tauâ€Đerived Peptides. ChemBioChem, 2023, 24, .	1.3	5
1331	Design, Synthesis, and Biological Evaluation of Pyrimidine Dihydroquinoxalinone Derivatives as Tubulin Colchicine Site-Binding Agents That Displayed Potent Anticancer Activity Both In Vitro and In Vivo. ACS Pharmacology and Translational Science, 2023, 6, 526-545.	2.5	5
1332	Investigation of the Antineoplastic Effects of 2-(4-Chlorophenyl)-13α-Estrone Sulfamate against the HPV16-Positive Human Invasive Cervical Carcinoma Cell Line SiHa. International Journal of Molecular Sciences, 2023, 24, 6625.	1.8	1

#	Article	IF	CITATIONS
1333	Dual Ruthenium-Catalyzed Alkene Isomerization–Hydrogen Auto-Transfer Unlocks Skipped Dienes as Pronucleophiles for Enantioselective Alcohol C–H Allylation. Journal of the American Chemical Society, 0, , .	6.6	2
1334	Effect of docetaxel added to bicalutamide in Hormone-NaÃ ⁻ ve non-metastatic prostate cancer with rising PSA, a randomized clinical trial (SPCG-14). Acta Oncológica, 2023, 62, 372-380.	0.8	2
1336	Epothilones as Lead Structures for New Anticancer Drugs. , 2012, , 339-373.		0
1347	Antibody–drug conjugates come of age in oncology. Nature Reviews Drug Discovery, 2023, 22, 641-661.	21.5	82
1349	Chemical Biology Studies on Aplyronine A, A PPI-Inducing Antitumor Macrolide from Sea Hare. , 2023, , 59-75.		0
1368	Privileged chalcone scaffolds in drug discovery. , 2023, , 41-63.		0
1376	Construction of functional microtubules and artificial motile systems based on peptide design. Polymer Journal, 2023, 55, 1261-1274.	1.3	0
1415	Semisynthesis of natural products through the insertion of oxygen atom under metal-free conditions. , 2024, , 329-351.		0
1416	Pt(<scp>iv</scp>) anticancer prodrugs bearing an oxaliplatin scaffold: what do we know about their bioactivity?. Inorganic Chemistry Frontiers, 2024, 11, 1639-1667.	3.0	1
1420	Functionalization of microtubules by Tau-derived peptides: encapsulation, cell manipulation, and construction of superstructures. , 2024, , 27-44.		0